Heterocyclic GLP-1 agonists
By developing heterocyclic GLP-1 agonists and pharmaceutical compositions, the problem of limited effectiveness of GLP-1 agonists in the treatment of type 2 diabetes in the prior art has been solved, and blood sugar and insulin levels have been effectively lowered, thereby improving patient symptoms.
Patent Information
- Application Number
- CN202380094113.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-22
- Filing Date
- 2023-12-21
- Publication Date
- 2025-09-26
AI Technical Summary
In the existing technology, GLP-1 agonists have limited effects in treating type 2 diabetes, especially in terms of insulin resistance and blood sugar regulation, and are unable to effectively increase insulin levels and lower blood sugar levels.
A heterocyclic GLP-1 agonist has been developed and is administered orally or through other routes, combined with other pharmaceutical compositions, to regulate patients' insulin and blood sugar levels, lower HbA1c and fasting blood sugar, increase insulin levels, and reduce BMI.
It effectively reduces HbA1c and fasting blood sugar levels, improves insulin levels, and lowers BMI in patients with type 2 diabetes. It can be combined with other drug therapies to provide multi-disease management.
Smart Images

Figure BDA0005548292470000021 
Figure BDA0005548292470000201 
Figure BDA0005548292470000221
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to international patent application No. PCT / CN2022 / 141073 filed on December 22, 2022, the contents of which are incorporated herein by reference in their entirety. Technical Field
[0002] The present application relates to GLP-1 agonists, pharmaceutical compositions, and methods of use thereof. Background Art
[0003] Incretin hormones include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) and are important in regulating blood glucose homeostasis. Drugs targeting this family of intestinal peptides, such as GLP-1 agonists, have been shown to inhibit glucagon production, reduce gastric motility, and increase satiety.
[0004] Diabetes refers to a group of metabolic disorders characterized by persistent high blood sugar levels. The most common form, type 2 diabetes (T2DM), is an acquired disease that accounts for more than 90% of diabetes cases. The disease typically develops in adults who are obese or sedentary and begins with insulin resistance. Although lifestyle changes may help treat this condition, patients with T2DM may need to take antidiabetic medications, particularly drugs such as dipeptidyl peptidase-4 inhibitors, SGLT2 inhibitors, and sulfonylureas.
[0005] In healthy individuals, the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) provide tandem modulation of the insulin secretory response to glucose ingestion. Although this incretin effect is significantly diminished (if present at all) in cases of T2DM, GLP-1 retains insulinotropic properties even when the endocrine pancreatic response to GIP is effectively blocked. Therefore, incretin mimetics and other GLP-1-based therapies can help stimulate insulin production in patients with T2DM. Summary of the Invention
[0006] The present application describes heterocyclic GLP-1 agonists, as well as pharmaceutical compositions comprising the compounds disclosed herein. The present application also provides methods of treating GLP-1 related diseases, disorders, and conditions.
[0007] In one aspect, the present application provides a compound of formula I: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof, wherein Ring A, Ring B, Z1 , Z 2 、R 1 、R 2 、R 4 、R 5 、R 6 、R 7 , and p are each independently as defined herein.
[0008] The present application also provides pharmaceutical compositions comprising: one or more compounds of Formula I or pharmaceutically acceptable salts, isotopically enriched analogs, stereoisomers, mixtures of stereoisomers or prodrugs thereof, and a pharmaceutically acceptable excipient.
[0009] The present application also provides a pharmaceutical composition comprising: a compound of Formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof, and a pharmaceutically acceptable excipient.
[0010] The present application also provides a method for treating type 2 diabetes in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof, or a pharmaceutical composition thereof.
[0011] The present application also provides a method for treating type 2 diabetes in a patient, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof, or a pharmaceutical composition thereof to a patient confirmed or diagnosed with type 2 diabetes.
[0012] The present application also provides a method for treating diabetes in a patient, the method comprising: determining that the patient has type 2 diabetes; and administering to the patient a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, or a pharmaceutical composition thereof. In some embodiments, the step of determining that the patient has type 2 diabetes comprises performing an assay to determine the level of an analyte in a sample from the patient, wherein the analyte is selected from: hemoglobin A1c (HbA1c), fasting blood glucose, non-fasting blood glucose, or any combination thereof. In some embodiments, the level of HbA1c is greater than or about 6.5%. In some embodiments, the fasting blood glucose level is greater than or about 126 mg / dL. In some embodiments, the non-fasting blood glucose level is greater than or about 200 mg / dL.
[0013] In some embodiments, the method further comprises obtaining a sample from the patient. In some embodiments, the sample is a body fluid sample. In some embodiments, the patient is about 40 to about 70 years old and is overweight or obese. In some embodiments, the patient has a body mass index (BMI) greater than or about 22 kg / m 2 In some embodiments, the patient's BMI is greater than or about 30 kg / m 2 .
[0014] In some embodiments, the method of treating type 2 diabetes comprises lowering fasting blood glucose levels. In some embodiments, fasting blood glucose levels are lowered to about or below 100 mg / dL.
[0015] In some embodiments, the method of treating type 2 diabetes comprises lowering HbA1c levels. In some embodiments, the HbA1c levels are lowered to about or below 5.7%.
[0016] In some embodiments, the method of treating type 2 diabetes comprises lowering glucagon levels.
[0017] In some embodiments, the method of treating type 2 diabetes comprises increasing insulin levels.
[0018] In some embodiments, the method of treating type 2 diabetes comprises reducing BMI. In some embodiments, the BMI is reduced to about or below 25 kg / m 2 .
[0019] In some embodiments, a compound of Formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, or a pharmaceutical composition thereof is administered orally.
[0020] In some embodiments, the method for treating type 2 diabetes further comprises administering another therapy or therapeutic agent to the patient. In some embodiments, another therapy or therapeutic agent is selected from antidiabetic drugs, antiobesity agents, GLP-1 receptor agonists, agents for treating nonalcoholic steatohepatitis (NASH), antiemetics, gastric electrical stimulation, dietary monitoring, physical activity, or any combination thereof. In some embodiments, antidiabetic drugs are selected from biguanides, sulfonylureas, glitazars, thiazolidinediones, dipeptidyl peptidase 4 (DPP-4) inhibitors, glinides, sodium-glucose coupled transporter 2 (SGLT2) inhibitors, glitazones, GRP40 agonists, glucose-dependent insulinotropic peptide (GIP), insulin or insulin analogs, alpha glucosidase inhibitors, sodium-glucose coupled transporter 1 (SGLT1) inhibitors, or any combination thereof. In some embodiments, biguanides are metformin. In some embodiments, the anti-obesity agent is selected from a neuropeptide Y receptor type 2 (NPYR2) agonist, an NPYR1 or NPYR5 antagonist, a human proislet peptide (HIP), a cannabinoid type 1 receptor (CB1R) antagonist, a lipase inhibitor, a melanocortin receptor 4 agonist, a farnesoid X receptor (FXR) agonist, phentermine, zonisamide, a norepinephrine / dopamine reuptake inhibitor, a GDF-15 mimetic, an opioid receptor antagonist, a cholecystokinin agonist, a serotonergic agent, a methionyl aminopeptidase 2 (MetAP2) inhibitor, amfepramone, phendimetrazine, benzphetamine, a fibroblast growth factor receptor (FGFR) modulator, an AMP-activated protein kinase (AMPK) activator, or any combination thereof. In some embodiments, the GLP-1 receptor agonist is selected from liraglutide, exenatide, dulaglutide, albiglutide, tasiglutide, lixisenatide, semaglutide, or any combination thereof. In some embodiments, the agent for treating NASH is selected from FXR agonists, PF-05221304, synthetic fatty acid bile conjugates, anti-lysyl oxidase homolog 2 (LOXL2) monoclonal antibodies, cysteine protease inhibitors, MAPK5 inhibitors, galectin 3 inhibitors, fibroblast growth factor 21 (FGF21) agonists, nicotinic acid analogs, leukotriene D4 (LTD4) receptor antagonists, acetyl-CoA carboxylase (ACC) inhibitors, hexokines (KHK) inhibitors, apical sodium-dependent bile acid transporter (IBAT) inhibitors, apoptosis signal-regulating kinase 1 (ASK1) inhibitors, or any combination thereof. In some embodiments, a compound of Formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, or a pharmaceutical composition thereof, and the additional therapeutic agent are administered as separate doses in any order.
[0021] The application also provides a method for regulating the insulin level of a patient in need of such regulation, the method comprising administering to the patient an effective amount of a compound of formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof, or a pharmaceutical composition thereof. In some embodiments, the regulation results in an increase in insulin levels.
[0022] The application also provides a method for regulating the blood glucose level of a patient in need of such regulation, the method comprising administering to the patient an effective amount of a compound of Formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof, or a pharmaceutical composition thereof. In some embodiments, the regulation results in a reduction in blood glucose level.
[0023] The present application also provides a method for treating a GLP-1-related disease, disorder or condition, which comprises administering to a patient in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof, or a pharmaceutical composition thereof. In some embodiments, the disease, disorder or condition is selected from type 1 diabetes, type 2 diabetes, early onset type 2 diabetes, idiopathic type 1 diabetes (type 1b), atypical diabetes of the young (YOAD), maturity-onset diabetes of the young (MODY), latent autoimmune diabetes of adults (LADA), obesity, weight gain from other medications, gout, excessive sugar cravings, hypertriglyceridemia, dyslipidemia, malnutrition-associated diabetes, gestational diabetes, kidney disease, disorders of adipocyte function, sleep apnea, visceral fat deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral arterial disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attack, atherosclerotic cardiovascular disease, traumatic brain injury, peripheral vascular disease, endothelial dysfunction, impaired vascular compliance, restenosis, thrombosis, hypertension, pulmonary hypertension, vascular restenosis after angioplasty, intermittent claudication, hyperglycemia, postprandial lipemia, metabolic acidosis, ketosis, hyperinsulinemia, dysglucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorder, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, premenstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, macular degeneration, cataracts, glomerulosclerosis, arthritis, osteoporosis, addiction treatment, cocaine dependence, bipolar disorder / major depressive disorder, skin and connective tissue disorders, foot ulcers, psoriasis, primary polydipsia, nonalcoholic steatosis hepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), ulcerative colitis, inflammatory bowel disease, colitis, irritable bowel syndrome, Crohn's disease, short bowel syndrome, Parkinson's disease, Alzheimer's disease, cognitive function disorders, schizophrenia, polycystic ovary syndrome (PCOS), or any combination thereof.In some embodiments, the disease, disorder or condition is selected from type 2 diabetes, early onset type 2 diabetes, obesity, weight gain from other medications, gout, excessive sugar cravings, hypertriglyceridemia, dyslipidemia, gestational diabetes, kidney disease, adipocyte function disorders, sleep apnea, visceral fat deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral arterial disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attack, atherosclerotic cardiovascular disease, hyperglycemia, postprandial lipidosis, metabolic acidosis, ketosis , hyperinsulinemia, abnormal glucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorder, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, premenstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, bipolar disorder / major depressive disorder, skin and connective tissue diseases, foot ulcer, psoriasis, primary polydipsia, nonalcoholic steatosis hepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), short bowel syndrome, Parkinson's disease, polycystic ovary syndrome (PCOS), or any combination thereof. In some embodiments, the disease, disorder, or condition includes but is not limited to type 2 diabetes, early onset type 2 diabetes, obesity, weight gain due to use of other medications, gout, excessive glucose craving, hypertriglyceridemia, dyslipidemia, gestational diabetes, disorders of adipocyte function, visceral fat deposition, myocardial infarction, peripheral arterial disease, stroke, transient ischemic attack, hyperglycemia, postprandial lipidosis, metabolic acidosis, ketosis, hyperinsulinemia, abnormal glucose metabolism, insulin resistance, hepatic insulin resistance, chronic renal failure, syndrome X, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, skin and connective tissue diseases, foot ulcers, or any combination thereof.
[0024] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated herein by reference. If there is a conflict between the publications, patents, or patent applications incorporated herein by reference and the content contained in this specification, the present specification is intended to supersede and / or take precedence over any such conflicting material. DETAILED DESCRIPTION
[0025] The present application provides heterocyclic GLP-1 agonists for use in treating T2DM and other conditions in which activation of GLP-1 activity is useful.
[0026] Before describing the compound and method of the present invention, it should be understood that the application is not limited to described method, protocol, cell line, determination and reagent, because these can change.It should also be understood that the term used in this application is intended to describe the embodiment of the application, and does not limit the scope of the present invention defined by the appended claims in any way. definition
[0027] The following describes exemplary embodiments of the present invention. However, it should be appreciated that this description is not intended to limit the scope of the present application, but is provided as a description of exemplary embodiments.
[0028] As used in this specification, the following words, phrases and symbols are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.
[0029] A dash ("-") that is not between two letters or symbols is used to indicate the point of attachment of a substituent. For example, -C(O)NH2 is attached through a carbon atom. Dashes preceding or ending a chemical group are for convenience; a chemical group may be depicted with or without one or more dashes without losing its usual meaning. A wavy or dashed line drawn through a line in a structure indicates a designated point of attachment for a group. Unless chemically or structurally required, the order in which chemical groups are written or named does not indicate or imply directionality or stereochemistry.
[0030] The prefix "C u-v " indicates that the following group has u to v carbon atoms. For example, "C 1-6 "Alkyl" means an alkyl group having 1 to 6 carbon atoms.
[0031] References herein to "about" a value or parameter include (and describe) embodiments involving the value or parameter itself. In certain embodiments, the term "about" includes ±10% of the specified amount. In other embodiments, the term "about" includes ±5% of the specified amount. In certain other embodiments, the term "about" includes ±1% of the specified amount. Similarly, reference to the term "about x" includes a description of "x." Similarly, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "the compound" includes a plurality of such compounds, and reference to "the assay" includes reference to one or more assays and equivalents thereof known to those skilled in the art.
[0032] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, an alkyl group has 1 to 20 carbon atoms (i.e., C 1-20 alkyl), 1 to 12 carbon atoms (i.e., C 1-12 alkyl), 1 to 8 carbon atoms (i.e., C 1-8 alkyl), 1 to 6 carbon atoms (i.e., C1-6 alkyl), or 1 to 4 carbon atoms (i.e., C 1-4 Alkyl). Examples of alkyl groups include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbon atoms is named by a chemical name or determined by a molecular formula, all isomers having that number of carbon atoms are included; thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3), and "propyl" includes n-propyl (i.e., -(CH2)2CH3), and isopropyl (i.e., -CH(CH3)2).
[0033] "Alkenyl" refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C 2-20 alkenyl), 2 to 12 carbon atoms (i.e., C 2-12 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 alkenyl), or 2 to 4 carbon atoms (ie, C 2-4 Examples of the alkenyl group include, for example, ethenyl, propenyl, butadienyl (including 1,2-butadienyl, and 1,3-butadienyl).
[0034] "Alkynyl" refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C 2-20 Alkynyl), 2 to 12 carbon atoms (i.e., C 2-12 Alkynyl), 2 to 8 carbon atoms (i.e., C 2-8 Alkynyl), 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl), or 2 to 4 carbon atoms (ie, C 2-4 The term "alkynyl" also includes those groups having one triple bond and one double bond.
[0035] Certain commonly used alternative chemical names may be used. For example, divalent groups such as divalent "alkyl" groups, divalent "aryl" groups, etc. may also be referred to as "alkylene" groups or "alkenyl" groups, "arylene" groups or "aralkenyl" groups, respectively.
[0036] “Alkoxy” refers to the group “alkyl-O—.” Examples of alkoxy groups include, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.
[0037] "Thioalkoxy" refers to the group "alkyl-S-."
[0038] "Haloalkyl" refers to an unbranched or branched alkyl group as defined above, in which one or more (e.g., 1 to 6, or 1 to 3) hydrogen atoms are replaced by a halogen. For example, when a residue is substituted with more than one halogen, it can be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl groups substituted with two ("di") or three ("tri") halogen groups, which can be, but are not necessarily, the same halogen. Examples of haloalkyl include, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.
[0039] "Haloalkoxy" refers to an alkoxy group as defined above in which one or more (eg, 1 to 6, or 1 to 3) hydrogen atoms are replaced by a halogen.
[0040] "Hydroxyalkyl" refers to an alkyl group as defined above in which one or more (eg, 1 to 6, or 1 to 3) hydrogen atoms are replaced by hydroxy groups.
[0041] "Cyanoalkyl" refers to an alkyl group as defined above in which one, or one or more (eg, 1 to 6, or 1 to 3) hydrogen atoms are replaced by a cyano group.
[0042] "Alkylthio" refers to the group "alkyl-S-."
[0043] "Acyl" refers to the group -C(O)R, where R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein. Examples of acyl include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.
[0044] "Amide" refers to the group -C(O)NR y R z The "C-amido" group and the representation refer to the group -NR y C(O)R z "N-amido" groups, wherein R y and R zis independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein, or R y and R z Together they form a cycloalkyl or heterocyclyl group; each of which may be optionally substituted as defined herein.
[0045] "Amino" refers to the group -NR y R z , where R y and R z is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein.
[0046] "Amidino" refers to -C(NR y) (NR z 2), where R y and R z is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein.
[0047] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including a fused system. As used herein, an aryl group has 6 to 20 ring carbon atoms (i.e., C 6-20 aryl), 6 to 12 ring carbon atoms (i.e., C 6-12 aryl), or 6 to 10 ring carbon atoms (i.e., C 6-10 Examples of aryl groups include, for example, phenyl, naphthyl, fluorenyl, and anthracenyl. However, aryl groups do not include or overlap in any way with heteroaryl groups as defined below. If one or more aryl groups are fused to a heteroaryl group, the resulting ring system is a heteroaryl group, regardless of the point of attachment. If one or more aryl groups are fused to a heterocyclyl group, the resulting ring system is a heterocyclyl group, regardless of the point of attachment. If one or more aryl groups are fused to a cycloalkyl group, the resulting ring system is a cycloalkyl group, regardless of the point of attachment.
[0048] "Carbamoyl" refers to the group -OC(O)NR y R z The "O-carbamoyl" group and the group -NR y C(O)OR z "N-carbamoyl" groups, wherein R y and R z Each is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein.
[0049] "Carboxyl ester" or "ester" refers to -OC(O)R x and -C(O)OR x Both, of which R x is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein.
[0050] "Cycloalkyl" refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term "cycloalkyl" includes cycloalkenyl (i.e., a cyclic group having at least one double bond) and carbocyclic fused ring systems having at least one sp3 carbon atom (i.e., at least one non-aromatic ring). As used herein, a cycloalkyl group has 3 to 20 ring carbon atoms (i.e., C 3-20 cycloalkyl), 3 to 14 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C 3-12 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C 3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C 3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C 3-6 Cycloalkyl). Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, and the like. In addition, the term cycloalkyl is intended to include any non-aromatic ring that may be fused to an aromatic ring, regardless of the connection to the rest of the molecule. Further still, when there are two substitution positions on the same carbon atom, cycloalkyl also includes "spirocycloalkyl", such as spiro[2.5]octyl, spiro[4.5]decyl, or spiro[5.5]undecyl.
[0051] "Imino" refers to the group -C(NR y )R z , where R y and R z Each is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein.
[0052] "Halogen" or "halo" refers to an atom from Group VIIA of the Periodic Table of the Elements, such as fluorine, chlorine, bromine, or iodine.
[0053] "Heteroalkyl" refers to an alkyl group in which one or more (and any associated hydrogen atoms) of the carbon atoms are each independently substituted by the same or different heteroatom groups. The term "heteroalkyl" includes unbranched or branched saturated chains with carbon atoms and heteroatoms. For example, 1, 2 or 3 carbon atoms can be independently substituted by the same or different heteroatom groups. Heteroatom groups include, but are not limited to, -NR-, -O-, -S-, -S(O)-, -S(O)2-, etc., where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclic radical, each of which can be optionally substituted. The example of heteroalkyl includes -OCH3, -CH2OCH3, -SCH3, -CH2SCH3, -NRCH3, and -CH2NRCH3, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which can be optionally substituted. As used herein, heteroalkyl groups include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
[0054] "Heteroalkylene" refers to a divalent heteroalkyl group. A "heteroalkylene" group must have at least one carbon atom and at least one heteroatom group within the chain. The term "heteroalkylene" includes unbranched or branched saturated chains having carbon atoms and heteroatoms. For example, 1, 2, or 3 carbon atoms may be independently substituted with the same or different heteroatom groups. Heteroatom groups include, but are not limited to, -NR y -, -O-, -S-, -S(O)-, -S(O)2-, etc., where R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted as defined herein. Examples of heteroalkylene groups include, for example, -CH2OCH2-, -CH(CH3)OCH2-, -CH2CH2OCH2-, -OCH2-, -CH(CH3)O-, -CH2CH2O-, -CH2CH2OCH2CH2OCH2-, -CH2CH2OCH2CH2O-, -CH2SCH2-, -CH(CH3)SCH2-, -CH2CH2SCH2-, -CH2CH2SCH2CH2SCH2-, -SCH2-, -CH(CH3)S-, -CH2CH2S-, -CH2CH2SCH2CH2S-, -CH2S(O)2CH2-, -CH(CH3)S(O)2CH2-, -CH2CH2S(O)2CH2CH2OCH2-, -CH2NR y CH2-, -CH(CH3)NR y CH2-, -CH2CH2NR y CH2-, -CH2CH2NR yCH2CH2NR y CH2- etc., where R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein. As used herein, heteroalkylene includes 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom. As used herein, the term "heteroalkylene" does not include groups such as amides or other functional groups having an oxo group present on one or more carbon atoms.
[0055] "Heteroaryl" refers to an aromatic group having a single ring or multiple fused rings with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, a heteroaryl group includes 1 to 20 ring carbon atoms (i.e., C 1-20 heteroaryl), 3 to 12 ring carbon atoms (ie, C 3-12 heteroaryl), or 3 to 8 ring carbon atoms (ie, C 3-8In some embodiments, the heteroaryl group comprises a 5-10 membered ring system, a 5-7 membered ring system, or a 5-6 membered ring system, each of which independently has 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom, and the ring heteroatoms are independently selected from nitrogen, oxygen, and sulfur. In some cases, the heteroaryl group comprises a 5-10 membered ring system, a 5-7 membered ring system, or a 5-6 membered ring system, each of which independently has 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom, and the ring heteroatoms are independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include, for example, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothienyl, furyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isothiazolyl, Indolyl, isoquinolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-pyridinyl oxide, 1-pyrimidinyl oxide, 1-pyrazinyl oxide, 1-pyridazinyl oxide, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolyl, thiazolyl, thiadiazolyl, thienyl, triazolyl, tetrazolyl, and triazinyl. Examples of fused heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolyl, isoquinolyl, benzo[b]thienyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5-a]pyridinyl, wherein the heteroaryl group may be attached through either ring of the fused system. Any aromatic ring, both single and multiple fused rings, containing at least one heteroatom is considered a heteroaryl group, regardless of how it is attached to the rest of the molecule (i.e., through any one of the fused rings). Heteroaryl groups do not include or overlap with the above-defined aryl groups.
[0056] "Heterocyclyl" refers to a saturated or partially unsaturated cyclic alkyl group having one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. The term "heterocyclyl" includes heterocycloalkenyl (i.e., a heterocyclyl group having at least one double bond), bridged heterocyclyl, fused heterocyclyl, and spiroheterocyclyl. A heterocyclyl group can be a single ring or multiple rings, wherein multiple rings can be fused, bridged, or spirocyclic, and can include one or more (e.g., 1 to 3) oxo (=O) or N-oxide (-O-) moieties. It is considered that any non-aromatic ring or fused ring system comprising at least one heteroatom and one non-aromatic ring is a heterocyclyl, regardless of the connection to the rest of the molecule. For example, fused ring systems such as decahydroquinazolinyl, 1,2,3,4-tetrahydroquinazolinyl, and 5,6,7,8-tetrahydroquinazolinyl are heterocyclyls, regardless of the connection (i.e., they can be connected by carbon atoms or heteroatoms). Additionally, the term heterocyclyl is intended to include any non-aromatic ring containing at least one heteroatom, which ring may be fused to a cycloalkyl, aryl, or heteroaryl ring, regardless of the attachment to the rest of the molecule. As used herein, a heterocyclyl group has from 2 to 20 ring carbon atoms (i.e., C 2-20 heterocyclyl), 2 to 12 ring carbon atoms (i.e., C 2-12 heterocyclyl), 2 to 10 ring carbon atoms (i.e., C 2-10 heterocyclyl), 2 to 8 ring carbon atoms (i.e., C 2-8 heterocyclyl), 3 to 12 ring carbon atoms (i.e., C 3-12 heterocyclyl), 3 to 8 ring carbon atoms (i.e., C 3-8 heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C 3-6heterocyclic radical); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom, the ring heteroatoms being independently selected from nitrogen, sulfur, or oxygen. Examples of heterocyclic radicals include, for example, azetidinyl, azepanyl, benzodioxolyl, benzo[b][1,4]dioxepanyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxanyl, benzopyranonyl, benzofuranonyl, dioxolane, dihydropyranyl, tetrahydropyranyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolyl, isothiazolidinyl, isoxazole Alkyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. The term "heterocyclyl" also includes "spiroheterocyclyl" when two substitution positions are present on the same carbon atom. Examples of spiroheterocyclyl rings include, for example, bicyclic and tricyclic ring systems such as oxabicyclo[2.2.2]octyl, 2-oxa-7-azaspiro[3.5]nonyl, 2-oxa-6-azaspiro[3.4]octyl, and 6-oxa-1-azaspiro[3.3]heptyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, wherein the heterocyclyl group can be attached via any one ring of the fused system.
[0057] "Sulfonyl" refers to the group -S(O)2R y , where R y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted as defined herein. Examples of sulfonyl groups are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.
[0058] "Alkylsulfonyl" refers to the group -S(O)2R where R is alkyl.
[0059] "Alkylsulfinyl" refers to the group -S(O)R, where R is alkyl.
[0060] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes instances where the event or circumstance occurs and instances where the event or circumstance does not occur. Similarly, the term "optionally substituted" means that any one or more (e.g., 1 to 5, or 1 to 3) hydrogen atoms on the designated atom or group may or may not be replaced with a moiety other than hydrogen.
[0061] As used herein, the term "compound" is intended to include any or all stereoisomers, geometric isomers, tautomers, and isotopically enriched analogs (e.g., deuterated analogs) of the structure shown. Unless otherwise indicated, compounds identified herein as a particular tautomeric form by name or structure are intended to include other tautomeric forms.
[0062] Some of the compounds exist as tautomers. Mutual equilibrium exists between the tautomers. For example, amide-containing compounds can exist in equilibrium with the imidic acid tautomers. No matter which tautomer is shown, and no matter how the equilibrium properties between the tautomers are, it is understood by those skilled in the art that these compounds include both amides and imidic acid tautomers. Therefore, it is believed that amide-containing compounds include their imidic acid tautomers. Equally, it is believed that imidic acid-containing compounds include their amide tautomers.
[0063] Any compound or structure given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compound. These forms of the compound may also be referred to as "isotopically enriched analogs." An isotopically labeled compound has a structure described herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, for example, 2 H, 3 H, 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 I. Various isotope-labeled compounds of the present application, for example, are combined with 3 H and 14Compounds containing radioactive isotopes such as C. Such isotope-labeled compounds can be used in metabolism studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), including drug or substrate tissue distribution assays, or for radiotherapy of patients.
[0064] The term "isotopically enriched analogs" of the compounds described herein includes "deuterated analogs" in which one or more hydrogens (e.g., one hydrogen on a carbon atom) are replaced by deuterium. Such compounds exhibit enhanced resistance to metabolism and, therefore, can be used to extend the half-life of any compound when administered to mammals, particularly humans. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci. 5(12): 524-527 (1984). Such compounds are synthesized by methods known in the art, for example, by using starting materials in which one or more hydrogens have been replaced by deuterium.
[0065] The deuterium-labeled or substituted therapeutic compounds of the present application can have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium can provide certain therapeutic advantages derived from greater metabolic stability, such as increased in vivo half-life, reduced dosage requirements, and / or improvements in therapeutic indicators. 18 F. 3 H. 11 Compounds labeled with C can be used in PET, SPECT, or other imaging studies. The isotopically labeled compounds and prodrugs of the present invention can generally be prepared by following the procedures disclosed in the schemes or examples and preparation methods described below, replacing non-isotopically labeled reagents with readily available isotopically labeled reagents. It should be understood that deuterium, in the relevant context, is considered a substituent in the compounds described herein.
[0066] The concentration of such heavier isotopes (particularly deuterium) can be defined by an isotopic enrichment factor. In the compounds of the present application, any atom not specifically designated as a particular isotope is intended to represent any stable isotope of that atom. Unless otherwise indicated, when a position is specifically designated as "H" or "hydrogen," that position is understood to be a hydrogen with a natural abundance isotopic composition. Therefore, in the compounds of the present application, a term specifically designated as deuterium (D) is intended to represent deuterium.
[0067] In many cases, the compounds of the present application are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or groups similar thereto.
[0068] The present application also provides pharmaceutically acceptable salts, hydrates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein. "Pharmaceutically acceptable" or "physiologically acceptable" refers to compounds, salts, compositions, dosage forms, and other materials used to prepare pharmaceutical compositions suitable for veterinary or human pharmaceutical use.
[0069] The term "pharmaceutically acceptable salt" of a given compound refers to a salt that retains the biological effectiveness and properties of the given compound and is not biologically or otherwise undesirable. "Pharmaceutically acceptable salts" or "physiologically acceptable salts" include, for example, salts formed with inorganic acids and salts formed with organic acids. Furthermore, if the compounds described herein are obtained as acid addition salts, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid according to conventional procedures for preparing acid addition salts from basic compounds. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include, for example, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, and the like. Salts derived from organic acids include, for example, acetate, propionate, gluconate, glycolate, pyruvate, oxalate, malate, malonate, succinate, maleate, fumarate, tartrate, citrate, benzoate, cinnamate, mandelate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, salicylate, etc. Similarly, pharmaceutically acceptable base addition salts can be prepared from inorganic bases and organic bases. By way of example only, salts derived from inorganic bases include sodium salts, potassium salts, lithium salts, aluminum salts, ammonium salts, calcium salts, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of NH3 or primary, secondary, or tertiary amines, for example, from N-containing heterocycles, N-containing heteroaryls, or from compounds of the formula N(R N )3 amine (for example, HN + (R N )3 or (alkyl) N + (R N )3) wherein R N Each is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each is optionally substituted with, for example, one or more (e.g., 1-5 or 1-3) substituents (e.g., halogen, cyano, hydroxy, amino, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or haloalkoxy). Specific examples of suitable amines include, by way of example only, isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
[0070] The term "substituted" means that any one or more hydrogen atoms on the designated atom or group are replaced by one or more substituents other than hydrogen, provided that the normal valence of the designated atom is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halogen, haloalkyl, haloalkoxy, heteroalkyl, heteroaryl, heterocyclyl, hydroxyl, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, sulfhydryl, thioketone, or a combination thereof. In some embodiments, the one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, cycloalkyl, cycloalkylalkyl, guanidino, halogen, haloalkyl, hydroxyalkyl, haloalkoxy, haloalkoxyalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydroxy, hydrazino, imino, imide, oxo, nitro, sulfinyl, sulfonic acid, sulfonyl, thiocyanate, sulfhydryl, thioketone, or a combination thereof.
[0071] The application is not intended to include polymers or similar infinite structures obtained by defining substituents with unlimited additional other substituents (for example, aryl with substituted alkyl, the alkyl itself is replaced by substituted aryl, the aryl further replaced by substituted heteroalkyl, etc.). Unless otherwise indicated, the maximum number of continuous substitutions in the compounds described herein is three. For example, continuous substitution of substituted aryl with two other substituted aryl groups is limited to aryl substituted by ((substituted aryl) substituted aryl). Similarly, the above definition is not intended to include substitution patterns that are not allowed (for example, methyl substituted by 5 fluorines or heteroaryl with two adjacent oxygen ring atoms). This substitution pattern that is not allowed is well known to those skilled in the art. When used to modify chemical groups, the term "substituted" can describe other chemical groups defined in the application. Unless otherwise specified, when a group is described as optionally substituted, any substituent of the group is itself unsubstituted. For example, in some embodiments, the term "substituted alkyl" refers to an alkyl group having one or more substituents, including hydroxyl, halogen, alkoxy, cycloalkyl, heterocyclic radical, aryl, and heteroaryl. In other embodiments, one or more substituents may be further substituted with halogen, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclic radical, aryl, or heteroaryl, each of which may be substituted. In other embodiments, substituents may be further substituted with halogen, alkyl, haloalkyl, alkoxy, hydroxyl, cycloalkyl, heterocyclic radical, aryl, or heteroaryl, each of which may be unsubstituted.
[0072] As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents with pharmaceutically active substances is well known in the art. Unless any conventional media or agent is incompatible with the active ingredient, its use in therapeutic compositions is contemplated. Supplementary active ingredients may also be incorporated into the compositions.
[0073] A "solvate" is formed by the interaction of a solvent and a compound. Also provided are solvates of the salts of the compounds described herein. Also provided are hydrates of the compounds described herein.
[0074] As used herein, when a ring is described as "aromatic," this means that the ring has a continuous delocalized π-electron system. Typically, the number of out-of-plane π electrons corresponds to the Hückel rule (4n+2). Examples of such rings include: benzene, pyridine, pyrimidine, pyrazine, pyridazine, pyridone, pyrrole, pyrazole, oxazole, thiazole, isoxazole, isothiazole, and the like. When a ring system comprising at least two rings is described as "aromatic," this means that the ring system comprises one or more aromatic rings. Thus, when a ring system comprising at least two rings is described as "non-aromatic," none of the constituent rings of the ring system is aromatic.
[0075] As used herein, when a ring is described as "partially unsaturated," this means that the ring has one or more additional degrees of unsaturation (in addition to the unsaturation attributable to the ring itself; for example, one or more double bonds between constituent ring atoms), provided that the ring is not aromatic. Examples of such rings include: cyclopentene, cyclohexene, cycloheptene, dihydropyridine, tetrahydropyridine, dihydropyrrole, dihydrofuran, dihydrothiophene, and the like. When a ring system comprising at least two rings is described as "partially unsaturated," this means that the ring system comprises one or more partially unsaturated rings, provided that none of the constituent rings of the ring system is aromatic.
[0076] As used herein, the term "compound" is intended to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structure. Unless otherwise specified, compounds identified herein as a particular tautomeric form by name or structure are intended to include other tautomeric forms.
[0077] The term "tautomer" as used herein refers to compounds whose structures differ significantly due to the arrangement of atoms but exist in easy and rapid equilibrium, and it is understood that the compounds provided herein can be depicted as different tautomers, and when a compound has tautomeric forms, all tautomeric forms are intended to be encompassed within the scope of the present application, and the naming of the compound does not exclude any tautomer.
[0078] As used herein, the term "GLP-1R" or "GLP-1 receptor" is intended to include, but is not limited to, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide chains, complementary sequences, peptides, polypeptides, proteins, homologous and / or orthologous GLP-1R molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.
[0079] As used herein, the term "GLP-1 related disease" is intended to include, but is not limited to, all those diseases, disorders, or conditions in which modulation of glucagon-like peptide-1 (GLP-1) receptor signaling can alter the pathology and / or symptoms and / or progression of the disease, disorder, or condition.
[0080] As used herein, the term "GLP-1 agonist" or "GLP-1RA" refers to an agonist of the glucagon-like peptide-1 (GLP-1) receptor. GLP-1RAs enhance glucose-dependent insulin secretion; inhibit inappropriate increases in glucagon levels in both the fasting and postprandial states; and slow gastric emptying. Karla et al., Glucagon-like peptide-1 receptoragonists in the treatment of type 2 diabetes: Past, present, and future, Indian J Endocrinol Metab. 2016 Mar-Apr; 20(2): 254–267. GLP-1RAs have been shown to be useful in the treatment of type 2 diabetes. Examples of GLP-1RAs include, but are not limited to, albiglutide Dulaglutide (LY2189265, ), efpeglenatide, exenatide ( Exendin-4), liraglutide ( NN2211), lixisenatide semaglutide Tielpotide, ZP2929, NNC0113-0987, BPI-3016, and TT401.
[0081] As used herein, the term "pharmaceutically acceptable" means that the compound or salt thereof or composition is chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the subject being treated therewith.
[0082] The term "administration" or "administering" refers to a method of administering a dose of a compound or pharmaceutical composition to a vertebrate or invertebrate (including mammals, birds, fish, or amphibians). The method of administration can vary depending on various factors, such as the components of the pharmaceutical composition, the site of the disease, and the severity of the disease.
[0083] The terms "effective amount" or "effective dose" or "pharmaceutically effective amount" or "therapeutically effective amount" as used herein refer to an amount of a chemical entity (e.g., a compound of Formula I or its minor general formula, or a pharmaceutically acceptable salt or solvate thereof) administered that is sufficient to alleviate to some extent one or more symptoms of the disease or condition being treated, and may include curing the disease. "Cure" means eliminating the symptoms of an active disease. The results include alleviating and / or relieving the signs, symptoms or causes of the disease, or any other desired changes in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein that is required to provide a clinically significant reduction in the symptoms of the disease. The appropriate "effective" amount in any individual case is determined using any suitable technique (e.g., a dose escalation study). In some embodiments, the "therapeutically effective amount" of a compound provided herein refers to the amount of the compound that is effective as a monotherapy or combination therapy.
[0084] The term "excipient" or "pharmaceutically acceptable excipient" means a pharmaceutically acceptable substance, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In some embodiments, each component is "pharmaceutically acceptable" in the sense that it is compatible with the other ingredients of the pharmaceutical formulation and is suitable for use in contact with human and animal tissues or organs without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications commensurate with a reasonable benefit-risk ratio. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash, eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson, ed.; CRC Press LLC: Boca Raton, FL, 2009.
[0085] The term "pharmaceutical composition" refers to a mixture of a compound of formula I provided herein or a pharmaceutically acceptable salt or solvate thereof and other chemical components (collectively referred to herein as "excipients"), such as carriers, stabilizers, diluents, dispersants, suspending agents, and / or thickening agents. Pharmaceutical compositions facilitate administration of compounds to organisms. A variety of techniques for administering compounds are available in the art, including, but not limited to, rectal, oral, intravenous, aerosol, parenteral, ocular, pulmonary, and topical administration.
[0086] The terms "treat," "treating," and "treatment" in the context of treating a disease, disorder, or condition are intended to include alleviating or eliminating the disease, disorder, or condition, or one or more of the symptoms associated with the disease, disorder, or condition; or slowing the progression, spread, or worsening of the disease, disorder, or condition, or one or more of its symptoms.
[0087] As used herein, the term "prevent" or "prevent" refers to the complete or partial prevention of the onset, recurrence, or spread of a disease or condition described herein, or its symptoms.
[0088] As used herein, the terms "subject," "patient," or "individual" are used interchangeably and refer to any animal, including mammals, such as mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, primates, and humans. In some embodiments, the terms refer to a subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired or needed. In some embodiments, the subject is a human. In some embodiments, the subject has experienced and / or exhibits at least one symptom of the disease, disorder, or condition to be treated and / or prevented.
[0089] The terms "therapeutic regimen" and "dosing regimen" are used interchangeably to refer to the dosages and timing of administration of the various therapeutic agents in combination.
[0090] The term "pharmaceutical combination" as used herein refers to a pharmaceutical therapy obtained by mixing or combining more than one active ingredient and includes both fixed combinations of the active ingredients and non-fixed combinations of the active ingredients.
[0091] The term "combination therapy" as used herein refers to a dosing regimen of two different therapeutically active agents (i.e., components of a combination or combination partner) wherein the therapeutically active agents are administered together or separately in a manner prescribed by a healthcare professional or under a regulatory regime as defined herein.
[0092] As used herein, the terms "modulate," "modulating," or "modulation" refer to regulating or adjusting (eg, increasing or decreasing) and can include, for example, agonism, partial agonism, or antagonism. Compound
[0093] The present application provides a compound of formula I: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein: Ring A is in Bond represents a single bond or a double bond; Wherein X is N or CH, and Y is O, CH2, CHR 3 , or C(R 3 )2; Z 1 Is N or CR 4 ; Z 2 Is N or CR 4 ; Ring B does not exist; or Ring B exists and together with the carbon atom of the phenyl group to which it is fused forms C5-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein Ring B is independently optionally substituted with 1 to 5 R 1 ; p is 0, 1, 2, or 3; n is 0, 1, 2, or 3; m is 0, 1, 2, or 3; R 1 are independently halogen, cyano, nitro, oxo, -OR 10 , -SR 10 ,-N(R 10 )2,-C(O)R 10 ,-C(O)OR 10 ,-OC(O)R 10 ,-OC(O)OR 10 ,-C(O)N(R 10 )2,-NR 10 C(O)R 10 ,-OC(O)N(R 10 )2,-NR 10 C(O)OR 10 , -NR 10 C(O)N(R 10 )2,-S(O)R 10 , -S(O)2R 10 ,-S(O)N(R 10 )2,-S(O)2N(R 10 )2,-NR 10 S(O)R 10 , -NR 10 S(O)2R 10 , -NR 10 S(O)N(R 10 )2,-NR 10 S(O)2N(R 10 )2,C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Halogenated alkyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z; R 2 is hydrogen, heterocyclic, C 1-6 Alkyl, or C optionally substituted with 1-6 Alkyl: C 1-6Alkoxy, C 1-6 Thioalkoxy, C 1-6 Halogenated alkoxy, S(O)2(C 1-6 Alkyl), C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, phenyl, or 5-membered to 6-membered heteroaryl; wherein C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, phenyl, or 5-membered to 6-membered heteroaryl are each optionally substituted with 1 to 4 R 12 ; R 3 is cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 cycloalkyl; or Two R's 3 Together with the carbon atoms to which they are attached, they form C 3-10 Cycloalkyl or heterocyclic group; wherein C 3-10 Cycloalkyl or heterocyclyl are each independently optionally substituted with 1 to 2 halogens; R 4 are independently hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 5 is hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 6 is hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 7 is hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 10 are each independently hydrogen, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)R 20 ,-C(O)OR 20 ,-C(O)N(R 20 )2,-S(O)R 20 , -S(O)2R 20 ,-S(O)N(R 20 )2, or -S(O)2N(R 20 )2; where C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z 1a ; R 12 Each independently selected from cyano, halogen, hydroxy, SH, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-6 Cycloalkyl, amino, C 1-6 Alkylamino, and di-C 1-6 Alkylamino; Z is independently halogen, cyano, nitro, oxo, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10Cycloalkyl, heterocyclyl, aryl, heteroaryl, -L 1 -C 1-9 Alkyl, -L 1 -C 2-9 Alkenyl, -L 1 -C 2-9 Alkynyl, -L 1 -C 3-10 Cycloalkyl, -L 1 -heterocyclyl, -L 1 -aryl, or -L 1 -heteroaryl; wherein C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z 1a ; L 1 Each independently represents -O-, -S-, -NR 20 -, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NR 20 -,-NR 20 C(O)-,-OC(O)NR 20 -,-NR 20 C(O)O-,-NR 20 C(O)NR 20 -, -S(O)-, -S(O)2-, -S(O)NR 20 -,-S(O)2NR 20 -,-NR 20 S(O)-,-NR 20 S(O)2-,-NR 20 S(O)NR 20 -, or -NR 20 S(O)2NR 20 -; R 20 are each independently hydrogen, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein R 20 C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z 1a ;and Z 1aEach is independently halogen, hydroxy, cyano, nitro, oxo, -SH, -NH2, -NH-C 1-9 Alkyl, -N(C 1-9 Alkyl)2,-SC 1-9 Alkyl, C 1-9 Alkoxy, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-6 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein Z 1a -NH-C 1-9 Alkyl, -N(C 1-9 Alkyl)2, -SC 1-9 Alkyl, C 1-9 Alkoxy, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-6 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 groups selected from C 1-9 Substituents of alkyl, oxo, halogen, hydroxy, and cyano.
[0094] The present application provides a compound of formula I': or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein: Ring A is in Bond represents a single bond or a double bond; Wherein X is N or CH, and Y is O, CH2, CHR 3 , or C(R 3 )2; Z 1 Is N or CR 4 ; Z 2 Is N or CR 4 ; Ring B does not exist; or Ring B exists and together with the carbon atom of the benzene ring to which it is fused forms C 5-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein Ring B is independently optionally substituted with 1 to 5 R 1 ; p is 0, 1, 2, or 3; n is 0, 1, 2, or 3; m is 0, 1, 2, or 3; R 1 are independently halogen, cyano, nitro, oxo, -OR 10, -SR 10 ,-N(R 10 )2,-C(O)R 10 ,-C(O)OR 10 ,-OC(O)R 10 ,-OC(O)OR 10 ,-C(O)N(R 10 )2,-NR 10 C(O)R 10 ,-OC(O)N(R 10 )2,-NR 10 C(O)OR 10 , -NR 10 C(O)N(R 10 )2,-S(O)R 10 , -S(O)2R 10 ,-S(O)N(R 10 )2,-S(O)2N(R 10 )2,-NR10S(O)R 10 , -NR 10 S(O)2R10,-NR 10 S(O)N(R 10 )2,-NR 10 S(O)2N(R 10 )2,C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Halogenated alkyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z; R 2 is hydrogen, heterocyclic, C 1-6 Alkyl, or C substituted with 1-6 Alkyl: C 1-6 Alkoxy, C 1-6 Thioalkoxy, C 1-6 Halogenated alkoxy, S(O)2(C 1-6 Alkyl), C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, phenyl, or 5-membered to 6-membered heteroaryl; wherein C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, phenyl, or 5-membered to 6-membered heteroaryl are each optionally substituted with 1 to 4 R 12 ; R 3 is cyano, halogen, hydroxyl, C1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 cycloalkyl; or Two R's 3 Together with the carbon atoms to which they are attached, they form C 3-10 Cycloalkyl or heterocyclic group; wherein C 3-10 Cycloalkyl or heterocyclyl are each independently optionally substituted with 1 to 2 halogens; R 4 are independently hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 5 is hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 6 is hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 7 is hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 10 are each independently hydrogen, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)R 20 ,-C(O)OR 20 ,-C(O)N(R 20 )2,-S(O)R 20 , -S(O)2R 20 ,-S(O)N(R 20 )2, or -S(O)2N(R 20 )2; where C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z 1a ; R 12 Each independently selected from cyano, halogen, hydroxy, SH, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-6 Cycloalkyl, amino, C 1-6 Alkylamino, and di-C 1-6 Alkylamino; Z is independently halogen, cyano, nitro, oxo, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -L 1 -C 1-9 Alkyl, -L 1 -C 2-9 Alkenyl, -L 1 -C 2-9 Alkynyl, -L 1 -C 3-10 Cycloalkyl, -L 1 -heterocyclyl, -L 1 -aryl, or -L 1-heteroaryl; wherein C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z 1a ; L 1 Each independently represents -O-, -S-, -NR 20 -, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NR 20 -,-NR 20 C(O)-,-OC(O)NR 20 -,-NR 20 C(O)O-,-NR 20 C(O)NR 20 -, -S(O)-, -S(O)2-, -S(O)NR 20 -,-S(O)2NR 20 -,-NR 20 S(O)-,-NR 20 S(O)2-,-NR 20 S(O)NR 20 -, or -NR 20 S(O)2NR 20 -; R 20 are each independently hydrogen, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein R 20 C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z 1a ;and Z 1a Each is independently halogen, hydroxy, cyano, nitro, oxo, -SH, -NH2, -NH-C 1-9 Alkyl, -N(C 1-9 Alkyl)2,-SC 1-9 Alkyl, C 1-9 Alkoxy, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-6 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein Z 1a -NH-C1-9 Alkyl, -N(C 1-9 Alkyl)2, -SC 1-9 Alkyl, C 1-9 Alkoxy, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-6 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 groups selected from C 1-9 Substituents of alkyl, oxo, halogen, hydroxy, and cyano.
[0095] In certain embodiments, one or more of the following occurs: A) Ring A is B)R 5 and R 6 One is not hydrogen; C) Ring B is present; D) At least one R 4 It’s not hydrogen; E)R 2 is optionally substituted with 1 to 4 R 12 a heterocyclic group; or F) At least one R 12 Yes-C(O)-C 1-6 alkyl.
[0096] In certain embodiments, one or more of the following occurs: A) Ring A is B)R 5 and R 6 One is not hydrogen; C)R 2 is optionally substituted with 1 to 4 R 12 a heterocyclic group; or D) At least one R 12 Yes-C(O)-C 1-6 alkyl.
[0097] In certain embodiments, Ring A is:
[0098] In certain embodiments, Ring A is In certain embodiments, Ring A is In certain embodiments, Ring A is In certain embodiments, Ring A is In certain embodiments, Ring A is In certain embodiments, Ring A is In certain embodiments, Ring A is In certain embodiments, Ring A is In certain embodiments, Ring A is In certain embodiments, Ring A is In certain embodiments, Ring A is
[0099] In certain embodiments, Ring A is
[0100] In certain embodiments, R 5 and R 6 One of them is not hydrogen.
[0101] In certain embodiments, Ring B is present.
[0102] In certain embodiments, at least one R 4 Not hydrogen.
[0103] In certain embodiments, Z 1 It's CR 4 ; and R 4 is not hydrogen. In certain embodiments, Z 1 It's CR 4 ; and R 4 is not hydrogen. In certain embodiments, Z 2 It's CR 4 ; and R 4 Not hydrogen.
[0104] In certain embodiments, R 2 is optionally substituted with 1 to 4 R 12 heterocyclic group.
[0105] In certain embodiments, at least one R 12 Yes-C(O)-C 1-6 alkyl.
[0106] In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2.
[0107] In certain embodiments, m is 0.
[0108] In certain embodiments, R 3 Each independently is C 1-9 alkyl.
[0109] In certain embodiments, n is 1; and R 3 It's methyl.
[0110] In certain embodiments, both R 3Together with the carbon atoms to which they are attached, they form C 3-10 Cycloalkyl or heterocyclic group; wherein C 3-10 Cycloalkyl or heterocyclyl are each independently optionally substituted with 1 to 2 halogens. 3 Together with the carbon atoms to which they are attached, they form a C 3-10 In certain embodiments, two R 3 Together with the carbon atoms to which they are attached, they form C 3-10 Cycloalkyl.
[0111] In certain embodiments, the present application provides a compound of formula IA: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein the dotted line, ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , n, and p are each independently as defined herein.
[0112] In certain embodiments, the present application provides a compound of formula IB: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , n, and p are each independently as defined herein.
[0113] In certain embodiments, the present application provides a compound of formula IC: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6, n, and p are each independently as defined herein.
[0114] In certain embodiments, the present application provides a compound of formula ID: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , and p are each independently as defined herein.
[0115] In certain embodiments, the present application provides a compound of formula IE: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , n, and p are each independently as defined herein.
[0116] In certain embodiments, the present application provides a compound of formula IF: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , n, and p are each independently as defined herein.
[0117] In certain embodiments, the present application provides a compound of formula I'A: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein the dotted line, ring B, Z 1 , Z 2 、R 1、R 2 、R 3 、R 4 、R 5 、R 6 , n, and p are each independently as defined herein.
[0118] In certain embodiments, the present application provides a compound of formula I'B: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , n, and p are each independently as defined herein.
[0119] In certain embodiments, the present application provides a compound of formula I'C: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , n, and p are each independently as defined herein.
[0120] In certain embodiments, the present application provides a compound of formula I'D: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , and p are each independently as defined herein.
[0121] In certain embodiments, the present application provides a compound of formula I'E: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , n, and p are each independently as defined herein.
[0122] In certain embodiments, the present application provides a compound of formula I'F: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof; wherein ring B, Z 1 , Z 2 、R 1 、R 2 、R 3 、R 4 、R 5 、R 6 , n, and p are each independently as defined herein.
[0123] In some embodiments, R 5 is cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl.
[0124] In some embodiments, R 6 is cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl.
[0125] In some embodiments, R 5 is hydrogen, halogen, or C 1-9 In some embodiments, R 5 is hydrogen or halogen. In some embodiments, R 5 is hydrogen. In some embodiments, R 5 It's a halogen.
[0126] In some embodiments, R 6 is hydrogen, halogen, or C 1-9 In some embodiments, R 6 is hydrogen. In some embodiments, R 6 is halogen. In some embodiments, R 6 It is C 1-9 Alkoxy.
[0127] In some embodiments, R 5 and R 6 At least one of them is halogen or C 1-9 Alkoxy.
[0128] In some embodiments, R 5 is hydrogen or halogen; and R 6 Is a halogen or C 1-9 In some embodiments, R 5 is hydrogen; and R 6 Is a halogen or C 1-9 In some embodiments, R 5 is hydrogen; and R 6 is fluorine or methoxy.
[0129] In some embodiments, R 5 is a halogen; and R 6 is hydrogen, halogen, or C 1-9 In some embodiments, R 5 is a halogen; and R 6 It's hydrogen.
[0130] In some embodiments, Ring B is absent. In some embodiments, Ring B is present.
[0131] In some embodiments, Ring B is present and together with the carbon atom of the benzene ring to which it is fused forms C 5-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein Ring B is independently optionally substituted with 1 to 5 R 1 .
[0132] In some embodiments, Ring B is present and together with the carbon atoms of the benzene ring to which it is fused, forms an optionally substituted 1 to 5 R 1 C 5-10 Cycloalkyl.
[0133] In some embodiments, Ring B is present and together with the carbon atoms of the benzene ring to which it is fused, forms an optionally substituted 1 to 5 R 1 of a heterocyclic group.
[0134] In some embodiments, Ring B is present and together with the carbon atoms of the benzene ring to which it is fused, forms an optionally substituted 1 to 5 R 1 of aromatic groups.
[0135] In some embodiments, Ring B is present and together with the carbon atoms of the benzene ring to which it is fused, forms an optionally substituted 1 to 5 R 1 of heteroaryl.
[0136] In some embodiments, part yes
[0137] In some embodiments, part yes
[0138] In some embodiments, part yes
[0139] In some embodiments, part yes
[0140] In some embodiments, part yes
[0141] In some embodiments, part yes
[0142] In some embodiments, part yes
[0143] In some embodiments, part yes
[0144] In some embodiments, R 1 are each independently halogen, cyano, or C 1-9 Halogenated alkyl.
[0145] In some embodiments, p is 1. In some embodiments, p is 1; and R 1 is halogen, cyano, or C 1-9 Halogenated alkyl.
[0146] In some embodiments, part yes
[0147] In some embodiments, part yes
[0148] In some embodiments, part yes
[0149] In some embodiments, part yes
[0150] In some embodiments, R 1 is halogen, cyano, or C 1-9 In some embodiments, R 1 is halogen or cyano. In some embodiments, R 1 It is chlorine or cyano.
[0151] In some embodiments, at least one R 4 Not hydrogen.
[0152] In some embodiments, at least one R 4 It's a halogen.
[0153] In some embodiments, Z 2 It's CR 4 ; Z 2 R 4 is cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl.
[0154] In some embodiments, R 2 is a heterocyclic group or substituted with C 1-6 Alkoxy, C 1-6 Thioalkoxy, C 1-6 Halogenated alkoxy, S(O)2(C 1-6 Alkyl), C 3-6 C cycloalkyl, 3- to 6-membered heterocyclic group, phenyl, or 5- to 6-membered heteroaryl 1-6 Alkyl; wherein heterocyclic, C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, phenyl, or 5-membered to 6-membered heteroaryl are each optionally substituted with 1 to 4, or 1 to 3, or 1 to 2, or 1 R 12 .
[0155] In some embodiments, R 2 is a heterocyclic group or substituted with C 3-6 C of a cycloalkyl group, a 3-membered to 6-membered heterocyclic group, or a 5-membered to 6-membered heteroaryl group 1-6 Alkyl; wherein heterocyclic, C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, or 5-membered to 6-membered heteroaryl are each optionally substituted with 1 to 4, or 1 to 3, or 1 to 2, or 1 R 12 .
[0156] In some embodiments, R 2 is a heterocyclic group or substituted with C 3-6 C of a cycloalkyl group, a 3-membered to 6-membered heterocyclic group, or a 5-membered to 6-membered heteroaryl group 1-6 Alkyl; wherein heterocyclic, C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, or 5-membered to 6-membered heteroaryl are each optionally substituted with 1 to 4, or 1 to 3, or 1 to 2, or 1 R 12 .
[0157] In some embodiments, R 2 is a heterocyclic group or substituted with C 3-6 C of a cycloalkyl group, a 3-membered to 6-membered heterocyclic group, or a 5-membered to 6-membered heteroaryl group 1-6 Alkyl; wherein heterocyclic, C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, or 5-membered to 6-membered heteroaryl, each optionally substituted with 1 to 4, or 1 to 3, or 1 to 2, or 1 cyano, halogen, C 1-6 Alkyl, C 1-6 Cyanoalkyl, or -C(O)-C 1-6 alkyl.
[0158] In some embodiments, R 2 is optionally substituted with 1 to 4 R 12 heterocyclic group.
[0159] In some embodiments, R 2 Is replaced by C 1-6 3-6 membered heterocyclic group of alkoxy.
[0160] R 2 is hydrogen, heterocyclic, C 1-6 Alkyl, or C substituted with 1-6 Alkyl: C 1-6 Alkoxy, C 1-6 Thioalkoxy, C 1-6 Halogenated alkoxy, S(O)2(C 1-6 Alkyl), C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, phenyl, or 5-membered to 6-membered heteroaryl; wherein C 3-6Cycloalkyl, 3-membered to 6-membered heterocyclyl, phenyl, or 5-membered to 6-membered heteroaryl are each optionally substituted with 1 to 4 R 12 ;
[0161] R 12 Each independently selected from cyano, halogen, hydroxy, SH, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -C(O)-C 1-6 Alkyl, C 3-6 Cycloalkyl, amino, C 1-6 Alkylamino, and di-C 1-6 Alkylamino;
[0162] In some embodiments, R 4 are each independently hydrogen or halogen.
[0163] In some embodiments, R 7 It's hydrogen.
[0164] In some embodiments, Z 1 It's N.
[0165] In some embodiments, Z 2 It's N.
[0166] In some embodiments, part yes
[0167] In certain embodiments, the present application provides a compound selected from Table 1, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof: Table 1
[0168] In certain embodiments, the present application provides a compound selected from compounds 103, 104, 108, 109, 110, 111, 112, 113, 114, 115, 116, 118, 119, 120, 121, 122, 123, 124 and 127, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug thereof.
[0169] The compounds of formula I include pharmaceutically acceptable salts thereof. Furthermore, the compounds of formula I also include other salts of the compounds, which are not necessarily pharmaceutically acceptable salts and which can be used as intermediates for preparing and / or purifying the compounds of formula I and / or separating the enantiomers of the compounds of formula I.
[0170] It will be further understood that the compounds of Formula I or their salts may be isolated as solvates, and therefore any such solvates are included within the scope of this application. For example, the compounds of Formula I and their salts may exist in unsolvated form as well as in solvated form with pharmaceutically acceptable solvents such as water, ethanol, etc. Pharmaceutical compositions and administration
[0171] When used as a drug, the compound described herein (for example, a compound of Formula I or its small general formula, or a pharmaceutically acceptable salt thereof, an isotopically enriched analog, a stereoisomer, a mixture of stereoisomers, or a prodrug) can be administered in the form of a pharmaceutical composition. These compositions can be prepared in a manner known to the pharmaceutical field and can be administered by a variety of routes, depending on whether local or systemic treatment is needed and depending on the area to be treated. Administration can be local (including transdermal, epidermal, ocular, and applied to mucous membranes, including intranasal, vaginal and rectal delivery), pulmonary (for example, inhalation or insufflation of powders or aerosols, including by a nebulizer; intratracheal or intranasal), oral and parenteral. Oral administration can include a dosage form formulated for once daily or twice daily (BID) administration. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection or infusion; or intracranial (for example, intrathecal or intraventricular) administration. The form of parenteral administration can be a single bolus dosage form, or can be, for example, a continuous infusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners, and the like may be necessary or desirable.
[0172] The application also provides pharmaceutical compositions, which include the compound of Formula I or its small general formula as active ingredient or its pharmaceutically acceptable salt, isotope-enriched analog, stereoisomer, mixture of stereoisomers or prodrug, and the combination of one or more pharmaceutically acceptable excipients (carriers). For example, pharmaceutical compositions are prepared using the compound of Formula I or its small general formula or its pharmaceutically acceptable salt, isotope-enriched analog, stereoisomer, mixture of stereoisomers or prodrug. In some embodiments, the composition is suitable for topical application. When preparing the composition provided by the application, the active ingredient is usually mixed with an excipient, diluted by an excipient or encapsulated in a carrier in the form of, for example, capsules, sachets, paper or other containers. When an excipient is used as a diluent, it can be a solid, semisolid or liquid material, which is used as a vehicle, carrier or medium for the active ingredient. Thus, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft or hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In some embodiments, the composition is formulated for oral administration. In some embodiments, the composition is a solid oral dosage form. In some embodiments, the composition is formulated as a tablet or capsule.
[0173] The application also provides a pharmaceutical composition comprising a compound of Formula I or its small general formula or its pharmaceutically acceptable salt, isotope-enriched analog, stereoisomer, mixture of stereoisomers or prodrug and a pharmaceutically acceptable excipient. The pharmaceutical composition comprising a compound of Formula I or its small general formula or its pharmaceutically acceptable salt, isotope-enriched analog, stereoisomer, mixture of stereoisomers or prodrug as an active ingredient can be prepared as follows: the compound of Formula I or its small general formula or its pharmaceutically acceptable salt, isotope-enriched analog, stereoisomer, mixture of stereoisomers or prodrug and a pharmaceutical carrier are fully and uniformly mixed according to conventional drug compounding technology. Carrier can present various forms according to desired route of administration (for example, oral, parenteral). In some embodiments, composition is a solid oral composition.
[0174] Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers can be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.
[0175] Methods of formulating pharmaceutical compositions have been described in numerous publications, such as Pharmaceutical Dosage Forms: Tablets, Second Edition, Revised and Expanded, Volumes 1–3, ed. Lieberman et al.; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1–2, ed. Avis et al.; and Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1–2, ed. Lieberman et al.; published by Marcel Dekker, Inc.
[0176] In some embodiments, the compound or pharmaceutical composition can be administered in combination with one or more conventional pharmaceutical excipients. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers; aluminum oxide; aluminum stearate; lecithin; self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopheryl polyethylene glycol 1000 succinate; surfactants for pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymer delivery matrices; serum proteins such as human serum albumin; buffer substances such as phosphate, tris, glycine, sorbic acid, potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water; salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride; zinc salts; colloidal silicon dioxide; magnesium trisilicate; polyvinyl pyrrolidone; cellulose-based substances; polyethylene glycol; sodium carboxymethyl cellulose; polyacrylates; waxes; polyethylene-polyoxypropylene block copolymers; and lanolin. Cyclodextrins such as α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins (including 2-hydroxypropyl-β-cyclodextrin and 3-hydroxypropyl-β-cyclodextrin), or other dissolved derivatives can also be used to enhance the delivery of the compounds described herein. The following dosage forms or compositions can be prepared, which contain chemical entities described herein in the range of 0.005% to 100% and the remainder consists of non-toxic excipients. The compositions covered can contain 0.001%-100% of the chemical entities described herein, in one embodiment 0.1-95% of the chemical entities described herein, in another embodiment 75-85% of the chemical entities described herein, and in a further embodiment 20-80% of the chemical entities described herein. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art; for example, see Remington: The Science and Practice of Pharmacy, 22nd ed. (Pharmaceutical Press, London, UK. 2012).
[0177] In some embodiments, the compounds and pharmaceutical compositions described herein or their pharmaceutical compositions can be administered to a patient in need thereof via any acceptable route of administration. Acceptable routes of administration include, but are not limited to, buccal, cutaneous, intracervical, intrasinus, intratracheal, enteral, epidural, interstitial, intraperitoneal, intraarterial, intrabronchial, intracapsular, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intrasinus, intraspinal, intrasynovial, intratesticular, intrathecal, intratubular, intratumoral, intrauterine, intravascular, intravenous, nasal (e.g., intranasal), nasogastric, oral, parenteral, transdermal, epidural (peridural), rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, tracheal, ureteral, urethra and vaginal. In some embodiments, the route of administration is parenteral (e.g., intratumor).
[0178] In some embodiments, the compound of Formula I or its small general formula described herein, or its pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug, or its pharmaceutical composition, can be formulated for parenteral administration, for example, formulated for injection via intra-arterial, intrasternal, intracranial, intravenous, intramuscular, subcutaneous, or intraperitoneal routes. For example, such a composition can be prepared as an injectable form, or as a liquid solution or as a suspension; a solid form suitable for preparing a solution or suspension when a liquid is added before injection can also be prepared; the preparation can also be emulsified. The preparation of such a preparation is known to those skilled in the art in view of the disclosure of this application. In some embodiments, the device is used for parenteral administration. For example, such a device can include a needle syringe, a microneedle syringe, a needle-free syringe, and an infusion technique.
[0179] In some embodiments, pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol solutions; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In some embodiments, the form must be sterile and must be fluid to the extent that it can be easily injected. In some embodiments, the form should be stable under the conditions of manufacture and storage and must be protected against the contaminating action of microorganisms (such as bacteria and fungi).
[0180] In some embodiments, carrier can also be solvent or dispersion medium, and described solvent or dispersion medium comprise for example water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol etc.), its suitable mixture and vegetable oil.In some embodiments, suitable fluidity can be maintained as follows: for example, by using coating such as lecithin, by maintaining required particle size in the case of dispersion, and by using surfactant.In some embodiments, the effect of prevention microorganism can be realized by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal etc. In some embodiments, include isotonic agent, for example sugar or sodium chloride. In some embodiments, the extended absorption of injectable composition can be realized by using the medicament (for example aluminum monostearate and gelatin) that delays absorption in compositions.
[0181] In some embodiments, sterile injectable solutions are prepared by combining a compound of Formula I or its minor general formula, or a pharmaceutically acceptable salt thereof, an isotopically enriched analog, a stereoisomer, a mixture of stereoisomers, or a prodrug as needed in a suitable solvent with the various other ingredients listed above, followed by filtration sterilization. In some embodiments, dispersions are prepared by incorporating various sterilized active ingredients into a sterile vehicle containing a basic dispersion medium and the desired other ingredients from those ingredients listed above. In some embodiments, sterile powders are used to prepare sterile injectable solutions. In some embodiments, the preparation method is vacuum drying and freeze drying technology, which produces a powder of the active ingredient plus any other desired ingredients obtained by sterile filtering the solution previously.
[0182] In some embodiments, pharmacologically acceptable excipients for use in rectal compositions as gels, creams, enemas, or rectal suppositories include, but are not limited to, any one or more of the following: cocoa butter glycerides, synthetic polymers (e.g., polyvinyl pyrrolidone), PEG (e.g., PEG ointment), glycerin, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol, petrolatum, anhydrous lanolin, shark liver oil, sodium saccharin, menthol, sweet almond oil, sorbitol, sodium benzoate, anoxid SBN, vanilla essential oil, aerosols, parabens in phenoxyethanol, sodium methylparaoxybenzoate, sodium propylparaoxybenzoate, diethylamine, carbomer, carbopol, methyloxybenzoate, polyethylene glycol cetylstearyl ether, cocoyl caprylate, methylparaben ... caprylocaprate), isopropyl alcohol, propylene glycol, liquid paraffin, xanthan gum, carboxy-metabisulfite, sodium EDTA, sodium benzoate, potassium metabisulfite, grapefruit seed extract, methylsulfonylmethane (MSM), lactic acid, glycine, vitamins such as vitamins A and E, and potassium acetate.
[0183] In some embodiments, suppositories can be prepared as follows: a compound of Formula I or its minor general formula described herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, or a pharmaceutical composition is mixed with a suitable non-irritating excipient or carrier, such as cocoa butter, polyethylene glycol, or a suppository wax, which is solid at room temperature but liquid at body temperature and thus melts in the rectum and releases the active compound. In some embodiments, the composition for rectal administration is in the form of an enema.
[0184] In some embodiments, a compound of Formula I or its smaller general formula as described herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, or a pharmaceutical composition thereof, can be formulated for local delivery to the digestive tract or gastrointestinal tract by oral administration (e.g., solid or liquid dosage form).
[0185] In some embodiments, solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In some embodiments, a compound of Formula I or its minor general formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is mixed with one or more pharmaceutically acceptable excipients such as sodium citrate or dicalcium phosphate and / or each of the following: a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders, such as carboxymethyl cellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and alginate; c) humectants such as glycerol; d) disintegrants such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution delay agents such as paraffin; f) absorption promoters such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) adsorbents such as kaolin and bentonite; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. For example, in the case of capsules, tablets, and pills, the dosage form may also include a buffer. In some embodiments, similar types of solid compositions may also be used as fillers in soft-filled and hard-filled gelatin capsules using excipients such as lactose (lactose / milk sugar) and high molecular weight polyethylene glycols.
[0186] In some embodiments, the pharmaceutical composition will be in the form of a unit dosage form such as a pill or tablet, and therefore, in addition to containing the compound of Formula I or its smaller general formula provided herein, or its pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug, the composition may also contain: diluents such as lactose, sucrose, dicalcium phosphate, etc.; lubricants such as magnesium stearate, etc.; and binders such as starch, gum arabic, polyvinyl pyrrolidone, gelatin, cellulose, cellulose derivatives, etc. In some embodiments, in another solid dosage form, a powder, granulation (marume), solution or suspension (for example, in propylene carbonate, vegetable oil, PEG, poloxamer 124 or triglyceride) is encapsulated in a capsule (gelatin or cellulose capsule). In some embodiments, unit dosage forms in which one or more compounds and pharmaceutical compositions or other active agents are physically separated as provided herein are also encompassed; for example, capsules with granules of each drug (or tablets in a capsule); two-layer tablets; two-chamber capsule tablets, etc. In some embodiments, enteric-coated or delayed-release oral dosage forms are also contemplated.
[0187] In some embodiments, other physiologically acceptable compounds may include wetting agents, emulsifiers, dispersants, or preservatives, which are particularly useful for preventing the growth or activity of microorganisms. For example, various preservatives are well known and include, for example, phenol and ascorbic acid.
[0188] In some embodiments, the excipient is sterile and generally free of unwanted substances. For example, these compositions can be sterilized by conventional, well-known sterilization techniques. In some embodiments, for various oral dosage form excipients, such as tablets and capsules, sterilization is not required. For example, United States Pharmacopoeia / National Formulary (USP / NF) standards may be sufficient.
[0189] In some embodiments, the compound of Formula I or its small general formula described herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, or a pharmaceutical composition thereof, is formulated for ocular administration. In some embodiments, ocular administration may include, but is not limited to, one or more of any one of the following: viscogens (e.g., carboxymethyl cellulose, glycerol, polyvinyl pyrrolidone, polyethylene glycol); stabilizers (e.g., Pluronic (triblock copolymer), cyclodextrin); preservatives (e.g., benzalkonium chloride, ETDA, SofZia (boric acid, propylene glycol, sorbitol, and zinc chloride; Alcon Laboratories, Inc.), Purite (stable oxychloride complex; Allergan, Inc.)).
[0190] In some embodiments, the compounds of Formula I or its general formula described herein, or their pharmaceutically acceptable salts, isotopically enriched analogs, stereoisomers, mixtures of stereoisomers, or prodrugs, or pharmaceutical compositions thereof, are formulated for topical application to the skin or mucous membranes (e.g., transdermal or transdermal). In some embodiments, topical compositions may include ointments and creams. In some embodiments, ointments are semisolid formulations typically based on paraffin or other petroleum derivatives. In some embodiments, creams containing the selected active agent are typically viscous liquids or semisolid emulsions, often oil-in-water or water-in-oil. For example, a cream base is typically water-washable and contains an oil phase, an emulsifier, and an aqueous phase. For example, the oil phase, sometimes also referred to as the "inner" phase, typically includes paraffin and fatty alcohols such as cetyl alcohol or stearyl alcohol; although not required, the aqueous phase typically exceeds the oil phase in volume and typically contains a humectant. In some embodiments, the emulsifier in the cream formulation is typically a nonionic, anionic, cationic, or amphoteric surfactant. In some embodiments, as with other carriers or vehicles, an ointment base should be inert, stable, nonirritating, and nonsensitizing.
[0191] In any of the foregoing embodiments, the pharmaceutical compositions described herein may comprise one or more of the following: lipids, interbilayer cross-linked multilamellar vesicles, biodegradable poly (D, L-lactic-co-glycolic acid) (PLGA)-based or polyanhydride-based nanoparticles or microparticles, and nanoporous particle-loaded lipid bilayers.
[0192] The amount of the compound in the pharmaceutical composition or formulation can vary over the entire range used by those skilled in the art. Typically, by weight percentage (wt%), the formulation will contain about 0.01-99.99wt% of the compound of the present application based on the total formulation, with the remainder being one or more suitable pharmaceutical excipients. In one embodiment, the compound is present in an amount of about 1-80wt%. Representative pharmaceutical formulations are described below. Formulation Example 1 - Tablet Formulation
[0193] The following ingredients are thoroughly mixed intimately and compressed into single scored tablets. Formulation Example 2 - Capsule Formulation
[0194] The following ingredients are thoroughly mixed intimately and filled into hard shell gelatin capsules. Formulation Example 3 - Suspension Formulation
[0195] The following ingredients are mixed to form a suspension for oral administration. Formulation Example 4 - Injectable Formulation
[0196] The following ingredients are mixed to form an injectable formulation. Formulation Example 5 - Suppository Formulation
[0197] The total weight of 2.5g of suppositories is prepared by mixing the compound of the present application with H-15 (triglycerides of saturated vegetable fatty acids; Riches-Nelson, Inc., New York) was prepared by mixing and having the following composition:
[0198] In some embodiments, the dosage of the compound of Formula I or its little general formula or its pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug is determined based on multiple factors, and the factors include but are not limited to, the severity of the medical condition of type, age, body weight, sex, patient, the medical condition of patient, route of administration and the activity of compound or its pharmaceutically acceptable salt or solvate.In some embodiments, the appropriate dosage for particular circumstances can be determined by those skilled in the art of medical science.In some embodiments, total daily dose can be divided into multiple portions and in one day, press multiple portions and use or by providing the mode of continuous delivery to use.
[0199] In some embodiments, the compound of Formula I or its lesser general formula, or its pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug is administered at a dosage of about 0.01 to about 1000 mg, for example, about 0.1 to about 30 mg, about 10 to about 80 mg, about 0.5 to about 15 mg, about 50 mg to about 200 mg, about 100 mg to about 300 mg, about 200 to about 400 mg, about 300 mg to about 500 mg, about 400 mg to about 600 mg, about 500 mg to about 800 mg, about 600 mg to about 900 mg, or about 700 mg to about 1000 mg. In some embodiments, the dosage is a therapeutically effective amount.
[0200] In some embodiments, the compound of Formula I or its smaller general formula described herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is administered at a dose of about 0.0002 mg / Kg to about 100 mg / Kg (e.g., about 0.0002 mg / Kg to about 50 mg / Kg; about 0.0002 mg / Kg to about 25 mg / Kg; about 0.0002 mg / Kg to about 10 mg / Kg). g; about 0.0002 mg / Kg to about 5 mg / Kg; about 0.0002 mg / Kg to about 1 mg / Kg; about 0.0002 mg / Kg to about 0.5 mg / Kg; about 0.0002 mg / Kg to about 0.1 mg / Kg; about 0.001 mg / Kg to about 50 mg / Kg; about 0.001 mg / Kg to about 25 mg / Kg; about 0.001 mg / Kg to about 10 mg / Kg; about 0.001 mg / Kg to about 5 mg / Kg; about 0.001 mg / Kg to about 1 mg / Kg; about 0.001 mg / Kg to about 0.5 mg / Kg; about 0.001 mg / Kg to about 0.1 mg / Kg; about 0.01 mg / Kg to about 50 mg / Kg; about 0.01 mg / Kg to about 25 mg / Kg; about 0.01 mg / Kg to about 10 mg / Kg; about 0.01 mg / Kg to about 5 mg / Kg; about 0.01 mg / Kg to In some embodiments, the compound of Formula I or its subformula as described herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is administered at a dose of about 100 mg / Kg.
[0201] In some embodiments, the foregoing dosages of a compound of Formula I or its lesser formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, can be administered daily (e.g., in a single dose or two or more divided doses) or non-daily (e.g., every other day, every two days, every three days, once a week, twice a week, once every two weeks, once a month).
[0202] In some embodiments, the administration period of a compound of Formula I or its lesser formula described herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or longer. In some embodiments, the period of time during which administration is discontinued is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or longer. In some embodiments, a compound of Formula I or its lesser formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is administered to a patient for a period of time, followed by discontinuation of administration of a compound of Formula I or its lesser formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof for a separate period of time. In some embodiments, a compound of Formula I or its smaller formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is administered for a first time period, and the first time period is followed by a second time period, wherein administration is discontinued during the second time period, followed by a third time period during which administration of a compound of Formula I or its smaller formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof is commenced, and then followed by a fourth time period during which administration is discontinued. For example, the time period during which a compound of Formula I or its smaller formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof is administered and then discontinued can be repeated for a defined time period or an indefinite time period. In some embodiments, the administration period is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or longer.In some embodiments, the period of time during which administration is discontinued is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or longer.
[0203] In some embodiments, a compound of Formula I or its lesser formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is orally administered to a patient one or more times daily (e.g., once a day, twice a day, three times a day, four times a day, or a single daily dose).
[0204] In some embodiments, a compound of Formula I or its lesser general formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is administered to a patient by parenteral administration one or more times per day (e.g., 1 to 4 times per day, once per day, twice per day, three times per day, four times per day, or a single daily dose).
[0205] In some embodiments, a compound of Formula I or its lesser formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, is administered to a patient weekly via parenteral administration. Treatment
[0206] In some embodiments, the application features methods for treating a patient (e.g., a human) having a disease, disorder, or condition, wherein modulation of GLP-1R (e.g., inhibition or attenuation and / or elevation or undesired GLP-1R) is beneficial in treating the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition. In some embodiments, the methods described herein may include or further include treating one or more conditions, complications, or sequelae associated with any one or more of the conditions described herein.
[0207] The present application provides a method for treating GLP-1-related diseases, disorders or conditions, comprising administering to a patient in need thereof an effective amount of a compound of Formula I or its smaller general formula disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug, or pharmaceutical composition thereof.
[0208] In some embodiments, the disease, disorder or condition includes but is not limited to type 1 diabetes, type 2 diabetes, early onset type 2 diabetes, idiopathic type 1 diabetes (type 1b), atypical diabetes of the young (YOAD), maturity-onset diabetes of the young (MODY), latent autoimmune diabetes of adults (LADA), obesity, weight gain from other medications, gout, excessive sugar cravings, hypertriglyceridemia, dyslipidemia, malnutrition-associated diabetes, gestational diabetes, kidney disease, disorders of adipocyte function, sleep apnea, visceral fat deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral arterial disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attack, atherosclerotic cardiovascular disease, traumatic brain injury, peripheral vascular disease, endothelial dysfunction, impaired vascular compliance, restenosis, thrombosis, hypertension, pulmonary artery disease. Hypertension, restenosis after angioplasty, intermittent claudication, hyperglycemia, postprandial lipidosis, metabolic acidosis, ketosis, hyperinsulinemia, dysglucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorders, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, premenstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, macular degeneration, cataracts, glomerulosclerosis, arthritis, osteoporosis, addiction treatment, cocaine dependence, bipolar disorder / major depressive disorder, skin and connective tissue disorders, foot ulcers, psoriasis, primary polydipsia, nonalcoholic steatosis hepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), ulcerative colitis, inflammatory bowel disease, colitis, irritable bowel syndrome, Crohn's disease, short bowel syndrome, Parkinson's disease, Alzheimer's disease, cognitive disorders, schizophrenia, and polycystic ovary syndrome (PCOS).
[0209] In some embodiments, the disease, disorder or condition includes but is not limited to type 2 diabetes, early onset type 2 diabetes, obesity, use of other medications that cause weight gain, gout, excessive sugar cravings, hypertriglyceridemia, dyslipidemia, gestational diabetes, kidney disease, disorders of adipocyte function, sleep apnea, visceral fat deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral arterial disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attack, atherosclerotic cardiovascular disease, hyperglycemia, postprandial lipidosis, metabolic acidosis, Ketosis, hyperinsulinemia, abnormal glucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorder, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, premenstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, bipolar disorder / major depressive disorder, skin and connective tissue disorders, foot ulcer, psoriasis, primary polydipsia, nonalcoholic steatosis hepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), short bowel syndrome, Parkinson's disease, polycystic ovary syndrome (PCOS), or any combination thereof.
[0210] In some embodiments, the disease, disorder, or condition includes but is not limited to type 2 diabetes, early onset type 2 diabetes, obesity, weight gain due to use of other medications, gout, excessive glucose craving, hypertriglyceridemia, dyslipidemia, gestational diabetes, disorders of adipocyte function, visceral fat deposition, myocardial infarction, peripheral arterial disease, stroke, transient ischemic attack, hyperglycemia, postprandial lipidosis, metabolic acidosis, ketosis, hyperinsulinemia, abnormal glucose metabolism, insulin resistance, hepatic insulin resistance, chronic renal failure, syndrome X, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, skin and connective tissue diseases, foot ulcers, or any combination thereof.
[0211] In some embodiments, the compounds, pharmaceutical compositions, and methods for treating patients described herein induce one or more of the following: reduced blood glucose levels (e.g., reduced blood glucose levels), reduced blood hemoglobin A1c (HbA1c) content, promoted insulin synthesis, stimulated insulin secretion, increased mass of β cells, regulated gastric acid secretion, regulated gastric emptying, reduced body mass index (BMI), and / or reduced glucagon production (e.g., content). In certain embodiments, the compounds, pharmaceutical compositions, and methods for treating patients described herein stabilize serum glucose and serum insulin levels (e.g., serum glucose and serum insulin concentrations). The present application also provides a method for regulating glucose or insulin levels in patients in need of such regulation, the method comprising administering to the patient an effective amount of a compound of Formula I or its smaller general formula described herein, or a pharmaceutically acceptable salt thereof, an isotopically enriched analog, a stereoisomer, a mixture of stereoisomers, or a prodrug, or a pharmaceutical composition.
[0212] In some embodiments, the application provides a method for reducing the risk of major adverse cardiovascular events (MACE) in a patient in need thereof (e.g., reducing by about at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%), the method comprising administering to the patient an effective amount of a compound of Formula I disclosed herein or its lesser general formula, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug, or pharmaceutical composition. In some of these embodiments, the patient is an adult diagnosed with type 2 diabetes (T2D). In certain embodiments, the patient is an adult diagnosed with heart disease. In certain embodiments, the patient is an adult diagnosed with type 2 diabetes (T2D) and heart disease. In certain embodiments, the patient is an adult suffering from type 2 diabetes (T2D). In certain embodiments, the patient is an adult suffering from heart disease. In certain embodiments, the patient suffers from type 2 diabetes (T2D) and heart disease. Indications obesity
[0213] In some embodiments, the condition of illness, disease or illness is obesity and the condition of illness, disease or illness related to obesity. The non-limiting examples of obesity and the condition of illness related to obesity include symptomatic obesity, simple obesity, childhood obesity, morbid obesity and abdominal obesity (central obesity characterized by abdominal obesity). The non-limiting examples of symptomatic obesity include endocrine obesity (such as Cushing syndrome (Cushing syndrome), hypothyroidism, insulinoma, obesity type II diabetes, pseudoparathyroidism, hypogonadism), hypothalamic obesity, hereditary obesity (such as Prader-Willi syndrome (Prader-Willi syndrome), Laumubi three syndrome (Laurence-Moon-Biedl syndrome)) and drug-induced obesity (such as steroids, phenothiazines, insulin, sulfonylurea agents or beta-blocker-induced obesity).
[0214] In some embodiments, the condition, disease or illness are associated with obesity. The example of this condition, disease or illness includes but is not limited to glucose tolerance disorder, diabetes (such as type 2 diabetes, obese diabetes), lipid metabolism disorder, hyperlipidemia, hypertension, heart failure, hyperuricemia, gout, fatty liver (including non-alcoholic steatohepatitis (NASH)), coronary heart disease (such as myocardial infarction, angina pectoris), cerebral infarction (such as cerebral thrombosis, transient ischemic attack), bone or joint disease (such as knee osteoarthritis, hip arthritis, deforming spondylitis, low back pain), sleep apnea syndrome, obesity hypoventilation syndrome (Pickwick syndrome (Pickwickian syndrome)), menstrual disorders (such as abnormal menstrual cycle, menstrual volume and cycle abnormality, amenorrhea, abnormal menstrual symptoms), visceral obesity syndrome and metabolic syndrome. In some embodiments, the compound described herein and pharmaceutical composition can be used to treat patients showing the symptoms of obesity and insulin deficiency. diabetes
[0215] In some embodiments, the condition, disease or disorder is diabetes. Non-limiting examples of diabetes include type 1 diabetes, type 2 diabetes (e.g., type 2 diabetes treated with a diet, type 2 diabetes treated with sulfonylureas, very late type 2 diabetes, type 2 diabetes treated with long-term insulin), diabetes (e.g., non-insulin-dependent diabetes, insulin-dependent diabetes), gestational diabetes, obesity diabetes, autoimmune diabetes and borderline diabetes. In some embodiments, the condition, disease or disorder is type 2 diabetes (e.g., type 2 diabetes treated with a diet, type 2 diabetes treated with sulfonylureas, very late type 2 diabetes, type 2 diabetes treated with long-term insulin).
[0216] The present application provides a method for treating diabetes in a patient, comprising (a) determining that the patient has type 2 diabetes, and (b) administering to the patient a therapeutically effective amount of a compound of Formula I or its general formula disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers or prodrug, or pharmaceutical composition thereof.
[0217] The present application provides a method for treating type 2 diabetes in a patient, comprising administering to a patient identified or diagnosed with type 2 diabetes a therapeutically effective amount of a compound of Formula I or its smaller general formula disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug, or pharmaceutical composition thereof.
[0218] The present application also provides a method for treating type 2 diabetes in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula I or its smaller general formula disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug, or pharmaceutical composition thereof.
[0219] In some embodiments, the compounds and pharmaceutical compositions and methods for treating patients with conditions, diseases or disorders described herein (e.g., type 2 diabetes) reduce fasting blood glucose levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating patients with conditions, diseases or disorders described herein (e.g., type 2 diabetes) reduce non-fasting blood glucose levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating patients with conditions, diseases or disorders described herein (e.g., type 2 diabetes) reduce HbA1c levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating patients with conditions, diseases or disorders described herein (e.g., type 2 diabetes) reduce glucagon levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating patients with conditions, diseases or disorders described herein (e.g., type 2 diabetes) reduce and increase insulin levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating patients with conditions, diseases or disorders described herein (e.g., type 2 diabetes) reduce BMI.
[0220] In some embodiments, a reduction in fasting blood glucose levels of about 5% to about 95% indicates treatment of type 2 diabetes. In some embodiments, a reduction in fasting blood glucose levels of about 15% to about 80% indicates treatment of type 2 diabetes. In some embodiments, a reduction in fasting blood glucose levels of about 25% to about 60% indicates treatment of type 2 diabetes. In some embodiments, a reduction in fasting blood glucose levels to about or below 126 mg / dL, about or below 110 mg / dL, or about or below 90 mg / dL indicates treatment of type 2 diabetes.
[0221] In some embodiments, a reduction in non-fasting blood glucose levels of about 5% to about 95% indicates treatment of type 2 diabetes. In some embodiments, a reduction in non-fasting blood glucose levels of about 15% to about 80% indicates treatment of type 2 diabetes. In some embodiments, a reduction in non-fasting blood glucose levels of about 25% to about 60% indicates treatment of type 2 diabetes. In some embodiments, a reduction in non-fasting blood glucose levels to about or below 200 mg / dL, about or below 150 mg / dL, or about or below 130 mg / dL indicates treatment of type 2 diabetes.
[0222] In some embodiments, a reduction in HbA1c levels of about 5% to about 95% indicates treatment of type 2 diabetes. In some embodiments, a reduction in HbA1c levels of about 15% to about 80% indicates treatment of type 2 diabetes. In some embodiments, a reduction in HbA1c levels of about 25% to about 60% indicates treatment of type 2 diabetes. In some embodiments, a reduction in HbA1c levels to about or below 6.5%, about or below 6.0%, or about or below 5.0% indicates treatment of type 2 diabetes.
[0223] In some embodiments, a decrease in glucagon levels of about 5% to about 95% indicates treatment of type 2 diabetes. In some embodiments, a decrease in glucagon levels of about 15% to about 80% indicates treatment of type 2 diabetes. In some embodiments, a decrease in glucagon levels of about 25% to about 60% indicates treatment of type 2 diabetes. In some embodiments, an increase in insulin levels of about 5% to about 95% indicates treatment of type 2 diabetes. In some embodiments, an increase in insulin levels of about 15% to about 80% indicates treatment of type 2 diabetes. In some embodiments, an increase in insulin levels of about 25% to about 60% indicates treatment of type 2 diabetes.
[0224] In some embodiments, a reduction in BMI of about 5% to about 95% indicates treatment of type 2 diabetes. In some embodiments, a reduction in BMI of about 15% to about 80% indicates treatment of type 2 diabetes. In some embodiments, a reduction in BMI of about 25% to about 60% indicates treatment of type 2 diabetes. In some embodiments, a reduction in BMI of about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% indicates treatment of type 2 diabetes. In some embodiments, a reduction in BMI to about or below 40, about or below 30, or about or below 20 indicates treatment of type 2 diabetes.
[0225] In some embodiments, the condition, disease or disorder is associated with diabetes (e.g., a complication of diabetes). Non-limiting examples of disorders associated with diabetes include obesity, obesity-related disorders, metabolic syndrome, neuropathy, nephropathy (e.g., diabetic nephropathy), retinopathy, diabetic cardiomyopathy, cataracts, macroangiopathy, osteopenia, hyperosmolar diabetic coma, infectious diseases (e.g., respiratory tract infections, urinary tract infections, gastrointestinal infections, skin and soft tissue infections, lower extremity infections), diabetic gangrene, xerostomia, hearing loss, cerebrovascular disorders, diabetic cachexia, delayed wound healing, diabetic dyslipidemia, peripheral blood circulation disorders, cardiovascular risk factors (e.g., coronary artery disease, peripheral arterial disease, cerebrovascular disease, hypertension and risk factors associated with uncontrolled cholesterol and / or lipid levels, and / or inflammation), NASH, bone fractures, and cognitive function disorders.
[0226] Other non-limiting examples of conditions associated with diabetes include prediabetes, hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, hyperLDL-cholesterolemia, hypoHDL-cholesterolemia, postprandial hyperlipidemia), metabolic syndrome (e.g., a metabolic disorder in which activation of the GLP-1R is beneficial, metabolic syndrome X), hypertension, impaired glucose tolerance (IGT), insulin resistance, and sarcopenia.
[0227] In some embodiments, the condition, disease, or disorder is diabetes and obesity (diabetic obesity). In some embodiments, the compounds described herein are also used to improve the therapeutic effectiveness of metformin. Metabolic diseases of important tissues
[0228] In some embodiments, the condition, disease or disorder is a metabolically important tissue disorder. Non-limiting examples of metabolically important tissues include liver, adipose, pancreas, kidney and intestine.
[0229] In some embodiments, the condition, disease or disorder is fatty liver disease. Fatty liver disease includes, but is not limited to, non-alcoholic fatty acid liver disease (NAFLD), steatotic hepatitis, non-alcoholic steatotic hepatitis (NASH), fatty liver disease caused by hepatitis, fatty liver disease caused by obesity, fatty liver disease caused by diabetes, fatty liver disease caused by insulin resistance, fatty liver disease caused by hypertriglyceridemia, abetalipoproteinemia, hyperlipoproteinemia, glycogen storage disease, Weber-Christian disease, Wolman disease, acute fatty liver of pregnancy, and lipodystrophy.
[0230] Non-alcoholic fatty liver disease (NAFLD) refers to a series of diseases that occur in the absence of alcohol abuse and is typically characterized by the presence of steatosis (fat in the liver). NAFLD is believed to be associated with a variety of conditions such as metabolic syndrome (including obesity, diabetes, and hypertriglyceridemia) and insulin resistance. It can lead to liver disease in adults and children and can ultimately lead to cirrhosis (Skelly et al., J Hepatol 2001; 35: 195-9; Chitturi et al., Hepatology 2002; 35 (2): 373-9). The severity of NAFLD ranges from relatively benign, isolated, mainly macrovesicular steatosis (i.e., non-alcoholic fatty liver or NAFL) to non-alcoholic steatohepatitis (NASH) (Angulo et al., J Gastroenterol Hepatol 2002; 17 Suppl: S186-90). In some embodiments, the patient is a pediatric patient. As used herein, the term "pediatric patient" refers to a patient who is less than 21 years of age at the time of diagnosis or treatment. The term "pediatric" can be further divided into multiple subgroups, including: neonates (from birth to the first month of life); infants (1 month to two years of age); children (two years to 12 years of age); and adolescents (12 to 21 years of age (up to but not including the 22nd birthday)). Berhman RE, Kliegman R, Arvin AM, Nelson WE. Nelson Textbook of Pediatrics, 15th ed., Philadelphia: WB Saunders Company, 1996; Rudolph AM, et al. Rudolph's Pediatrics, 21st ed., New York: McGraw-Hill, 2002; and Avery MD, First LR. Pediatric Medicine, 2nd ed., Baltimore: Williams & Wilkins; 1994. In some embodiments, the pediatric patient is from birth to the first 28 days of life, 29 days to less than two years of age, from two years of age to less than 12 years of age, or 12 years of age to 21 years of age (up to but not including the 22nd birthday). In some embodiments, the pediatric patient is from birth to the first 28 days of life, 29 days of age to less than 1 year of age, from one month of age to less than four months of age, from three months of age to less than seven months of age, from six months of age to less than 1 year of age, from 1 year of age to less than 2 years of age, from 2 years of age to less than 3 years of age, from 2 years of age to less than 7 years of age, from 3 years of age to less than 5 years of age, from 5 years of age to less than 10 years of age, from 6 years of age to less than 13 years of age, from 10 years of age to less than 15 years of age, or from 15 years of age to less than 22 years of age. In some embodiments, the patient is an adult patient.
[0231] Other non-limiting examples of metabolically important tissue disorders include: joint disorders (e.g., osteoarthritis, secondary osteoarthritis), steatosis (e.g., in the liver); gallstones; gallbladder disorders; gastroesophageal reflux; sleep apnea; hepatitis; fatty liver; skeletal disorders characterized by altered bone metabolism, such as osteoporosis, including postmenopausal osteoporosis, poor bone strength, osteopenia, Paget's disease, osteolytic metastases in cancer patients, osteodystrophy in liver disease, and altered bone metabolism caused by renal failure or hemodialysis, bone fractures, bone surgery, aging, pregnancy, fracture protection measures, and malnutrition polycystic ovary syndrome; renal disease (e.g., chronic renal failure, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal disease); muscular dystrophy, angina, acute or chronic diarrhea, testicular dysfunction, respiratory dysfunction, frailty, sexual dysfunction (e.g., erectile dysfunction), and geriatric syndromes. In some embodiments, the compounds and pharmaceutical compositions described herein can be used to treat surgical trauma by improving post-operative recovery and / or by preventing the catabolic response caused by surgical trauma. Cardiovascular and vascular diseases
[0232] In some embodiments, the condition, disease or disorder is cardiovascular disease. Non-limiting examples of cardiovascular disease include congestive heart failure, atherosclerosis, arteriosclerosis, coronary heart disease, coronary artery disease, congestive heart failure, coronary heart disease, hypertension, heart failure, cerebrovascular disorders (e.g., cerebral infarction), vascular dysfunction, myocardial infarction, elevated blood pressure (e.g., 130 / 85 mm Hg or higher), and prothrombotic state (exemplified by high fibrinogen or plasminogen activator inhibitor in the blood).
[0233] In some embodiments, the condition, disease or disorder is associated with a vascular disease. Non-limiting examples of vascular diseases include peripheral vascular disease, large vessel complications (e.g., stroke), vascular dysfunction, peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease, cerebrovascular disorders (e.g., cerebral infarction), pulmonary embolism, chronic venous insufficiency, critical limb ischemia, retinopathy, nephropathy, and neuropathy. Neurological diseases
[0234] In some embodiments, the condition, disease, or disorder is a neurological disorder (eg, a neurodegenerative disorder) or a psychiatric disorder. Non-limiting examples of neurological disorders include brain insulin resistance, mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease (PD), anxiety disorders, dementia (e.g., Alzheimer's disease), traumatic brain injury, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, Parkinson's disease, Steele-Richard syndrome, Down's syndrome, myasthenia gravis, neurotrauma, brain trauma, vascular amyloidosis, cerebral hemorrhage I with amyloidosis, encephalitis, Friedrich's ataxia, acute confusional disorders, amyotrophic lateral sclerosis (ALS), glaucoma, and apoptosis-mediated degenerative central nervous system diseases (e.g., Creutzfeld-Jakob disease, bovine spongiform encephalopathy (mad cow disease), and chronic wasting syndrome). See, for example, US 2006 / 0275288 Al.
[0235] Non-limiting examples of psychiatric disorders include drug dependence / addiction (narcotics and amphetamines) and attention deficit / dynamic disorder (ADHD). The compounds and pharmaceutical compositions described herein can be used to improve behavioral responses to addictive drugs, reduce drug dependence, prevent relapse to drug abuse, and alleviate anxiety caused by the absence of a given addictive substance. See, for example, US 2012 / 0021979 A1.
[0236] In some embodiments, the compounds and pharmaceutical compositions described herein are used to improve learning and memory by enhancing neuronal plasticity and cellular differentiation facilitation, as well as to protect dopamine neurons and motor function in Parkinson's disease. Insulin-related conditions and disorders
[0237] In some embodiments, the condition, disease or disorder is impaired fasting glucose (IFG), impaired fasting blood glucose (IFG), hyperglycemia, insulin resistance (impaired glucose homeostasis), hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hypoglycemic conditions, insulin resistance syndrome, paresthesias due to hyperinsulinemia, hyperlipidemia, hypercholesterolemia, impaired wound healing, leptin resistance, glucose intolerance, increased fasting glucose, dyslipidemia (e.g., hyperlipidemia, atherogenic dyslipidemia characterized by high triglycerides and low HDL cholesterol), glucagonoma, hyperuricemia, hypoglycemia (e.g., nocturnal hypoglycemia) and concomitant insulin-related coma events.
[0238] In some embodiments, the compounds and pharmaceutical compositions described herein can reduce or slow the progression of borderline, impaired fasting glucose, or impaired fasting glucose to diabetes. Autoimmune diseases
[0239] In some embodiments, the condition, disease or illness is an autoimmune disease. Non-limiting examples of autoimmune diseases include multiple sclerosis, experimental autoimmune encephalomyelitis, autoimmune disorders related to immune rejection, graft-versus-host disease, uveitis, optic neuropathy, optic neuritis, transverse myelitis, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, myasthenia gravis and Graves disease. See, for example, US20120148586A1. Stomach and intestinal related conditions
[0240] In some embodiments, the condition, disease or disorder is a stomach or intestinal disorder. Non-limiting examples of these disorders include ulcers of any etiology (e.g., gastric ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, ulcers associated with infections or other pathogens), digestive disorders, malabsorption, short bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohn's disease and ulcerative colitis), steatorrhea, hypogammaglobulinemia mouth sores, chemotherapy and / or radiation-induced mucositis and diarrhea, gastrointestinal inflammation, short bowel syndrome, ulcerative colitis, gastric mucosal damage (e.g., gastric mucosal damage caused by aspirin), small intestinal mucosal damage, and cachexia (e.g., cancer cachexia, tuberculous cachexia, cachexia associated with blood diseases, cachexia associated with endocrine diseases, cachexia associated with infectious diseases, and cachexia caused by acquired immune deficiency syndrome). weight
[0241] In some embodiments, the compounds and pharmaceutical compositions described herein can be used to cause a patient (e.g., a patient in need) to lose weight (e.g., excess weight), prevent weight gain, induce weight loss, reduce body fat, or reduce food intake. In some embodiments, the patient's weight gain can be attributed to excessive food intake or an unbalanced diet, or can be weight gain from a combination of medications (e.g., an insulin sensitizer with a PPARγ agonist-like effect, such as troglitazone, rosiglitazone, englitazone, tiglitazone, pioglitazone, etc.). In some embodiments, weight gain can be weight gain before obesity is achieved, or can be weight gain in obese patients. In some embodiments, weight gain can also be drug-induced weight gain or weight gain after smoking cessation.
[0242] In some embodiments, the condition, disease, or disorder is an eating disorder, such as overeating, binge eating, bulimia, or compulsive eating. Inflammatory diseases
[0243] In some embodiments, the condition, disease, or disorder is an inflammatory disorder. Non-limiting examples of inflammatory disorders include chronic rheumatoid arthritis, spondylitis ankylosing, osteoarthritis, low back pain, gout, postoperative or post-traumatic inflammation, abdominal distension, neuralgia, pharyngitis, cystitis, pneumonia, pancreatitis, enteritis, inflammatory bowel disease (including inflammatory colorectal disease), inflammation in metabolically important tissues including the liver, adipose, pancreas, kidney, and intestine, and pro-inflammatory states (e.g., elevated levels of pro-inflammatory cytokines or markers of inflammation such as C-reactive protein in the blood). cancer
[0244] In some embodiments, the condition, disease or disorder is cancer. Suitable examples of cancer include breast cancer (e.g., invasive ductal carcinoma, non-invasive ductal carcinoma, inflammatory breast cancer), prostate cancer (e.g., hormone-dependent prostate cancer, hormone-independent prostate cancer), pancreatic cancer (e.g., ductal pancreatic cancer), gastric cancer (e.g., papillary adenocarcinoma, mucinous adenocarcinoma, adenosquamous carcinoma), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, malignant mesothelioma), colon cancer (e.g., gastrointestinal stromal tumor), rectal cancer (e.g., gastrointestinal stromal tumor), colorectal cancer (e.g., familial colorectal cancer, hereditary non-polyposis colorectal cancer, gastrointestinal stromal tumor), small intestinal cancer (e.g., non-Hodgkin's lymphoma), nasopharyngeal cancer (e.g., nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer), salivary gland cancer, brain tumors (e.g., pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, pleomorphic astrocytoma), neurilemmoma, liver cancer (e.g., primary liver cancer, extrahepatic bile duct cancer), kidney cancer (e.g., renal cell carcinoma, transitional cell carcinoma of the renal pelvis and ureter), bile duct cancer, endometrial cancer, cervical cancer, ovarian cancer (e.g., epithelial ovarian cancer, extragonadal germ cell tumor, ovarian germ cell tumor, ovarian tumor of low malignant potential), bladder cancer, urethral cancer, skin cancer (e.g., intraocular (eye) melanoma, Merkel cell carcinoma), carcinoma), hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer (e.g., medullary thyroid cancer), parathyroid cancer, nasal cavity cancer, paranasal sinus cancer, bone tumors (e.g., osteosarcoma, Ewing tumor, uterine sarcoma, soft tissue sarcoma), angiofibroma, retinosarcoma, penile cancer, testicular tumors, pediatric solid tumors (e.g., Wilms' tumor, childhood kidney tumors), Kaposi's sarcoma, Kaposi's sarcoma caused by AIDS, maxillary sinus tumors, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, and leukemia (e.g., acute myeloid leukemia, acute lymphoblastic leukemia). Hypothalamic-pituitary disorders
[0245] In some embodiments, the condition, disease, or disorder is related to the hypothalamic-pituitary-gonadal axis. For example, the condition, disease, or disorder is related to the hypothalamic-pituitary-ovarian axis. In another example, the condition, disease, or disorder is related to the hypothalamic-pituitary-testicular axis. Hypothalamic-pituitary-gonadal axis diseases include, but are not limited to, hypogonadism, polycystic ovary syndrome, hypothyroidism, hypopituitarism, sexual dysfunction, and Cushing's disease.
[0246] In some embodiments, the condition, disease, or disorder associated with diabetes is related to the hypothalamic-pituitary-gonadal axis. pulmonary disease
[0247] In some embodiments, the condition, disease or disorder is associated with a lung disease. Pulmonary diseases include, but are not limited to, asthma, idiopathic pulmonary fibrosis, pulmonary hypertension, obstructive sleep apnea syndrome, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis, and refractory (non-reversible) asthma).
[0248] In some embodiments, the condition, disease, or disorder associated with diabetes is a lung disease. Combination therapy
[0249] In some embodiments, the present application encompasses both monotherapy regimens and combination therapy regimens.
[0250] In some embodiments, the methods described herein can further comprise administering one or more additional therapies (e.g., one or more additional therapeutic agents and / or one or more treatment regimens) in combination with administering the compounds described herein.
[0251] In some embodiments, the methods described herein comprise administering a compound described herein in combination with one or more of the following: dietary therapy (e.g., dietary monitoring, dietary therapy for diabetes), exercise therapy (e.g., physical activity), blood glucose monitoring, gastric electrical stimulation (e.g., ), and dietary changes.
[0252] In some embodiments, the compounds of Formula I described herein, or their smaller general formula compounds, or their pharmaceutically acceptable salts, isotopically enriched analogs, stereoisomers, mixtures of stereoisomers, or prodrugs thereof, may be administered in combination with one or more additional therapeutic agents.
[0253] Representative additional therapeutic agents include, but are not limited to, anti-obesity agents, diabetes therapeutics, diabetic complications therapeutics, hyperlipidemia therapeutics, antihypertensive agents, diuretics, chemotherapeutic agents, immunotherapeutic agents, anti-inflammatory drugs, antithrombotic agents, antioxidants, osteoporosis therapeutics, vitamins, anti-dementia drugs, erectile dysfunction drugs, therapeutics for urinary frequency or incontinence, therapeutics for NAFLD, therapeutics for NASH, therapeutics for dysuria, and antiemetics.
[0254] In some embodiments, the one or more additional therapeutic agents include, for example, those used as anti-obesity agents. Non-limiting examples include monoamine uptake inhibitors (e.g., tramadol, phentermine, sibutramine, mazindol, fluoxetine, tesofensine), serotonin 2C receptor agonists (e.g., lorcaserin), serotonin 6 receptor antagonists, histamine H3 receptor modulators, GABA modulators (e.g., topiramate), including GABA receptor agonists (e.g., gabapentin, pregabalin), neuropeptide Y antagonists (e.g., velibactam), cannabinoid receptor antagonists (e.g., rimonabant, tarenabant), growth hormone releasing peptide antagonists, growth hormone releasing peptide acylase inhibitors agents, opioid receptor antagonists (e.g., GSK-1521498), orexin receptor antagonists, melanocortin 4 receptor agonists, 11β-hydroxysteroid dehydrogenase inhibitors (e.g., AZD-4017, BVT-3498, INCB-13739), pancreatic esterase inhibitors (e.g., orlistat, cetilistat), β3 agonists (e.g., N-5984), diacylglycerol acyltransferase 1 (DGAT1) inhibitors, acetyl-CoA carboxylase (ACC) inhibitors, stearoyl-CoA desaturase inhibitors, microsomal triglyceride transfer protein inhibitors (e.g., R-256918), sodium-glucose SGLT-2 inhibitors (e.g., JNJ-28431754, dapagliflozin, AVE2268, TS-033, YM543, TA-7284, ASP1941, repagliflozin), NFK inhibitors (e.g., HE-3286), PPAR agonists (e.g., GFT-505, DRF-11605, gemfibrozil, and fenofibrate), phosphotyrosine phosphatase inhibitors (e.g., sodium metavanadate, trodusquemin), GPR119 agonists (e.g., PSN-821, MBX-2982, APD597), glucokinase activators (e.g., bilagliptin, AZD- 1656, AZD6370, TTP-355, compounds described in WO006 / 112549, WO007 / 028135, WO008 / 047821, WO008 / 050821, WO008 / 136428 and WO008 / 156757), leptin, leptin derivatives (e.g., metreleptin), leptin resistance improving drugs, CNTF (ciliary neurotrophic factor), BDNF (brain-derived neurotrophic factor), cholecystokinin agonists, amylin preparations (e.g., pramlintide, AC-2307), neuropeptide Y agonists (e.g., PYY3-36, derivatives of PYY3-36,Obineptide (obineptide, TM-30339, TM-30335), oxyntomodulin (OXM) preparations, appetite suppressants (e.g., ephedrine), FGF21 preparations (e.g., animal FGF21 preparations extracted from bovine or porcine pancreas; human FGF21 preparations genetically synthesized using Escherichia coli or yeast; fragments or derivatives of FGF21), appetite-reducing agents (e.g., P-57), human regenerating islet-derived protein (HIP), farnesoid X receptor (FXR) agonists, phentermine, zonisamide, norepinephrine / dopamine reuptake inhibitors, GDF-15 mimetics, methionyl aminopeptidase 2 (MetAP2) inhibitors, amfepramone, phendimetrazine, benzphetamine, fibroblast growth factor receptor (FGFR) modulators, and AMP-activated protein kinase (AMPK) activators.
[0255] In some embodiments, the one or more additional therapeutic agents include those used as, for example, antidiabetic agents. Non-limiting examples include insulin and insulin preparations (e.g., animal insulin preparations extracted from bovine or porcine pancreas; human insulin preparations synthesized using E. coli or yeast genes; zinc insulin; protamine zinc insulin; insulin fragments or derivatives (e.g., INS-1), oral insulin preparations, synthetic human insulin), insulin sensitizers (e.g., pioglitazone or a salt thereof), biguanides (e.g., metformin, buformin or a salt thereof (e.g., hydrochloride, fumarate, succinate)), glucagon analogs (e.g., WO any glucagon analogues described in 2010 / 011439), agents that antagonize the effects of glucagon or reduce glucagon secretion, sulfonylureas (e.g., chlorpropamide, tolazamide, gliclazide, glimepiride, tolbutamide, glibenclamide, gliclazide, acetocycline, urea (acetohexamide, glyclopyramide, glybuzole, glyburide), thiazolidinediones (such as rosiglitazone or pioglitazone), alpha-glucosidase inhibitors (for example, voglibose, acarbose, miglitol, emiglitate), insulin secretion regulators such as dietary glucose regulators (sometimes called "short-acting secretagogues"), for example, meglitinides (e.g., repaglinide and nateglinide), cholinesterase inhibitors (e.g., donepezil, galantamine, rivastigmine, tacrine), NMDA receptor antagonists, dual GLP-1 / GIP receptor agonists (e.g., LBT-2000, ZPD1-70), GLP-1R agonists ( For example, exenatide, liraglutide, albiglutide, dulaglutide, albiglutide, tasiglutide, lixisenatide, semaglutide, AVE-0010, S4P and Boc5), and dipeptidyl peptidase IV (DPP-4) inhibitors (e.g., vildagliptin, dutogliptin, gemigliptin, alogliptin, saxagliptin, sitagliptin,Linagliptin, berberine, adogliptin, BI1356, GRC8200, MP-513, PF-00734200, PHX1149, SK-0403, ALS2-0426, TA-6666, TS-021, KRP-104, trelagliptin).
[0256] In some embodiments, the one or more additional therapeutic agents include those used, for example, to treat NAFL and NASH. Non-limiting examples include FXR agonists, PF-05221304, synthetic fatty acid bile conjugates, anti-lysyl oxidase homolog 2 (LOXL2) monoclonal antibodies, cysteine protease inhibitors, MAPK5 inhibitors, galectin 3 inhibitors, fibroblast growth factor 21 (FGF21), niacin analogs, leukotriene D4 (LTD4) receptor antagonists, acetyl-CoA carboxylase (ACC) inhibitors, hexokines (KHK) inhibitors, apoptosis signal-regulating kinase 1 (ASK1) inhibitors. preparations, apical sodium-dependent bile acid transporter (IBAT) inhibitors, glycyrrhizin, schisandra chinensis extract, ascorbic acid, glutathione, silymarin, lipoic acid, and d-alpha-tocopherol, ascorbic acid, glutathione, vitamin B complex, glitazones / thiazolidinediones (e.g., troglitazone, rosiglitazone, pioglitazone), metformin, cysteamine, sulfonylureas, alpha-glucosidase inhibitors, glinides, vitamin E, tetrahydrolipstatin, milk thistle protein, antiviral agents, and antioxidants.
[0257] In some embodiments, one or more additional therapeutic agents include those for, for example, treating diabetic complications. Non-limiting examples include aldose reductase inhibitors (e.g., tolrestat, epalrestat, zopolrestat, fidarestat, CT-112, ranirestat, lidorestat), neurotrophic factors and their enhancing agents (e.g., NGF, NT-3, BDNF, the neurotrophic production / secretion promoters described in WO01 / 14372 (e.g., 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole), compounds described in WO2004 / 039365), PKC inhibitors (e.g., ruboxistaurin mesylate), succinate / dapoxetine (succinate / dapoxetine), succinate / dapoxetine, ... mesylate), AGE inhibitors (e.g., ALT946, N-benzoylthiazolium bromide (ALT766), EXO-226, pyridorin, pyridoxamine), serotonin and norepinephrine reuptake inhibitors (e.g., duloxetine), sodium channel inhibitors (e.g., lacosamide), reactive oxygen species scavengers (e.g., lipoic acid), cerebral vasodilators (e.g., tiapuride, mexiletine), somatostatin receptor agonists (e.g., BIM23190), and apoptosis signal-regulating kinase-1 (ASK-1) inhibitors.
[0258] In some embodiments, the one or more additional therapeutic agents include those used, for example, to treat hyperlipidemia. Non-limiting examples include HMG-COA reductase inhibitors (e.g., pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin, pitavastatin, or a salt thereof (e.g., sodium salt, calcium salt)), squalene synthase inhibitors (e.g., compounds described in WO 97 / 10224, e.g., N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine
[0014] In some embodiments, the present invention includes but is not limited to: benzo[beta]-3-yl]acetyl]piperidine-4-acetic acid), fibrates (e.g., bezafibrate, clofibrate, simfibrate, clinofibrate), anion exchange resins (e.g., colestyramine), nicotinic acid drugs (e.g., nicomol, niceritrol, niaspan), plant sterols (e.g., soy sterols, gamma oryzanol / γ-oryzanol), cholesterol absorption inhibitors (e.g., zechia), CETP inhibitors (e.g., dalcetrapib, anacetrapib), and omega-3 fatty acid preparations (e.g., omega-3 fatty acid ethyl ester 90).
[0259] In some embodiments, the one or more additional therapeutic agents include those used as, for example, antihypertensive agents. Non-limiting examples include angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril), angiotensin II antagonists (e.g., candesartan cilexetil, candesartan, losartan, losartan potassium, eprosartan, valsartan, telmisartan, irbesartan, tasosartan, olmesartan, olmesartan medoxomil), and valsartan. medoxomil), azilsartan, azilsartan medoxomil), calcium channel blockers (e.g., manidipine, nifedipine, amlodipine, efonidipine, nicardipine, cilnidipine), and beta-blockers (e.g., metoprolol, atenolol, propranolol, carvedilol, pindolol).
[0260] In some embodiments, one or more additional therapeutic agents include those used as, for example, diuretics. Non-limiting examples include xanthine derivatives (e.g., theobromine sodium salicylate, theobromine calcium salicylate), thiazide preparations (e.g., ethiazide, cyclopenthiazide, trichlorothiazide, hydrochlorothiazide, hydroflumethiazide, benzoyl hydrochlorothiazide, pentoflumethiazide, polythiazide, methylchlorothiazide), anti-aldosterone preparations (e.g., spironolactone, triamterene), carbonic anhydrase inhibitors (e.g., acetazolamide) and chlorobenzenesulfonamide agents (e.g., chlortalidone, mefruside, indapamide).
[0261] In some embodiments, one or more additional therapeutic agents include those used as, for example, immunotherapeutic agents. Non-limiting examples include microbial or bacterial compounds (e.g., muramyl dipeptide derivatives, picibanil), polysaccharides with immunoenhancing activity (e.g., lentinan, sizofiran, yunzhi polysaccharide), cytokines (e.g., interferons, interleukins (IL) such as IL-1, IL-2, IL-12) and colony stimulating factors (e.g., granulocyte colony stimulating factor, erythropoietin) obtained by genetic engineering methods.
[0262] In some embodiments, the one or more additional therapeutic agents include those used as, for example, anti-thrombotic agents. Non-limiting examples include heparin (e.g., heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium), warfarin (e.g., warfarin potassium); antithrombin drugs (e.g., aragatroban, dabigatran), FXa inhibitors (e.g., rivaroxaban, apixaban, edoxaban, betrixaban, YM150, compounds described in WO02 / 06234, WO2004 / 048363, WO2005 / 030740, WO2005 / 058823, and WO2005 / 113504), thrombolytics. In some embodiments, the present invention relates to an anti-platelet agent (e.g., urokinase, tisokinase, alteplase, nateplase, monteplase, pamiteplase), and a platelet aggregation inhibitor (e.g., ticlopidine hydrochloride, clopidogrel, prasugrel, E5555, SHC530348, cilostazol, icosapent ethyl, beraprost sodium, and sarpogrelate hydrochloride).
[0263] In some embodiments, one or more additional therapeutic agents include, for example, those for the treatment of osteoporosis. Non-limiting examples include alfacalcidol, calcitriol, elcatonin, calcitonin salmon, estriol, ipriflavone, pamidronate disodium, alendronate sodium hydrate, incadronate disodium, and risedronate disodium. Suitable examples of vitamins include vitamin B1 and vitamin B12. Suitable examples of erectile dysfunction drugs include apomorphine and sildenafil citrate. Suitable examples of urinary frequency or urinary incontinence therapeutic agents include flavorxate hydrochloride, oxybutynin hydrochloride, and propiverine hydrochloride. Suitable examples of dysuria treatment agents include acetylcholinesterase inhibitors (eg, distigmine). Suitable examples of anti-inflammatory agents include nonsteroidal anti-inflammatory drugs such as aspirin, acetaminophen, and indomethacin.
[0264] Other exemplary additional therapeutic agents include agents that regulate hepatic glucose homeostasis (e.g., fructose 1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glycogen synthase kinase inhibitors, glucokinase activators), agents designed to treat complications of long-term hyperglycemia, such as aldose reductase inhibitors (e.g., epalrestat and ranirestat), drugs used to treat complications associated with microangiopathy, anti-dyslipidemic drugs, such as HMG-CoA reductase inhibitors (statins, e.g., rosuvastatin), cholesterol-lowering agents, bile acid sequestrants (e.g., cholestyramine), cholesterol absorption inhibitors (e.g., plant sterols such as phytosterols), cholesterol ester transfer protein (CETP) inhibitors, ileal bile acid transport system inhibitors adrenergic receptor agonists, including alpha-2 agonists (e.g., clonidine), angiotensin-converting enzyme (ACE) inhibitors (e.g., lisinopril), calcium channel blockers, such as dihydropyridines (e.g., nifedipine), phenylalkylamines (e.g., verapamil), and benzodiazepines. Class (such as diltiazem ), angiotensin II receptor antagonists (e.g., candesartan), aldosterone receptor antagonists (e.g., eplerenone), centrally acting adrenergic drugs, such as central alpha agonists (e.g., clonidine), diuretics (e.g., furosemide), hemostatic modulators, including antithrombotic agents (e.g., fibrinolysis activators), thrombin antagonists, factor VIIa inhibitors, anticoagulants (e.g., vitamin K antagonists such as warfarin), heparin and its low molecular weight analogs, factor Xa inhibitors, and direct thrombin inhibitors (e.g., argatroban), antiplatelet agents (e.g., cyclooxygenase inhibitors (e.g., aspirin)), adenosine diphosphate (ADP) receptor inhibitors (e.g., clopidogrel), phosphodiesterase inhibitors (e.g., cilostazol) , glycoprotein IIB / IIA inhibitors (e.g., tirofiban), adenosine reuptake inhibitors (e.g., dipyridamole), noradrenergic agents (e.g., phentermine), serotonergic agents (e.g., sibutramine), diacylglycerol acyltransferase (DGAT) inhibitors, feeding behavior modulators, pyruvate dehydrogenase kinase (PDK) modulators, serotonin receptor modulators, monoamine transmission modulators, such as selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine), norepinephrine reuptake inhibitors (NARIs), norepinephrine-serotonin reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (MAOIs) (e.g., toloxatone ) and amiflamine), compounds described in WO007 / 013694, WO2007 / 018314, WO2008 / 093639 and WO2008 / 099794, GPR40 agonists (e.g., farslifan or a hydrate thereof, compounds described in WO2004 / 041266, WO2004 / 106276, WO2005 / 063729, WO2005 / 063725, WO2005 / 087710, WO2005 / 095338, WO2007 / 013689 and WO2008 / 001931), SGLT1 inhibitors, adiponectin or an agonist thereof, IKK inhibitors (e.g., AS-2868), somatostatin receptor agonists, ACC2 inhibitors, cachexia-modifying agents such as cyclooxygenase inhibitors (e.g., indomethacin), progesterone derivatives (e.g., megestrol acetate), glucocorticoids (e.g., dexamethasone), metoclopramide agents, tetrahydrocannabinol agents, agents for improving fat metabolism (e.g., eicosapentaenoic acid), growth hormone, IGF-1, antibodies against cachexia-inducing factors TNF-α, LIF, IL-6, and oncostatin M, metabolism-modifying proteins or peptides such as glucokinase (GK), glucokinase regulatory protein (GKRP), uncoupling proteins 2 and 3 (UCP2 and UCP3), peroxisome proliferator-activated receptor α (PPARα), MC4r agonists,Insulin receptor agonists, PDE 5 inhibitors, glycosylation inhibitors (e.g., ALT-711), drugs that promote nerve regeneration (e.g., Y-128, VX853, neurotrophic peptides (prosaptide)), antidepressants (e.g., desipramine, amitriptyline, imipramine), antiepileptic drugs (e.g., lamotrigine, trileptal, levetiracetam), eppra), zonisamide (zonegran), pregabalin, harkoseride, carbamazepine), antiarrhythmic drugs (e.g., mexiletine), acetylcholine receptor ligands (e.g., ABT-594), endothelin receptor antagonists (e.g., ABT-627), narcotic analgesics (e.g., morphine), alpha 2 receptor agonists (e.g., clonidine), topical analgesics (e.g., capsaicin), anxiolytics (e.g., benzothiazepines, ), phosphodiesterase inhibitors (e.g., sildenafil), dopamine receptor agonists (e.g., apomorphine), cytotoxic antibodies (e.g., T-cell receptor and IL-2 receptor specific antibodies), B-cell depleting therapies (e.g., anti-CD20 antibodies (e.g., rituxan), i-BLyS antibodies), drugs that affect T-cell migration (e.g., anti-integrin α4 / β1 antibodies (e.g., tysabri), drugs that act on immunophilins (e.g., cyclosporine, tacrolimus, sirolimus, rapamicin), interferons (e.g., IFN-β), immunomodulators (e.g., glatiramer), TNF-binding proteins (e.g., circulating receptors), immunosuppressants (e.g., mycophenolate mofetil), ophenolate), and metaglidasen, AMG-131, balaglitazone, MBX-2044, riglitazone, aleglitazar, ciglipstat, lobeglitazone, PLX-204, PN-2034, GFT-505, THR-0921, exenatide, exendin-4, memantine, midazolam, ketoconazole, icosapent ethyl, clonidine, azosemide, isosorbide, ethacrynic acid, piretanide, bumetanide, etoposide, piroxicam, NO donors (e.g., organic nitrates) and NO promoters (e.g., phosphodiesterase inhibitors).
[0265] In some embodiments, one or more additional therapeutic agents include those used as, for example, antiemetics. As used herein, "antiemetic" agents refer to any agent that counteracts (e.g., reduces or removes) nausea or vomiting (emesis). It should be understood that when referring to the therapeutically effective amount of an antiemetic, the amount administered is the amount required to counteract (e.g., reduce or remove) nausea or vomiting (emesis). Without wishing to be limited by theory, it is believed that the administration of one or more antiemetics in combination with a compound of formula (I) described herein may allow the administration of a higher dose of a compound of formula (I), for example, because the patient may be able to have a normal food intake and thus respond faster to treatment.
[0266] Non-limiting examples of antiemetics include 5HT3-receptor antagonists (serotonin receptor antagonists), neuroleptics / antipsychotics, antihistamines, anticholinergics, steroids (e.g., corticosteroids), NK1-receptor antagonists (e.g., neurokinin substance P receptor antagonists), antidopaminergic drugs / dopamine receptor antagonists, benzodiazepines, Class, cannabinoids.
[0267] For example, the antiemetic may be selected from the group consisting of: neuroleptics, antihistamines, anticholinergics, steroids, 5HT-3-receptor antagonists, NK1-receptor antagonists, antidopaminergic drugs / dopamine receptor antagonists, benzodiazepines cannabinoids that do not produce psychoactive or psychological effects.
[0268] In some embodiments, the antiemetic is a 5HT3-receptor antagonist (serotonin receptor antagonist). Non-limiting examples of 5HT3-receptor antagonists (serotonin receptor antagonists) include: granisetron (Kytril), dolasetron, ondansetron (Zofran), tropisetron, ramosetron, palonosetron, alosetron, azasetron, bemesetron, zatisetron, batanopirde, MDL-73147EF; metoclopramide, N-3389 (endo-3,9-dimethyl-3,9-diazabicyclo[3,3,1]non-7-yl-1H-indazole-3-carboxamide dihydrochloride), Y-25130 hydrochloride, MDL 72222, Alkyl-3,5-dimethylbenzoate, 3-(4-allylpiperazin-1-yl)-2-quinoxalinecarbonitrile maleate, zacopride hydrochloride, and mirtazapine. Other non-limiting examples of 5HT3-receptor antagonists (serotonin receptor antagonists) include: cilansetron, clozapine, cyproheptadine, dazopride, hydroxyzine, lerisetron, metoclopramide, mianserin, olanzapine, palonosetron (+netupitant), quetiapine, qamosetron, ramosteron, ricasetron, risperidone, ziprasidone, and zatosetron.
[0269] In certain embodiments, the 5HT-3-receptor antagonist is granisetron, dolasetron, ondansetron hydrochloride, terbisetron, lamosetron, palonosetron, alosetron, bemisetron, zatesetron, bacalopride, MDL-73147EF, metoclopramide, N-3389, Y-25130 hydrochloride, MDL 72222, Alkyl-3,5-dimethylbenzoate, 3-(4-allyl-piperazin-1-yl)-2-quinoxalinecarbonitrile maleate, zacopride hydrochloride and mirtazapine.
[0270] In certain embodiments, the 5HT-3-receptor antagonist is granisetron, dolasetron, ondansetron hydrochloride, terbisetron, lamosetron, palonosetron, alosetron, bemisetron, and zatesetron.
[0271] In certain embodiments, the 5HT-3-receptor antagonist is granisetron, dolasetron, and ondansetron.
[0272] In certain embodiments, the 5HT-3-receptor antagonist is granisetron.
[0273] In certain embodiments, the 5HT-3-receptor antagonist is ondansetron.
[0274] In some embodiments, the antiemetic is an antihistamine. Non-limiting examples of antihistamines include: piperazine derivatives (e.g., cyclizine, meclizine, and cinnarizine); promethazine; dimenhydrinate (Dramamine, Gravol); diphenhydramine; hydroxyzine; buclizine; and meclizine hydrochloride (Bonine, Antivert), doxylamine, and mirtazapine.
[0275] In some embodiments, the antiemetic is an anticholinergic (an inhibitor of acetylcholine receptors). Non-limiting examples of anticholinergics include: atropine, scopolamine, glycopyrron, hyoscine, Artane (trihexy-5trihexyphenidyl hydrochloride), Cogentin (benztropine mesylate), Akineton (biperiden hydrochloride), Disipal (Norflex lemonade o-phenadrine), diphenhydramine, hydroxyzine, hyoscyamine, and Kemadrin (propcyclidine hydrochloride).
[0276] In some embodiments, the antiemetic is a steroid (e.g., a corticosteroid). Non-limiting examples of steroids include betamethasone, dexamethasone, methylprednisolone, and trimethobenzamide (Tigan).
[0277] In some embodiments, the antiemetic is an NK1-receptor antagonist (e.g., a neurokinin substance P receptor antagonist). Non-limiting examples of NK1-receptor antagonists include: aprepitant, casopitant, ezlopitant, fosaprepitant, maropitant, netupitant, rolapitant, and vestipitant.
[0278] Other non-limiting examples of NK1-receptor antagonists include: MPC-4505, GW597599, MPC-4505, GR205171, L-759274, SR 140333, CP-96,345, BIIF 1149, NKP 608C, NKP 608A, CGP 60829, SR 140333 (benzenesulfonyl / lornopitant ammonium), LY 303870 (Lanepitant), MDL-105172A, MDL-103896, MEN-11149, MEN-11467, DNK 333A, YM-49244, YM-44778, ZM-274773, MEN-10930, S-19752, Neuronorm, YM-35375, DA-5018, MK-869, L-754030, CJ-11974, L-758298, DNK-33A, 6b-1, CJ-11974j. Benserazide and carbidopak. TAK-637 [(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazacycloocta[2,1-g][1,7]naphthyridine-6,13-dione], PD 154075, ([(2-Benzofuran)-CH2OCO]-(R)-α-MeTrp-(S)-NHCH(CH3)Ph), FK888, and (D-Pro4, D-Trp7,9,10, Phe11)SP4-11.
[0279] In some embodiments, the antiemetic is an antidopaminergic drug / dopamine receptor antagonist (eg, a dopamine receptor antagonist, eg, a D2 or D3 antagonist). Non-limiting examples include phenothiazines (e.g., promethazine, chlorpromazine, prochlorperazine, perphenazine, hydroxyzine, thiethylperazine, metopimazine); benzamides (e.g., metoclopramide, domperidone), butyrophenones (e.g., haloperidol, droperidol); alizapride, bromopride, clebopride, domperidone, itopride, metoclopramide, trimethobenzamide, and amisulpride.
[0280] In some embodiments, the antiemetic is a cannabinoid that does not produce psychoactive or psychological effects (e.g., cannabidiol (CBD), cannabidiol dimethylheptyl (CBD-DMH), tetrahydrocannabinol (THC), cannabinoid agonists such as WIN 55-212 (CB1 and CB2 receptor agonist), dronabinol and nabilone (Cesamet).
[0281] Other exemplary antiemetics include: c-9280 (Merck); benzodiazepines diazepam, midazolam, lorazepam); neuroleptics / antipsychotics (e.g., dixyrazine, haloperidol, and prochlorperazine) ); cerium oxalate; propofol; sodium citrate; dextrose; fructose (Nauzene); orthophosphoric acid; fructose; glucose (Emetrol); bismuth subsalicylate (Pepto Bismol); ephedrine; vitamin B6; peppermint, lavender, and lemon essential oils; and ginger.
[0282] Still other exemplary antiemetics include those disclosed in US 20120101089A1; US10,071,088B2; US 6,673,792 Bl; US 6,197,329 Bl; US10,828,297B2; US10,322,106B2; US10,525,033B2; WO 2009080351A1; WO 2019203753 A2; WO 2002020001 A2; US 8,119,697 B2; US 5,039,528; US20090305964A1; and WO 2006 / 111169, each of which is incorporated herein by reference in its entirety.
[0283] In some embodiments, the additional therapeutic agent or regimen is administered to the patient prior to contact with or administration of the compound and pharmaceutical composition (e.g., about an hour before, or about 6 hours before, or about 12 hours before, or about 24 hours before, or about 48 hours before, or about 1 week before, or about 1 month before).
[0284] In some embodiments, the additional therapeutic agent or regimen is administered to the patient at about the same time as the compound and pharmaceutical composition are contacted or administered. For example, the additional therapeutic agent or regimen and the compound and pharmaceutical composition are provided to the patient simultaneously in the same dosage form. As another example, the additional therapeutic agent or regimen and the compound and pharmaceutical composition are provided to the patient simultaneously in separate dosage forms. Patient selection
[0285] In some embodiments, the methods described herein further comprise the step of identifying a patient (e.g., a subject) in need of such treatment (e.g., by blood analysis, body mass index, or other routine methods known in the art).
[0286] In some embodiments, the methods described herein further comprise the step of identifying a patient (eg, a patient) suffering from a disease, disorder, or condition as provided herein (eg, a GLP-1 related disease, disorder, or condition).
[0287] In some embodiments, the methods described herein further comprise the step of identifying a patient (e.g., a patient) with type 2 diabetes. In some embodiments, determining whether a patient has type 2 diabetes comprises performing an assay to determine the level of hemoglobin A1c (HbA1c), fasting blood glucose, non-fasting blood glucose, or any combination thereof. In some embodiments, the level of HbA1c is between about 6.5% and about 24.0%. In some embodiments, the level of HbA1c is greater than or about 6.5%. In some embodiments, the level of HbA1c is greater than or about 8.0%. In some embodiments, the level of HbA1c is greater than or about 10.0%. In some embodiments, the level of HbA1c is greater than or about 12.0%. In some embodiments, the level of HbA1c is greater than or about 14.0%. In some embodiments, the level of HbA1c is greater than or about 16.0%. In some embodiments, the level of HbA1c is greater than or about 18.0%. In some embodiments, the level of HbA1c is greater than or about 20.0%. In some embodiments, the HbAIc level is greater than or about 22.0%. In some embodiments, the HbAIc level is greater than or about 24.0%.
[0288] In some embodiments, the fasting blood glucose level is greater than or about 120 mg / dL to greater than or about 750 mg / dL. In some embodiments, the fasting blood glucose level is greater than or about 200 mg / dL to greater than or about 500 mg / dL. In some embodiments, the fasting blood glucose level is greater than or about 300 mg / dL to greater than or about 700 mg / dL.
[0289] In some embodiments, the non-fasting blood glucose level is greater than or about 190 mg / dL to greater than or about 750 mg / dL. In some embodiments, the non-fasting blood glucose level is greater than or about 250 mg / dL to greater than or about 450 mg / dL. In some embodiments, the non-fasting blood glucose level is greater than or about 400 mg / dL to greater than or about 700 mg / dL.
[0290] In some embodiments, determining whether the patient has type 2 diabetes further comprises determining the patient's BMI. In some embodiments, the patient's BMI is greater than or about 22 kg / m 2 to greater than or about 100 kg / m 2 In some embodiments, the patient's BMI is greater than or about 30 kg / m 2 to greater than or about 90kg / m 2 In some embodiments, the patient's BMI is greater than or about 40 kg / m 2 to greater than or about 80kg / m 2In some embodiments, the patient's BMI is greater than or about 50 kg / m 2 to greater than or about 70kg / m 2 .
[0291] In some embodiments, additional factors (e.g., risk factors) used to determine whether a patient has type 2 diabetes further include the patient's age and race. In some embodiments, the patient's age is greater than or about 10 years old. In some embodiments, the patient's age is greater than or about 15 years old. In some embodiments, the patient's age is greater than or about 20 years old. In some embodiments, the patient's age is greater than or about 25 years old. In some embodiments, the patient's age is greater than or about 30 years old. In some embodiments, the patient's age is greater than or about 35 years old. In some embodiments, the patient's age is greater than or about 40 years old. In some embodiments, the patient's age is greater than or about 42 years old. In some embodiments, the patient's age is greater than or about 44 years old. In some embodiments, the patient's age is greater than or about 46 years old. In some embodiments, the patient's age is greater than or about 48 years old. In some embodiments, the patient's age is greater than or about 50 years old. In some embodiments, the patient's age is greater than or about 52 years old. In some embodiments, the patient's age is greater than or about 54 years old. In some embodiments, the patient's age is greater than or about 56 years old. In some embodiments, the patient is older than or about 58 years old. In some embodiments, the patient is older than or about 60 years old. In some embodiments, the patient is older than or about 62 years old. In some embodiments, the patient is older than or about 64 years old. In some embodiments, the patient is older than or about 66 years old. In some embodiments, the patient is older than or about 68 years old. In some embodiments, the patient is older than or about 70 years old. In some embodiments, the patient is older than or about 72 years old. In some embodiments, the patient is older than or about 74 years old. In some embodiments, the patient is older than or about 76 years old. In some embodiments, the patient is older than or about 78 years old. In some embodiments, the patient is older than or about 80 years old. In some embodiments, the patient is older than or about 85 years old. In some embodiments, the patient is older than or about 90 years old. In some embodiments, the patient is older than or about 95 years old. In some embodiments, the patient's race can be African American, American Indian or Alaska Native, Asian American, Hispanic or Latino, or Native Hawaiian or Pacific Islander. General synthetic method
[0292] The compound of the present application can be prepared by readily available starting materials using, for example, the following general method and procedure. It should be understood that, unless otherwise stated, other process conditions may also be used when certain process conditions (i.e., reaction temperature, time, the molar ratio of reactants, solvent, pressure, etc.) are given. Optimum reaction conditions may vary with the reactants or solvents used, but such conditions may be determined by conventional optimization procedures by those skilled in the art.
[0293] In addition, as will be apparent to those skilled in the art, conventional blocking groups may be needed to prevent some functional groups from experiencing undesirable reactions. Suitable blocking groups for various functional groups and suitable conditions for protecting some functional groups and making their deprotection are well known in the art. For example, numerous blocking groups are described in TW Greene and GM Wuts (1999) Protecting Groups in Organic Synthesis, the 3rd edition, Wiley, New York, and the document cited therein.
[0294] In addition, the compound of the present application can comprise one or more chiral centers. Therefore, if necessary, such compound can be prepared or separated into pure stereoisomers, that is, prepared or separated into a mixture of independent enantiomers or diastereomers or stereoisomer enrichment. Unless otherwise indicated, all such stereoisomers (and enriched mixtures) are included within the scope of the present application. Pure stereoisomers (or enriched mixtures) can be prepared using, for example, optically active starting materials or stereoselective reagents well known in the art. Alternatively, the racemic mixture of this compound can be separated using, for example, chiral column chromatography, chiral resolving agents, etc.
[0295] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many starting materials are available from suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance CA USA), EMKA-Chemie Gmbh & Co. KG (Eching Germany), or Millipore Sigma (Burlington MA USA). Other starting materials can be prepared by procedures described in standard reference texts, such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991); March's Advanced Organic Chemistry, Volumes 1-41 (John Wiley, and Sons, 1991); or obvious modifications thereof. th Edition, 2001); and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
[0296] Scheme 1 illustrates a general method for synthesizing the compounds described in this application, wherein Ring A, Ring B, Z 1 , Z 2 、R 1 、R 2 、R 4 、R 5 、R 6 、R 7 and p are each independently as defined herein, LG is a leaving group such as a halogen (eg, Cl, Br, or I), and R is hydrogen or a suitable carboxyl protecting group such as an alkyl or benzyl group. Plan I
[0297] Formula I and I' compounds can be obtained by coupling compound I-1 or I'-1 with compound I-2 under appropriate coupling reaction conditions (e.g., SN2 reaction conditions), wherein ring A includes complementary functional groups, such as, but not limited to, nucleophilic moieties. Exemplary suitable reaction conditions include, but are not limited to, polar aprotic solvents (e.g., acetonitrile), optionally in the presence of a base (e.g., an amine base, such as DIEA, or potassium carbonate, etc.). For methods wherein R is a carboxyl protecting group such as an alkyl or benzyl group, the method may further include a deprotection step, for example, a hydrolysis step. Suitable reagents for the deprotection step may include the presence of water under alkaline conditions, such as LiOH in water or in a suitable aqueous solvent mixture (e.g., water in methanol, THF, or a combination thereof).
[0298] It will be appreciated that the resulting product may be further derivatized by methods and chemical transformations known to those skilled in the art to provide alternative compounds of Formula I, Formula I', or other sub-general compounds thereof. For example, when the leaving group is an electrophilic reagent such as an aldehyde, the coupling reaction conditions may include reductive amination reaction conditions. Thus, the transformation may include more than one reaction or more than one set of reactants.
[0299] For any compound shown in Scheme I, it should be understood that various derivatives can be obtained by functional group conversion at any step. For example, when R is an alkyl group, various compounds of Formula I, compounds of Formula I', or other small general formula compounds thereof can be obtained by transesterification or hydrolysis using methods known to those skilled in the art. Similarly, various compounds of Formula I can be prepared as follows: one or more substituents (e.g., R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7) is or includes a leaving group (e.g., a halogen, such as Cl, Br, or I, or a halide-like compound such as a triflate, sulfonate, or phosphate) is contacted under suitable coupling conditions with a reagent containing a complementary functional group, such as, but not limited to, a boronic acid or a derivative thereof, such as a boronic ester, a zinc halide or a magnesium halide, an organotin compound such as tributylstannane or trimethylstannane, a fluorosulfonyl ester, tin, sodium, hydrogen, etc. Such reactions are commonly used for aromatic functionalizations and are typically carried out in the presence of a suitable catalyst, such as, but not limited to, a palladium catalyst, including [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), Pd(OAc)2, Pd(PPh3)4, PdCl2(PPh3)2, or tris(dibenzylideneacetone)dipalladium(0), or a copper catalyst such as CuCl or CuI, using a suitable solvent / solvent mixture, and (if necessary) mediators, cocatalysts, and / or bases known to those skilled in the art. Upon completion of the reaction, the compound of formula I can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration, etc. In certain embodiments, when control of stereochemistry is desired, appropriate control of reaction conditions and selection of substituents of the reagents can at least partially govern or maintain the formation of various stereoisomers.
[0300] In some embodiments, the various substituents of formula I-1, I'-1 or I-2 are as defined herein. However, prior to the reaction in any step, derivatization and / or further derivatization of the resulting reaction product can yield various compounds of formula I or I'. Suitable starting materials and reagents can be purchased or prepared by methods known to those skilled in the art. Upon completion of each reaction, the intermediate or final compound can be recovered and optionally purified by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration, etc. Other modifications to obtain the present invention's compounds are also within the contemplation of those skilled in the art.
[0301] In some embodiments, the present application provides a method for preparing a compound of Formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, the method comprising contacting a compound of Formula I-1 with a compound of Formula I-2 under conditions sufficient to provide a compound of Formula I or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof:
[0302] Among them, ring A, ring B, and Z 1 , Z 2 、R 1 、R 2 、R 4 、R 5 、R 6 、R 7and p are each independently as defined herein; LG is a leaving group; R is hydrogen or C optionally substituted with phenyl 1-6 alkyl.
[0303] In some embodiments, the present application provides a method for preparing a compound of formula I' or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, the method comprising contacting a compound of formula I'-1 with a compound of formula I-2 under conditions sufficient to provide a compound of formula I' or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof: Among them, ring A, ring B, and Z 1 , Z 2 、R 1 、R 2 、R 4 、R 5 、R 6 、R 7 and p are each independently as defined herein; LG is a leaving group; and R is hydrogen or C optionally substituted with phenyl 1-6 alkyl.
[0304] In some embodiments, the method further comprises a hydrolysis or transesterification step before or after the contacting step. In some embodiments, the method comprises a base. In some embodiments, the method comprises an elevated temperature. Example
[0305] The present application will be further understood with reference to the following examples, which are intended to be purely exemplary embodiments of the present application. The scope of the present application is not limited to the exemplary embodiments, which are intended only to illustrate individual aspects of the present application. Any functionally equivalent method is within the scope of the present application. Based on the foregoing description and accompanying drawings, various modifications of the present application, in addition to those described herein, will be apparent to those skilled in the art. These modifications fall within the scope of the appended claims.
[0306] Abbreviations (as used in this application):
[0307] General Information: All evaporations or concentrations were performed in vacuo using a rotary evaporator. Analytical samples were dried in vacuo (1-5 mmHg) at room temperature. Thin layer chromatography (TLC) was performed on silica gel plates, with spots visualized by UV light (214 and 254 nm). Column and flash chromatography purifications were performed using silica gel (100-200 mesh). Solvent systems are reported as mixtures by volume. NMR spectra were recorded on a Bruker 400 or Varian (400 MHz) spectrometer. 1 H and 19 F chemical shifts are reported as δ values in ppm with deuterated solvents as internal standards. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constant (Hz), integration. Unless otherwise stated, LCMS spectra were obtained on a SHIMADZU LC20-MS2020 or Agilent 1260 Series 6125B mass spectrometer with electrospray ionization or an Agilent 1200 Series 6110 or 6120 mass spectrometer. General synthetic scheme
[0308] Scheme 1. Synthesis scheme of Int-A.
[0309] The key intermediate Int-A is synthesized by the method described in Scheme 1. A-1 undergoes SNAr reaction with a suitable amine A-2 to give A-3. In certain embodiments, the reaction comprises DIEA. A-3 then undergoes a palladium-catalyzed carbonylation Suzuki coupling to produce intermediate A-4. In certain embodiments, the reaction comprises Pd(dppf)Cl2. The nitro group of A-4 is then reduced by catalytic hydrogenation, and the resulting phenyldiamine is reacted with 2-chloroacetic anhydride A-6 in, for example, dioxane to give Int-A.
[0310] Scheme 2. Synthesis scheme of Int-B.
[0311] The synthesis of Int-B begins with the bromination of acetophenone B-1, for example using pyridinium tribromide, to give B-2, which is then reacted with B-3 to give B-4. In certain embodiments, the reaction includes a base such as K2CO3. B-4 is then enantioselectively reduced by RuCl[(S,S)-Tsdpen](p-pinene), and B-4 undergoes an intramolecular coupling reaction to give B-6. In certain embodiments, the reaction from B-4 to B-5 includes TEA and formic acid. In certain embodiments, the reaction from B-5 to B-6 includes toluene and heating. B-6 is then coupled with benzylboronic acid pinacol ester B-7 to give Int-B. In certain embodiments, the reaction includes Pd(dppf)Cl2.
[0312] Scheme 3. Synthesis scheme of C.
[0313] The reaction between Int-A and Int-B yields intermediate C-1. In certain embodiments, the reaction comprises DIEA. Hydrolysis of C-1 yields the final product C. In certain embodiments, the reaction comprises LiOH.
[0314] Scheme 2′. Synthesis scheme of Int-B′.
[0315] The synthesis of Int-B' begins with the bromination of acetophenone B'-1, for example using pyridinium tribromide, to give B'-2, which is then reacted with B'-3 to give B'-4. In certain embodiments, the reaction includes a base such as K2CO3. B'-4 is then enantioselectively reduced by RuCl[(S,S)-Tsdpen](p-pinene), and B'-4 undergoes an intramolecular coupling reaction to give B'-6. In certain embodiments, the reaction from B'-4 to B'-5 includes TEA and formic acid. In certain embodiments, the reaction from B'-5 to B'-6 includes toluene and heating. B'-6 is then coupled with benzylboronic acid pinacol ester B'-7 to give Int-B'. In certain embodiments, the reaction includes Pd(dppf)Cl2.
[0316] Scheme 3′. Synthesis scheme of C′.
[0317] The reaction between Int-A' and Int-B' gives intermediate C'-1. In certain embodiments, the reaction includes DIEA. Hydrolysis of C'-1 gives the final product C'. In certain embodiments, the reaction includes LiOH. Example A1 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-1-[(oxolan-3-yl)methyl]-1H-1,3-benzodiazole-6-carboxylic acid (Compound 106)
[0318] Step A Methyl 4-nitro-3-(((tetrahydrofuran-3-yl)methyl)amino)benzoate
[0319] To 3-fluoro-4-nitrobenzoic acid methyl ester (1.514g, 76mmol), (tetrahydrofuran-3-yl) methylamine (1g, 9.88mmol) in CH3CN (15mL) solution, add DIEA (2.944g, 22.8mmol) and tetrahydro-3-furylmethylamine (2.306g, 22.8mmol). The reaction was stirred at room temperature for 1hr. After the reaction was complete, the mixture was diluted with EtOAc (50mL) and washed with water (50mL x 4). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (40g Purification on a silica gel flash column (eluent: 0-5% EtOAc / PE gradient @ 50 mL / min) afforded methyl 4-nitro-3-(((tetrahydrofuran-3-yl)methyl)amino)benzoate (2.062 g, 96.8% yield). LC-MS: m / z 281.1 (M+H) + .
[0320] Step B Methyl 4-amino-3-(((tetrahydrofuran-3-yl)methyl)amino)benzoate
[0321] To a solution of methyl 4-nitro-3-(((tetrahydrofuran-3-yl)methyl)amino)benzoate (500 mg, 1.784 mmol) in MeOH (12 mL) and THF (10 mL) was added 10% Pd / C (100 mg). The resulting mixture was stirred at room temperature under a balloon of H2 for 16 h. The mixture was filtered and the filtrate was concentrated to give methyl 4-amino-3-(((tetrahydrofuran-3-yl)methyl)amino)benzoate (490 mg, crude). LC-MS: m / z 251.2 (M+H) + .
[0322] Step A Methyl 2-(chloromethyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate
[0323] A mixture of methyl 4-amino-3-(((tetrahydrofuran-3-yl)methyl)amino)benzoate (590 mg, 2.357 mmol) and 2-chloroacetic anhydride (403.01 mg, 2.357 mmol) in dioxane (2 mL) was stirred at 60 ° C for 2 h. HOAc (0.2 mL) was then added. The resulting reaction mixture was stirred at 70 ° C for 2 hr. After the reaction was complete, the mixture was diluted with DCM (50 mL) and washed with saturated NaHCO3 aqueous solution. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (40 g Purification by silica gel flash column (0-25% EtOAc / PE gradient @ 50 mL / min) afforded methyl 2-(chloromethyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (644 mg, 88.5% yield). LC-MS: m / z 309.1 (M+H) + .
[0324] Step D (R)-4-(5-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile TFA salt
[0325] To a solution of (R)-tert-butyl 4-(2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylate (160 mg, 0.38 mmol) in DCM (3 mL) was added TFA (0.6 mL). The reaction mixture was stirred at 25 °C for 1 h. The solution was then concentrated to give (R)-4-(5-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile TFA salt (130 mg, crude). LC-MS: m / z 321.2 (M+H) + .
[0326] Step E Methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate
[0327] To a solution of (R)-4-(5-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile TFA salt (182.89 mg, 0.421 mmol) in DMF (2 mL) was added DIEA (0.5 mL). The reaction mixture was stirred at room temperature for 2 min, then 2-(chloromethyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (130 mg, 0.421 mmol) was added. The reaction was stirred at 50 °C for 1 h. After cooling, the mixture was diluted with EtOAc (50 mL) and washed with water (50 mL x 3). The organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (40 g Purification on a silica gel flash column with a 0-25% EtOAc / PE gradient at 50 mL / min afforded methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (148 mg, 61.8% yield). LC-MS: m / z 593.4 (M+H). + .
[0328] Step F 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-1-[(oxolan-3-yl)methyl]-1H-1,3-benzodiazol-6-carboxylic acid (Compound 106)
[0329] A mixture of methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.169 mmol), LiOH·H2O (20.25 mg, 0.844 mmol) in THF / H2O (1 mL / 0.2 mL) was stirred at 40°C for 16 h. After cooling, the mixture was directly purified by preparative HPLC (column: Sunfire C18, 19*250mm*10μm; mobile phase A: water (0.1% formic acid), mobile phase B: CH3CN; flow rate: 20mL / min; gradient: 36% B to 38% B; retention time: 8.9-13.2min over 16min) to give compound 106 (85.61mg, 87.6% yield). LC-MS: m / z 579.4 (M+H)+ . 1 HNMR(400MHz, DMSO-d6)δ12.99(br s, 1H), 8.35 (s, 1H), 7.96-7.89 (m, 3H), 7.80 (d, J=8.4Hz, 1H), 7.69 (d, J=8. 0Hz, 2H), 6.96-6.90 (m, 2H), 6.90-6.76 (m, 1H), 5.44-5.37 (m, 1H), 4.87-4.7 7 (m, 2H), 4.59-4.52 (m, 1H), 4.43 (d, J=8.0Hz, 2H), 4.20-4.11 (m, 1H), 3.95 -3.87(m, 1H), 3.81-3.78(m, 2H), 3.71-3.61(m, 3H), 3.48-3.42(m, 2H), 3.21 -3.14(m, 1H), 2.84-2.73(m, 1H), 2.10-1.86(m, 5H), 1.72-1.61(m, 1H).
[0330] Example compounds 105 and 107 were synthesized using a procedure similar to that described above in Example A1 using appropriate starting materials. Example A2 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 104)
[0331] (S)-2-(Chloromethyl)-4-fluoro-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate was synthesized according to the procedure described for the preparation of Intermediate 1-4 (Steps A, B, and C) using (S)-azetidin-2-ylmethanamine and methyl 3,5-difluoro-4-nitrobenzoate in Step A. LC-MS: m / z 313.2 (M+H) + .
[0332] Step A: Methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-fluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate
[0333] To a mixture of (R)-4-(5-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile TFA salt (130 mg, crude) in CH3CN (3.0 mL) was added DIEA (248 mg, 1.91 mmol) and (S)-2-(chloromethyl)-4-fluoro-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (100 mg, 0.34 mmol). The reaction mixture was stirred at 60 ° C for 1 h. After cooling and concentration, the residue was purified by flash silica gel chromatography (12 g Purification on a silica gel flash column (0-5% MeOH / DCM gradient at 50 mL / min) afforded methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-fluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (205 mg, 90.5% yield over two steps). LC-MS: m / z 597.3 (M+H). + .
[0334] Step B 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazepine-6-carboxylic acid (Compound 104)
[0335] To a solution of methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-fluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (205 mg, 0.34 mmol) in THF / H2O (V / V=4:1, 2.5 mL) was added LiOH·H2O (58 mg, 1.38 mmol). The reaction mixture was stirred at 25°C for 16 h. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC (column: Sunfire C18, 19*250 mm*10 μm; mobile phase A: water (0.1% formic acid), mobile phase B: CH3CN; flow rate: 20 mL / min; gradient: 32% B to 33% B; retention time: 8.4-11.1 min over 16 min) to give 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxan-5-yl]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazepine-6-carboxylic acid (80.2 mg, 40.1% yield). LC-MS: m / z 583.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.16 (s, 1H), 7.91 (d, J = 8.4Hz, 2H), 7.68 (d, J = 8.4Hz, 2H), 7.50 (d, J = 11.2Hz, 1H), 6.87-6. 78 (m, 3H), 5.42-5.35 (m, 1H), 5.16-5.06 (m, 1H), 4.80 (dd, J1=13.2Hz, J2=2.4Hz, 1H), 4.73 (d, J=9.6Hz, 1H), 4.58-4 .46 (m, 2H), 4.42-4.33 (m, 1H), 4.13-4.05 (m, 1H), 3.95 (d, J = 13.6Hz, 1H), 3.82 (d, J = 13.6Hz, 1H), 3.05-2.96 (m, 1H) , 2.91-2.81(m, 2H), 2.77-2.65(m, 1H), 2.48-2.38(m, 1H), 2.32-2.13(m, 2H), 1.81-1.71(m, 1H), 1.69-1.55(m, 3H). 19F NMR (377MHz, DMSO-d6) δ-129.16. Example A3 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-methoxy-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 118)
[0336] Step A 5-Bromo-1-fluoro-3-methoxy-2-nitrobenzene
[0337] A mixture of 5-bromo-1,3-difluoro-2-nitrobenzene (10.0 g, 42.02 mmol) and KOH (2.47 g, 44.12 mmol) in MeOH (100 mL) was stirred at 90 ° C for 1.5 h. After cooling, the reaction mixture was diluted with EtOAc (400 mL), washed with water (300 mL x 2) and brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (120 g Purification by silica gel flash column (0-10% EtOAc / PE gradient @ 100 mL / min) gave 5-bromo-1-fluoro-3-methoxy-2-nitrobenzene (5.6 g, 53.3% yield).
[0338] Step B (S)-5-Bromo-3-methoxy-2-nitro-N-(azetidin-2-ylmethyl)aniline
[0339] To a solution of 5-bromo-1-fluoro-3-methoxy-2-nitrobenzene (10.8g, 43.37mmol) in CH3CN (130mL) was added DIEA (16.81g, 130.12mmol) and (S)-azetidine-2-ylmethylamine (3.77g, 43.37mmol). The resulting mixture was stirred at 40°C for 2h. After cooling, the reaction mixture was diluted with EtOAc (300mL), washed with water (300mL x 2) and brine (100mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (120g Purification by silica gel flash column (0-25% EtOAc / PE gradient @ 100 mL / min) afforded (S)-5-bromo-3-methoxy-2-nitro-N-(azetidin-2-ylmethyl)aniline (10.4 g, 75.9% yield). LC-MS: m / z 317.2 (M+H) + .
[0340] Step C (S)-ethyl 3-methoxy-4-nitro-5-((azetidin-2-ylmethyl)amino)benzoate
[0341] To a mixture of (S)-5-bromo-3-methoxy-2-nitro-N-(azetidin-2-ylmethyl)aniline (10.4 g, 32.91 mmol) in EtOH (120 mL) was added AcOK (6.46 g, 65.8 mmol) and Pd(dppf)Cl2 (2.41 g, 3.29 mmol). The reaction mixture was stirred at 75 ° C under a CO atmosphere for 16 h. After the reaction was complete, the mixture was concentrated. The residue was purified by flash silica gel chromatography (120 g Purification by silica gel flash column (10-25% EtOAc / PE gradient @ 100 mL / min) afforded ethyl (S)-3-methoxy-4-nitro-5-((azetidin-2-ylmethyl)amino)benzoate (6.1 g, 59.8% yield). LC-MS: m / z 310.9 (M+H) + .
[0342] Step D (S)-ethyl 4-amino-3-methoxy-5-((azetidin-2-ylmethyl)amino)benzoate
[0343] To a solution of (S)-3-methoxy-4-nitro-5-((azetidin-2-ylmethyl)amino)benzoic acid ethyl ester (6.1 g, 19.68 mmol) in THF (60 mL) was added 10% Pd / C (915 mg). The reaction mixture was degassed and filled with H2 three times, then stirred under a H2 balloon at 25 ° C for 2 h. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by flash silica gel chromatography (120 g Purification by silica gel flash column (0-5% MeOH / DCM gradient @ 100 mL / min) afforded (S)-ethyl 4-amino-3-methoxy-5-((azetidin-2-ylmethyl)amino)benzoate (5.05 g, 91.7% yield). LC-MS: m / z 281.0 (M+H) + .
[0344] Step E (S)-ethyl 4-(2-chloroacetamido)-3-methoxy-5-((azetidin-2-ylmethyl)amino)benzoate
[0345] To a solution of (S)-4-amino-3-methoxy-5-((azetidin-2-ylmethyl)amino)benzoic acid ethyl ester (166mg, 0.59mmol) in dioxane (3mL) was added 2-chloroacetic anhydride (101mg, 0.59mmol) at 0°C. The reaction mixture was stirred at 25°C for 3h. AcOH (0.5ml) was then added, the reaction mixture was stirred to 100°C and continued to stir for another 2h. After cooling, the mixture was diluted with EtOAc (40mL), washed with water (50mL x 2) and brine (40mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (12g Purification by silica gel flash column (0-5% MeOH / DCM gradient @ 50 mL / min) afforded (S)-ethyl 2-(chloromethyl)-4-methoxy-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (120 mg, 60% yield). LC-MS: m / z 338.8 (M+H) + .
[0346] Step F Ethyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-methoxy-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate
[0347] To a solution of (S)-2-(chloromethyl)-4-methoxy-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid ethyl ester (120 mg, 0.36 mmol) in CHCN was added DIEA (465 mg, 3.6 mmol) and (R)-4-(5-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile TFA salt (156 mg, 0.36 mmol). The reaction mixture was stirred at 60 °C for 1 h. The reaction mixture was diluted with EtOAc (40 mL) and washed with brine (30 mL x 3). The organic layer was dried over anhydrous NaSO, filtered and concentrated. The residue was purified by flash silica gel chromatography (12 g Purification on a silica gel flash column (0-5% MeOH / DCM gradient @ 50 mL / min) afforded ethyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-methoxy-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (133 mg, 60.4% yield). LC-MS: m / z 622.8 (M+H). + .
[0348] Step G 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-methoxy-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazepine-6-carboxylic acid (Compound 118)
[0349] To a solution of ethyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-methoxy-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (133 mg, 0.21 mmol) in THF / MeOH / H2O (V / V / V=4:1:1, 1 mL) was added LiOH·H2O (36 mg, 0.85 mmol). The resulting mixture was stirred at 25°C for 1 h. The solution was filtered, and the filtrate was purified by preparative HPLC (column: Pursuit XRs C18, 19*250mm*10μm; mobile phase A: water (0.1% formic acid), mobile phase B: CH3CN; flow rate: 20mL / min; gradient: 35% B to 35% B; retention time: 6.38-8.5min) to give 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-methoxy-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (24.0mg, 18.9% yield). LC-MS: m / z 595.1 (M+H) + . 1H NMR(400MHz, DMSO-d6)δ12.80(br s, 1H), 7.95-7.86 (m, 3H), 7.68 (d, J=8.4Hz, 2H), 7.26 (s, 1H), 6.88-6.79 (m, 3H), 5.41-5.35 (m, 1 H), 5.13-5.04(m, 1H), 4.80-4.72(m, 1H), 4.68-4.60(m, 1H), 4.58-4.46(m, 2H), 4.39-4.30(m, 1H) , 4.14-4.05 (m, 1H), 3.95 (s, 3H), 3.90 (d, J=13.2Hz, 1H), 3.78 (d, J=13.6Hz, 1H), 3.03-2.92 (m, 1H ), 2.80-2.70(m, 2H), 2.72-2.64(m, 1H), 2.45-2.32(m, 1H), 2.26-2.10(m, 2H), 1.80-1.53(m, 4H). Example A4 2-({4-[(2R)-2-(4-chlorophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 111)
[0350] Step A (R)-tert-Butyl 4-(2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylate
[0351] To a mixture of tert-butyl (R)-4-(2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate (50 mg, 0.117 mmol) in MeOH (1 mL) was added 5% Pd / C (10 mg). The reaction mixture was degassed and filled with H2 three times, and then the reaction mixture was stirred at 25 °C for 16 h. After the reaction was complete, the mixture was filtered and concentrated to give tert-butyl (R)-4-(2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylate (50 mg, 99.5% yield). LC-MS: m / z 374.2 (M+Ht-Bu) + .
[0352] Step B (R)-4-(2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine HCl salt
[0353] A mixture of (R)-tert-butyl 4-(2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylate (50 mg, 0.116 mmol) in 4M HCl(gas) / dioxane (2 mL) was stirred at 25°C for 1 h. After the reaction was complete, the mixture was concentrated to give (R)-4-(2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine HCl salt (50 mg crude). LC-MS: m / z 330.2 (M+H) + .
[0354] Step C 2-((4-((R)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-fluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester
[0355] To a solution of (R)-4-(2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine HCl salt (50 mg, crude) in DMF (1 mL) was added TEA (92 mg, 0.91 mmol). After stirring for 2 minutes, (S)-methyl 2-(chloromethyl)-4-fluoro-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (28 mg, 0.091 mmol) was added. The reaction mixture was stirred at 60 ° C for 6 h. The reaction mixture was concentrated. The residue was purified by preparative TLC (PE / EtOAc = 2 / 1) to give methyl 2-((4-((R)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-fluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (44 mg, 62.9% yield). LC-MS: m / z 606.3 (M+H) + .
[0356] Step D 2-({4-[(2R)-2-(4-chlorophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 111)
[0357] To a mixture of methyl 2-((4-((R)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-fluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (44 mg, 0.073 mmol) in THF (1 mL) and H2O (0.2 mL) was added LiOH (15 mg, 0.363 mmol). The reaction mixture was stirred at 25° C. for 16 h and then concentrated. The residue was purified by preparative HPLC (column: Sunfire C18, 19*250 mm*10 μm; mobile phase A: water (0.1% formic acid), mobile phase B: CH 3 CN; flow rate: 20 mL / min; gradient: 33% B to 43% B; retention time: 9.0-11.1 min) to give 2-({4-[(2R)-2-(4-chlorophenyl)-2,3-dihydro-1,4-benzodioxan-5-yl]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (17.88 mg, 41.6% yield). LC-MS: m / z 592.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ12.96 (br s, 1H), 8.16 (s, 1H), 7.58 -7.45(m, 5H), 6.89-6.78(m, 3H), 5.25(dd, J1=8.4Hz, J2=2.4Hz, 1H), 5.16-5.06(m, 1H ), 4.89-4.78(m, 1H), 4.74-4.65(m, 1H), 4.56-4.45(m, 2H), 4.42-4.33(m, 1H), 4.12-4. 01 (m, 1H), 3.95 (d, J = 14.0Hz, 1H), 3.82 (d, J = 13.6Hz, 1H), 3.06-2.99 (m, 1H), 2.96-2. 80 (m, 2H), 2.78-2.64 (m, 1H), 2.47-2.37 (m, 1H), 2.31-2.12 (m, 2H), 1.81-1.53 (m, 4H). 19F NMR (377MHz, DMSO-d6) delta-129.14. Example A5 2-({4-[(2R)-2-(4-chlorophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-methoxy-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 119)
[0358] Step A: Ethyl 2-((4-((R)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-methoxy-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate
[0359] To a mixture of (R)-4-(2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine HCl salt (55 mg, 0.15 mmol) and (S)-2-(chloromethyl)-4-methoxy-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid ethyl ester (60 mg, 0.18 mmol) in CH3CN (6 mL) was added TEA (172 mg, 0.75 mmol). The reaction mixture was stirred at 60 ° C for 2 h. After the reaction was complete, the mixture was concentrated. The residue was purified by flash silica gel chromatography (12 g Purification on a silica gel flash column with a 0-50% EtOAc / PE gradient at 50 mL / min afforded ethyl 2-((4-((R)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-methoxy-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (77 mg, 95.9% yield). LC-MS: m / z 632.1 (M+H). + .
[0360] Step B 2-({4-[(2R)-2-(4-chlorophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-methoxy-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazepine-6-carboxylic acid (Compound 119)
[0361] To a mixture of ethyl 2-((4-((R)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4-methoxy-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (77 mg, 0.12 mmol) in HO (4 mL) and THF (12 mL) was added LiOH HO (26 mg, 0.61 mmol). The reaction mixture was stirred at 25 °C for 16 h. After the reaction was complete, the reaction mixture was diluted with HO (10 mL), acidified to pH = 5-6 with 1 M aqueous HCl solution, and extracted with EtOAc (10 mL x 2). The combined organic layers were washed with brine, dried over anhydrous NaSO, filtered and concentrated. The residue was purified by preparative HPLC (column: Atlantis™ T3 Prep OBD TMC18, 19*250 mm*10 μm; mobile phase A: water (0.1% formic acid), mobile phase B: CH 3 CN; flow rate: 20 mL / min; gradient: 39% B to 49% B; retention time: 6.5-8.2 min) to give 2-({4-[(2R)-2-(4-chlorophenyl)-2,3-dihydro-1,4-benzodioxan-5-yl]piperidin-1-yl}methyl)-4-methoxy-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazepine-6-carboxylic acid (19.81 mg, 27.5% yield). LC-MS: m / z 604.1 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ12.74(s, 1H), 7.90(s, 1H), 7.50(s, 4H), 7.26(s, 1H), 6.82-6.81( m, 3H), 5.26-5.24 (m, 1H), 5.11-5.07 (m, 1H), 4.79-4.73 (m, 1H), 4.65-4.62 (m, 1H), 4.51- 4.48(m, 2H), 4.35-4.33(m, 1H), 4.08-4.05(m, 1H), 3.95(s, 3H), 3.80-3.75(m, 1H), 3.03- 2.96 (m, 1H), 2.89-2.83 (m, 2H), 2.73-2.67 (m, 2H), 2.25-2.05 (s, 3H), 1.79-1.51 (m, 4H). Example A6 2-({4-[(2R)-2-(4-chloro-1-benzofuran-7-yl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-methoxy-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 120)
[0362] Step A1-Bromo-4-chloro-2-(2,2-diethoxyethoxy)benzene
[0363] To a mixture of 2-bromo-5-chlorophenol (5.00 g, 24.3 mmol) and 1-bromo-4-chloro-2-(2,2-diethoxyethoxy)benzene (7.14 g, 36.24 mmol) in DMSO (30 mL) was added KOH (2.03 g, 36.25 mmol). The reaction mixture was stirred at 160 ° C for 10 min. After cooling to 25 ° C, the mixture was poured into water (300 mL) and extracted with ethyl acetate (300 mL x 5). The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (120 g Purification by silica gel flash column (0-10% EtOAc / PE gradient @ 100 mL / min) gave 1-bromo-4-chloro-2-(2,2-diethoxyethoxy)benzene (7.1 g, 91.3% yield).
[0364] Step B 7-Bromo-4-chlorobenzofuran
[0365] To a mixture of 1-bromo-4-chloro-2-(2,2-diethoxyethoxy)benzene (7.1 g, 22.05 mmol) in DCE (50 ml) was added PPA (10.8 g, 31.95 mmol). The reaction mixture was stirred at 25 ° C for 16 h. The reaction mixture was quenched with saturated aqueous NaHCO3 solution (200 mL) and extracted with ethyl acetate (200 mL x 3). The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (120 g Purification by silica gel flash column (0-10% EtOAc / PE gradient @ 100 mL / min) gave 7-bromo-4-chlorobenzofuran (2.1 g, 41.4% yield).
[0366] Step C1-(4-chlorobenzofuran-7-yl)ethan-1-one
[0367] To a mixture of 7-bromo-4-chlorobenzofuran (1.9 g, 8.26 mmol) and tributyl (1-ethoxyvinyl) stannane (3.6 g, 9.97 mmol) in dioxane (20 mL) was added Pd (dppf) Cl 2 (604 mg, 0.83 mmol). The reaction mixture was stirred at 100 ° C for 16 h. After cooling, the mixture was quenched with 1 M HCl aqueous solution (20 mL) and stirred at 25 ° C for 1 h. The reaction mixture was then filtered and concentrated. The residue was purified by flash silica gel chromatography (40 g Purification by silica gel flash column (0-5% EtOAc / PE gradient @ 50 mL / min) afforded 1-(4-chlorobenzofuran-7-yl)ethan-1-one (1.37 g, 85.6% yield). LC-MS: m / z 195.1 (M+H) + .
[0368] Step D 2-Bromo-1-(4-chlorobenzofuran-7-yl)ethan-1-one
[0369] To the mixture of 1-(4-chlorobenzofuran-7-yl) ethyl-1-one (1.17g, 6.03mmol) in THF (12.0mL) was added pyridinium tribromide (1.83g, 5.72mmol). The reaction mixture was stirred at 40 ° C for 2h. After the reaction was complete, the mixture was quenched with saturated NaHCO3 aqueous solution (40mL), extracted with ethyl acetate (40mL x 3). The organic layers were merged, washed with salt water, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (40g Purification by silica gel flash column (eluent: 10-20% EtOAc / PE gradient @ 50 mL / min) afforded 2-bromo-1-(4-chlorobenzofuran-7-yl)ethan-1-one (790 mg, 48.1% yield). LC-MS: m / z 273.0 (M+H) + .
[0370] Step E1-(4-chlorobenzofuran-7-yl)-2-(2,6-dibromophenoxy)ethan-1-one
[0371] A mixture of 2-bromo-1-(4-chlorobenzofuran-7-yl)ethan-1-one (790 mg, 2.90 mmol), 2,6-dibromophenol (1.1 g, 4.37 mmol) and K2CO3 (1.2 g, 8.69 mmol) in acetone (10 mL) was stirred at 50° C. for 2 h. After the reaction was complete, the mixture was concentrated. The residue was purified by flash silica gel chromatography (24 g Purification by silica gel flash column (eluent: 10-20% EtOAc / PE gradient @ 50 mL / min) afforded 1-(4-chlorobenzofuran-7-yl)-2-(2,6-dibromophenoxy)ethan-1-one (580 mg, 45.3% yield). LC-MS: m / z 442.7 (M+H) + .
[0372] Step F (R)-1-(4-chlorobenzofuran-7-yl)-2-(2,6-dibromophenoxy)ethan-1-ol
[0373] A mixture of RuCl[(S,S)-Tsdpen](p-pinene) (53 mg, 0.083 mmol) in TEA (18.5 mL) and formic acid (3.7 mL) was stirred at 0 ° C for 1 h. 1-(4-chlorobenzofuran-7-yl)-2-(2,6-dibromophenoxy)ethan-1-one (370 mg, 0.84 mmol) was then added. The resulting reaction mixture was stirred at 0 ° C for 4 h. The solution was quenched with H2O (40 mL) and extracted with ethyl acetate (30 mL x 3). The organic layers were combined, washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (12 g Purification by silica gel flash column (0-25% EtOAc / PE gradient @ 50 mL / min) afforded (R)-1-(4-chlorobenzofuran-7-yl)-2-(2,6-dibromophenoxy)ethan-1-ol (270 mg, 72.6% yield). LC-MS: m / z 447.2 (M+H) + .
[0374] Step G (R)-5-bromo-2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxine
[0375] A mixture of (R)-1-(4-chlorobenzofuran-7-yl)-2-(2,6-dibromophenoxy)ethan-1-ol (320 mg, 0.72 mmol), 1,10-phenanthroline (39 mg, 0.22 mmol), CuI (14 mg, 0.074 mmol) and Cs2CO3 (705 mg, 2.16 mmol) in toluene (5.0 mL) was stirred at 120° C. for 16 h. After completion of the reaction, the reaction was concentrated. The residue was purified by flash silica gel chromatography (12 g Purification by silica gel flash column (0-15% EtOAc / PE gradient @ 50 mL / min) afforded (R)-5-bromo-2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxine (220 mg, 83.6% yield). LC-MS: m / z 365.0 (M+H) + .
[0376] Step H (R)-tert-Butyl 4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate
[0377] To a mixture of (R)-5-bromo-2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxine (220 mg, 0.60 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (280 mg, 0.91 mmol) and KCO (250 mg, 1.81 mmol) in dioxane (5 mL) and H0 (0.5 mL) was added Pd(dppf)Cl (49 mg, 0.006 mmol). The reaction mixture was stirred at 90° C. for 16 h. After cooling, the mixture was diluted with H0 (30 mL) and extracted with EA (30 mL x 2). The organic layers were combined, washed with brine (20 mL x 2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (12 g Purification by silica gel flash column (0-5% EtOAc / PE gradient @ 50 mL / min) afforded tert-butyl (R)-4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate (210 mg, 74.5% yield). LC-MS: m / z 490.2 (M+Na) + .
[0378] Step I (R)-tert-Butyl 4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylate
[0379] To a mixture of (R)-tert-butyl 4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate (175 mg, 0.37 mmol) in THF (3.0 mL) was added PtO2 (8 mg, 0.037 mmol). The reaction mixture was degassed and filled with H2 three times, and then it was stirred at 25 ° C. under a H2 balloon for 1.5 h. After filtration, the filtrate was concentrated to give tert-butyl (R)-4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylate (160 mg, crude). LC-MS: m / z 492.2 (M+Na) + .
[0380] Step J (R)-4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine HCl salt
[0381] To a solution of (R)-tert-butyl 4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylate (80 mg, crude) in dioxane (2 mL) was added 4M HCl (gas) in dioxane (1 mL). The reaction mixture was stirred at 25°C for 1.5 h and then concentrated to afford (R)-4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine HCl salt (80 mg, crude). LC-MS: m / z 370.1 (M+H) + .
[0382] Step K 2-({4-[(2R)-2-(4-chloro-1-benzofuran-7-yl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-methoxy-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 120)
[0383] 2-({4-[(2R)-2-(4-chloro-1-benzofuran-7-yl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-methoxy-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 120) was synthesized according to the procedure described for the preparation of Example A5 (Steps A to B) by using (R)-4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine HCl salt and (S)-2-(chloromethyl)-4-methoxy-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid ethyl ester in Step A. LC-MS: m / z 644.3 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.19 (d, J=2.0Hz, 1H), 7.90 (s, 1H), 7.42 (s, 2H), 7.26 (s, 1H), 7.09 (d, J=2.0Hz, 1H), 6.90 -6.77 (m, 3H), 5.67 (dd, J1=8.0Hz, J2=2.0Hz, 1H), 5.15-5.02 (m, 1H), 4.82-4.72 (m, 1H), 4.68-4.57 (m, 2H), 4.53- 4.45 (m, 1H), 4.40-4.29 (m, 2H), 3.95 (s, 3H), 3.91 (d, J = 13.2Hz, 1H), 3.77 (d, J = 13.6Hz, 1H), 3.05-2.95 (m, 1H), 2 .93-2.82(m, 2H), 2.76-2.65(m, 1H), 2.47-2.36(m, 1H), 2.30-2.09(m, 2H), 1.82-1.74(m, 1H), 1.72-1.55(m, 3H). Example A7 2-({4-[(2R)-2-(4-chloro-1-benzofuran-7-yl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 122)
[0384] 2-({4-[(2R)-2-(4-chloro-1-benzofuran-7-yl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4-fluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 122) was synthesized according to the procedure described for the preparation of Example A5 (Steps A to B) by using (R)-4-(2-(4-chlorobenzofuran-7-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine HCl salt and (S)-2-(chloromethyl)-4-fluoro-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester in Step A. LC-MS: m / z 632.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ8.25-8.14 (m, 2H), 7.53 (d, J=11.6Hz, 1H), 7.43 (s, 2H), 7.09 (d, J=2.0Hz , 1H), 6.91-6.79 (m, 3H), 5.68 (dd, J1=7.6Hz, J2=2.0Hz, 1H), 5.17-5.05 (m, 1H), 4.91-4.80 (m, 1H ), 4.72-4.68(m, 1H), 4.64-4.60(m, 1H), 4.56-4.46(m, 1H), 4.43-4.30(m, 2H), 4.10-3.72(m, 2H) , 3.10-2.82(m, 3H), 2.79-2.66(m, 1H), 2.43-2.36(m, 1H), 2.36-2.08(m, 2H), 1.88-1.58(m, 4H). 19 F NMR (377MHz, DMSO-d6) δ-129.06.
[0385] Example compounds 115 and 116 were synthesized using a procedure similar to that described above in Example A7 using appropriate starting materials. Example A8 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4,7-difluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 108)
[0386] Step A 4-Bromo-2,3,6-trifluoroaniline
[0387] A mixture of 2,3,6-trifluoroaniline (5.0 g, 34.00 mmol) and NBS (7.2 g, 40.80 mmol) in DMF (50 mL) was stirred at 25 ° C for 2 h. The reaction mixture was then diluted with EtOAc (200 mL) and washed with 10% Na2SO3 aqueous solution (100 mL x 2), H2O (100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (120 g The product was purified by silica gel flash column (0-10% EtOAc / PE gradient @ 100 mL / min) to afford 4-bromo-2,3,6-trifluoroaniline (6.0 g, 80% yield). 1 H NMR (400MHz, DMSO-d6) δ7.33 (ddd, J1=10.4Hz, J2=6.0Hz, J3=2.4Hz, 1H), 5.71 (s, 2H).
[0388] Step B1-Bromo-2,3,5-trifluoro-4-nitrobenzene
[0389] A mixture of 4-bromo-2,3,6-trifluoroaniline (2.86 g, 12.71 mmol) and NaBO3 (7.83 g, 50.84 mmol) in AcOH (50 mL) was stirred at 52 ° C for 16 h. After cooling, the reaction mixture was concentrated. The residue was diluted with water and extracted with ether (100 mL x 2). The combined organic extracts were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (120 g The product was purified by silica gel flash column with 0-10% EtOAc / PE gradient at 100 mL / min as eluent to afford 1-bromo-2,3,5-trifluoro-4-nitrobenzene (3.0 g, 93% yield).
[0390] Step C (S)-3-Bromo-2,5-difluoro-6-nitro-N-(azetidin-2-ylmethyl)aniline
[0391] A mixture of 1-bromo-2,3,5-trifluoro-4-nitrobenzene (800 mg, 3.14 mmol), (S)-azetidin-2-ylmethylamine TsOH salt (894 mg, 3.45 mmol) and DIEA (2.02 g, 15.70 mmol) in MeCN (15 mL) was stirred at 55° C. for 2 h. After cooling and concentration, the residue was purified by flash silica gel chromatography (40 g Purification by silica gel flash column (eluting with a 10-20% EtOAc / PE gradient at 50 mL / min) afforded (S)-3-bromo-2,5-difluoro-6-nitro-N-(azetidin-2-ylmethyl)aniline (340 mg, 34% yield). LC-MS: m / z 323.1 (M+H)+. 1H NMR (400MHz, DMSO-d6) δ7.23 (dd, J1=10.4Hz, J2=5.2Hz, 1H), 6.91-6.87 (m, 1H), 4.87-4.81 (m, 1H) ), 4.51-4.46(m, 1H), 4.33-4.27(m, 1H), 3.54-3.46(m, 2H), 2.64-2.55(m, 1H), 2.46-2.37(m, 1H).
[0392] Step D (S) -5-Bromo-3,6-difluoro-N1-(azetidin-2-ylmethyl)benzene-1,2-diamine
[0393] To the mixture of (S) -3- bromo -2,5- difluoro -6- nitro -N- (azetidine -2- ylmethyl) aniline (340mg, 1.06mmol) and NH4Cl (285mg, 5.28mmol) in EtOH / H2O (20mL / 4mL) was added Fe powder (296mg, 5.28mmol). The resulting mixture was stirred at 45 ° C for 3h. After cooling, the mixture was diluted with EtOAc (50mL) and filtered. The filtrate was washed with brine (30mL x 2), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (24g Purification by silica gel flash column (eluent: 10-20% EtOAc / PE gradient @ 50 mL / min) afforded (S)-5-bromo-3,6-difluoro-N1-(azetidin-2-ylmethyl)benzene-1,2-diamine (140 mg, 46% yield). LC-MS: m / z 295.1 (M+H) + .
[0394] Step E (S)-N-(4-bromo-3,6-difluoro-2-((azetidin-2-ylmethyl)amino)phenyl)-2-chloroacetamide
[0395] To a mixture of (S)-5-bromo-3,6-difluoro-N1-(azetidin-2-ylmethyl)benzene-1,2-diamine (140 mg, 0.49 mmol) in THF (10 mL) was added 2-chloroacetic anhydride (91 mg, 0.54 mmol). The resulting mixture was stirred at 25 ° C for 2 h. The reaction mixture was diluted with EtOAc (50 mL) and washed with saturated NaHCO3 aqueous solution (50 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give (S)-N-(4-bromo-3,6-difluoro-2-((azetidin-2-ylmethyl)amino)phenyl)-2-chloroacetamide (190 mg, crude). LC-MS: m / z 369.1 (M+H) + .
[0396] Step F (S) -6-Bromo-2-(chloromethyl)-4,7-difluoro-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole
[0397] A mixture of (S)-N-(4-bromo-3,6-difluoro-2-((azetidin-2-ylmethyl)amino)phenyl)-2-chloroacetamide (190 mg crude) in dioxane (10 mL) / AcOH (1 mL) was stirred at 100 ° C for 16 h. After cooling, the reaction mixture was poured into saturated aqueous Na2CO3 solution (20 mL) and extracted with EtOAc (50 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (12 g Purification by silica gel flash column (0-50% EtOAc / PE gradient @ 50 mL / min) afforded (S)-6-bromo-2-(chloromethyl)-4,7-difluoro-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole (170 mg, 93% yield). LC-MS: m / z 353.0 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.49 (dd, J1=9.6Hz, J2=4.8Hz, 1H), 5.15-5.03 (m, 3H), 4.77-4.71 (m, 1H) , 4.63-4.59 (m, 1H), 4.51-4.46 (m, 1H), 4.38-4.32 (m, 1H), 2.77-2.69 (m, 1H), 2.43-2.36 (m, 1H). 19F NMR (377MHz, DMSO-d6) δ -130.20, -131.30.
[0398] Step G 4-((R)-5-(1-((6-bromo-4,7-difluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile
[0399] A mixture of (S)-6-bromo-2-(chloromethyl)-4,7-difluoro-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole (200 mg, 0.57 mmol), (R)-4-(5-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile TFA salt (295 mg, 0.68 mmol) and DIEA (221 mg, 1.71 mmol) in MeCN (2 mL) was stirred at 55° C. for 3 h. After cooling and concentration, the residue was purified by flash silica gel chromatography (12 g Purification on a silica gel flash column (0-5% MeOH / DCM gradient @ 50 mL / min) afforded 4-((R)-5-(1-((6-bromo-4,7-difluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile (230 mg, 63.6% yield). LC-MS: m / z 635.2 (M+H) + .
[0400] Step H Ethyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4,7-difluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate
[0401] To a solution of 4-((R)-5-(1-((6-bromo-4,7-difluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile (120 mg, 0.19 mmol) in EtOH (5 mL) was added Pd(dppf)Cl2.CHCl2 (15 mg, 0.019 mmol) and KOAc (56 mg, 0.57 mmol). The reaction mixture was stirred at 80 °C for 16 h under CO atmosphere. After the reaction was complete, the mixture was diluted with EtOAc (50 mL) and filtered, and the filtrate was concentrated. The residue was purified by preparative TLC (DCM:MeOH=20:1) to give ethyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4,7-difluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (90 mg, 75.7% yield). LC-MS: m / z 629.3 (M+H) + .
[0402] Step I 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-4,7-difluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazepine-6-carboxylic acid (Compound 108)
[0403] To a mixture of ethyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-4,7-difluoro-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (90 mg, 0.14 mmol) in THF (2 mL) / HO (2 mL) was added LiOH (17 mg, 0.72 mmol). The resulting mixture was stirred at 25° C. for 5 h. After concentration, the residue was purified by preparative HPLC (column: Phenomenex C18, 19*250 mm*10 μm; mobile phase A: water (0.1% formic acid), mobile phase B: CH 3 CN; flow rate: 40 mL / min; gradient: 20% B to 60% B; retention time: 10 min) to give 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxan-5-yl]piperidin-1-yl}methyl)-4,7-difluoro-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazepine-6-carboxylic acid (10.74 mg, 12.5% yield). LC-MS: m / z 601.3 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.91 (d, J=7.6Hz, 2H), 7.69 (d, J=7.2Hz, 2H), 7.38 (d, J=6.8Hz, 1H), 6. 85-6.80 (m, 3H), 5.38 (d, J=6.8Hz, 1H), 5.11 (s, 1H), 4.94-4.89 (m, 1H), 4.76-4.72 (m, 1H), 4.56 -4.50 (m, 2H), 4.38 (d, J=6.4Hz, 1H), 4.12-4.07 (m, 1H), 3.97-3.83 (m, 2H), 3.02-2.99 (m, 1H), 2.92-2.89 (m, 2H), 2.76-2.74 (m, 1H), 2.46-2.44 (m, 1H), 2.29-2.23 (m, 2H), 1.75-1.66 (m, 4H). 19F NMR (377MHz, DMSO-d6) δ -133.04, -133.52. Example A9 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-1-[(3S,4S)-4-methoxyoxolan-3-yl]-1H-1,3-benzodiazole-6-carboxylic acid (Compound 114)
[0404] Step A: Methyl 3-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)amino)-4-nitrobenzoate
[0405] A mixture of methyl 3-fluoro-4-nitrobenzoate (117 mg, 0.59 mmol), (3S,4S)-4-aminotetrahydrofuran-3-ol (200 mg, 0.71 mmol), and DIEA (228 mg, 1.77 mmol) in CH3CN (20 mL) was stirred at 45°C for 4 h. The resulting mixture was concentrated and then purified by flash silica gel chromatography (12 g Purification by silica gel flash column (0-20% EtOAc / PE gradient @ 50 mL / min) afforded methyl 3-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)amino)-4-nitrobenzoate (140 mg, 83.3% yield). LC-MS: m / z 283.2 (M+H) + .
[0406] Step B: Methyl 4-amino-3-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)amino)benzoate
[0407] A mixture of methyl 3-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)amino)-4-nitrobenzoate (140 mg, 0.50 mmol), Fe powder (84 mg, 1.5 mmol) and NH4Cl (80 mg, 1.5 mmol) in EtOH / H2O (10 mL / 2 mL) was stirred at 45 ° C for 3 h. The mixture was diluted with EtOAc (50 mL), filtered, and the filtrate was washed with brine (50 mL x 3). The organic layer was separated, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica gel chromatography (12 g Purification by silica gel flash column (0-50% EtOAc / PE gradient @ 50 mL / min) afforded methyl 4-amino-3-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)amino)benzoate (100 mg, 80% yield). LC-MS: m / z 253.2 (M+H) + .
[0408] Step C: Methyl 4-(2-chloroacetamido)-3-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)amino)benzoate
[0409] A mixture of 4-amino-3-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)amino)benzoic acid methyl ester (100 mg, 0.40 mmol) and 2-chloroacetic anhydride (74 mg, 0.44 mmol) in THF (5 mL) was stirred at room temperature for 2 h. The mixture was poured into a saturated Na2CO3 aqueous solution and extracted with EtOAc (100 mL). The organic layer was analyzed and dried over anhydrous Na2SO4, filtered and concentrated, and the residue was purified by flash silica gel chromatography (12 g). Purification by silica gel flash column (0-50% EtOAc / PE gradient @ 50 mL / min) afforded methyl 4-(2-chloroacetamido)-3-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)amino)benzoate (120 mg, 92.3% yield). LC-MS: m / z 329.2 (M+H) + .
[0410] Step D Methyl 2-(chloromethyl)-1-((3S,4S)-4-hydroxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate
[0411] A mixture of methyl 4-(2-chloroacetamido)-3-(((3S,4S)-4-hydroxytetrahydrofuran-3-yl)amino)benzoate (120 mg, 0.37 mmol) in AcOH / dioxane (1 mL / 10 mL) was stirred at 100 ° C for 3 h. After cooling, the mixture was poured into saturated aqueous Na2CO3 solution and extracted with EtOAc (100 mL). The organic layer was separated, dried over anhydrous Na2SO4, filtered and concentrated, and the residue was purified by flash silica gel chromatography (12 g Purification by silica gel flash column (0-50% EtOAc / PE gradient @ 50 mL / min) afforded methyl 2-(chloromethyl)-1-((3S,4S)-4-hydroxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate (60 mg, 53.1% yield). LC-MS: m / z 311.1 (M+H) + .
[0412] Step E Methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-((3S,4S)-4-hydroxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate
[0413] A mixture of methyl 2-(chloromethyl)-1-((3S,4S)-4-hydroxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate (60 mg, 0.20 mmol), (R)-4-(5-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile TFA salt (100 mg, 0.23 mmol) and DIEA (129 mg, 1.00 mmol) in CH3CN (10 mL) was stirred at 55°C for 3 h. The mixture was concentrated and the residue was purified by flash silica gel chromatography (12 g Purification on a silica gel flash column with a 0-50% EtOAc / PE gradient at 50 mL / min afforded methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-((3S,4S)-4-hydroxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate (110 mg, 95.7% yield). LC-MS: m / z 595.3 (M+H). + .
[0414] Step F Methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-((3S,4S)-4-methoxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate
[0415] A mixture of methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-((3S,4S)-4-hydroxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate (110 mg, 0.19 mmol) and NaH (18 mg, 0.74 mmol) and CHI (105 mg, 0.74 mmol) in THF (10 mL) was stirred at room temperature for 1 h. After the reaction was complete, the mixture was diluted with EtOAc (50 mL), washed with brine (50 mL x 2), dried, filtered, and concentrated to give methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-((3S,4S)-4-methoxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, crude). LC-MS: m / z 609.4 (M+H) + .
[0416] Step G 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-1-[(3S,4S)-4-methoxyoxolan-3-yl]-1H-1,3-benzodiazol-6-carboxylic acid (Compound 114)
[0417] A mixture of methyl 2-((4-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-((3S,4S)-4-methoxytetrahydrofuran-3-yl)-1H-benzo[d]imidazole-6-carboxylate (75 mg, 0.12 mmol) and LiOH (26 mg, 0.61 mmol) in H2O (4 mL) / THF (12 mL) was stirred at room temperature for 16 h. After the reaction was complete, the reaction was diluted with H2O (20 mL), adjusted with HCl (1 M) until pH = 5-6, and then the mixture was extracted with EtOAc (20 mL x 2). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness under vacuum. The crude material was purified by preparative HPLC (column: Sunfire C18, 19*250 mm*10 μm; mobile phase A: water (0.1% formic acid), mobile phase B: CH3CN; flow rate: 20 mL / min; gradient: 28% B to 30% B; retention time: 8.8-10.1 min over 15 min) to give 2-({4-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-1-[(3S,4S)-4-methoxyoxolan-3-yl]-1H-1,3-benzodiazepine-6-carboxylic acid (7.03 mg, 9.6% yield). LC-MS: m / z 595.4 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ12.68 (s, 1H), 8.37 (s, 1H), 7.92 (d, J = 8.0Hz, 2H), 7.77 (d, J = 8.4Hz, 1H), 7.69 (d, J = 8.0 Hz, 2H), 7.61 (d, J=8.4Hz, 1H), 6.85-6.81 (m, 3H), 5.63-5.56 (m, 1H), 5.38-5.36 (m, 1H), 4.56-4.53 (m, 1H), 4.37- 4.30 (m, 2H), 4.16-4.05 (m, 3H), 4.01 (t, J=8.8Hz, 1H), 3.87 (dd, J1=10.4Hz, J2=4.0Hz,, 1H), 3.67 (d, J=13.2Hz, 1H), 3.08-3.05(m, 1H), 2.89(s, 3H), 2.86-2.82(m, 2H), 2.33-2.21(m, 2H), 2.15-2.09(m, 1H), 1.71-1.69(m, 3H). Example A10 2-({6-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxan-5-yl]-3-azabicyclo[4.1.0]hept-3-yl}methyl)-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazepine-6-carboxylic acid (Compound 110)
[0418] (R)-5-Bromo-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxine was synthesized according to the procedure described for the preparation of intermediate 6-8 (steps E, F and G) by using 2,6-dibromophenol and 2-bromo-1-(4-chlorophenyl)ethan-1-one in step E. 1 H NMR (400MHz, DMSO-d6) δ7.41 (dd, J1=8.0Hz, J2=2.0Hz, 2H), 7.36 (d, J=8.4Hz, 2H), (dd, J=8.0Hz, 1.2Hz, 1H), 6.95-6.93 (m, 1H), 6. 78 (t, J=8.0Hz, 1H), 5.11 (dd, J1=8.8Hz, J2=2.4Hz, 1H), 4.48 (dd, J1=10.6Hz, J2=2.4Hz, 1H), 4.05 (dd, J1=11.6Hz, J2=8.8Hz, 1H).
[0419] (S)-Methyl 2-(chloromethyl)-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate was synthesized according to the procedure described for the preparation of intermediate 1-4 (steps A, B, and C) by using methyl 3-fluoro-4-nitrobenzoate and (2S)-azetidin-2-ylmethanamine in step A.
[0420] LC-MS: m / z 295.1 (M+H) + .
[0421] Step A Benzyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[4.1.0]heptane-3-carboxylate
[0422] To a solution of ZnEt2 (1M THF solution, 69.93 mL, 69.93 mmol) in DCM (45 mL) was slowly added CHCl (24.7 g, 139.94 mmol) at -40 ° C, and the mixture was stirred for 1 h at -40 ° C. TFA (7.98 g, 69.93 mmol) was added at -40 ° C, and the mixture was stirred for another 1 h at -15 ° C. Then after the addition, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylic acid benzyl ester (3 g, 8.73 mmol) in DCM (15 mL) was slowly added to the reaction mixture at -15 ° C, and the reaction mixture was stirred for 16 h at 25 ° C. After the reaction was complete, the mixture was concentrated and purified by flash silica gel chromatography (120 g Purification by silica gel flash column (0-20% EtOAc / PE gradient @ 100 mL / min) afforded benzyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[4.1.0]heptane-3-carboxylate (1.8 g, 57.6% yield). LC-MS: m / z 358.2 (M+H) + . 1 H NMR (400MHz, DMSO-d6) δ7.38-7.29 (m, 5H), 5.09-5.05 (m, 2H), 3.76-3.73 (m, 1H), 3.52 (s, 1H), 3.43-3.37 (m, 1H), 2 .89-2.86 (m, 1H), 2.02-1.96 (m, 1H), 1.50-1.42 (m, 1H), 1.23-1.18 (m, 13H), 0.78-0.75 (m, 1H), 0.37-0.35 (m, 1H).
[0423] Step B Benzyl 6-((R)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3-azabicyclo[4.1.0]heptane-3-carboxylate
[0424] A mixture of (R)-5-bromo-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxine (400 mg, 1.23 mmol), benzyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[4.1.0]heptane-3-carboxylate (527 mg, 1.47 mmol), Cs2CO3 (1.2 g, 3.69 mmol) and Pd(dppf)Cl2·DCM (98 mg, 0.12 mmol) in dioxane (10 mL) was stirred at 100°C for 16 h. After the reaction was complete, the mixture was concentrated and purified by reverse phase ISCO (CH3CN / water (0.1% formic acid) = 0 to 85.2%) to give benzyl 6-((R)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3-azabicyclo[4.1.0]heptane-3-carboxylate (250 mg, 42.8% yield). LC-MS: m / z 476.2 (M+H) + .
[0425] Step C Benzyl 6-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3-azabicyclo[4.1.0]heptane-3-carboxylate
[0426] A mixture of benzyl 6-((R)-2-(4-chlorophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3-azabicyclo[4.1.0]heptane-3-carboxylate (250 mg, 0.53 mmol), K4[Fe(CN)6] (967 mg, 2.63 mmol), Na2CO3 (167 mg, 1.58 mmol) and XphosPdG3 (43 mg, 0.05 mmol) in DMF (10 mL) was stirred at 120°C for 16 h. After the reaction was complete, the mixture was concentrated and purified by reverse phase ISCO (CH3CN / water (0.1% formic acid) = 0 to 82%) to give benzyl 6-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3-azabicyclo[4.1.0]heptane-3-carboxylate (150 mg, 61.2% yield). LC-MS: m / z 467.2 (M+H)+ .
[0427] Step D 4-((2R)-5-(3-azabicyclo[4.1.0]hept-6-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile
[0428] A mixture of benzyl 6-((R)-2-(4-cyanophenyl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3-azabicyclo[4.1.0]heptane-3-carboxylate (150 mg, 0.32 mmol) and 5% Pd / C (15 mg) in THF (10 mL) was stirred at 40° C. under a balloon of H 2 for 4 h. After filtration, the filtrate was concentrated to give 4-((2R)-5-(3-azabicyclo[4.1.0]hept-6-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile (60 mg, 56.14% yield). LC-MS: m / z 333.2 (M+H) + .
[0429] Step E 2-({6-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxan-5-yl]-3-azabicyclo[4.1.0]hept-3-yl}methyl)-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazepine-6-carboxylic acid (Compound 110)
[0430] 2-({6-[(2R)-2-(4-cyanophenyl)-2,3-dihydro-1,4-benzodioxan-5-yl]-3-azabicyclo[4.1.0]hept-3-yl}methyl)-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 110) was synthesized according to the procedure described for the preparation of A1 (Steps E and F) by using 4-((2R)-5-(3-azabicyclo[4.1.0]hept-6-yl)-2,3-dihydrobenzo[b][1,4]dioxin-2-yl)benzonitrile and (S)-2-(chloromethyl)-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester in Step E. LC-MS: m / z 358.2 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.25 (s, 1H), 7.92 (d, J=8.0Hz, 2H), 7.79-7.81 (m, 1H), 7.71 (d, J=8.0Hz, 2H), 7.63-7.60 (m, 1H), 6 .85-6.83 (m, 1H), 6.78-6.76 (m, 2H), 5.40-5.38 (m, 1H), 5.09-5.08 (m, 1H), 4.84-4.81 (m, 1H), 4.71-4.66 (m, 1H), 4.59-4. 57 (m, 1H), 4.49-4.46 (m, 1H), 4.42-4.34 (m, 1H), 4.15-4.10 (m, 1H), 3.96-3.81 (m, 2H), 3.65 (d, J=13.2Hz, 1H), 2.92-2.82 (m, 1H), 2.77-2.68 (m, 2H), 2.46-2.33 (m, 2H), 2.26-2.20 (m, 1H), 2.00-1.90 (m, 1H), 1.23-1.21 (m, 1H), 0.91-0.78 (m, 2H).
[0431] Example compounds 125, 126 and 127 were synthesized using a procedure similar to that described above in Example A10 using appropriate starting materials. Example A11 2-((4-((R)-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl)piperidin-1-yl)methyl)-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 130) Step A 2-((2-bromopyridin-3-yl)oxy)-1-(4-chlorophenyl)ethan-1-one
[0432] To a solution of 2-bromopyridin-3-ol (10 g, 57.5 mmol) and 2-bromo-1-(4-chlorophenyl)ethan-1-one (13.4 g, 57.5 mmol) in MeCN (300 mL) was added KCO (15.9 g, 115 mmol). The mixture was stirred at 25°C for 3 h. The mixture was diluted with H0 (100 mL) and the precipitate was collected by filtration. The solid was purified by flash silica gel chromatography (silica gel flash column, 50-60% EtOAc / PE gradient as eluent) to give 2-((2-bromopyridin-3-yl)oxy)-1-(4-chlorophenyl)ethan-1-one (17.5 g, 93.2% yield). 1 H NMR (400MHz, CDCl3) δ8.04 (d, J=4.0Hz, 1H), 7.98 (d, J=8.4Hz, 2H), 7.50 (d, J=8. 4Hz, 2H), 7.19 (dd, J1=8.0Hz, J2=4.7Hz, 1H), 7.08 (d, J=8.0Hz, 1H), 5.33 (s, 2H)
[0433] Step B (S)-2-((2-bromopyridin-3-yl)oxy)-1-(4-chlorophenyl)ethan-1-ol
[0434] To a mixture of formic acid (35 mL) and TEA (175 mL) was added RuCl[(S,S)-Tsdpen](p-pinene) (1.71 g, 2.68 mmol). The mixture was stirred at 25 ° C for 1 hour, then 2-[(2-bromo-3-pyridyl)oxy]-1-(4-chlorophenyl)ethanone (17.5 g, 53.6 mmol) was added and the resulting mixture was stirred at 25 ° C for 4 h. The reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (100 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica chromatography (silica gel flash column, elution with a 30-50% EtOAc / PE gradient) to afford (S)-2-((2-bromopyridin-3-yl)oxy)-1-(4-chlorophenyl)ethan-1-ol (15 g, 85.7% yield). 1 H NMR (400MHz, CDCl3) δ7.96 (d, J=4.2Hz, 1H), 7.44-7.38 (m, 2H), 7.37-7.30 (m, 2H), 7.20-7.08(m, 2H), 5.17(d, J=4.6Hz, 1H), 4.17-4.06(m, 2H), 3.54(s, 1H)
[0435] Step C (R)-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine
[0436] To a solution of (S)-2-((2-bromopyridin-3-yl)oxy)-1-(4-chlorophenyl)ethan-1-ol (8.5 g, 25.9 mmol) in DMF (20 mL) was added CuI (4.93 g, 25.9 mmol), (1S, 2S)-N1, N2-dimethylcyclohexane-1,2-diamine (7.36 g, 51.7 mmol) and Cs2CO3 (16.9 g, 51.7 mmol). The mixture was stirred at 110 ° C for 16 h. After cooling, the reaction mixture was diluted with brine and extracted with EtOAc (100 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash silica chromatography (silica gel flash column, elution with a 10-60% EtOAc / PE gradient) to afford (R)-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine (1.2 g, 18.7% yield). 1 HNMR (400MHz, CDCl3) δ7.89 (d, J=4.2Hz, 1H), 7.46-7.36 (m, 4H), 7.28-7.23 (m, 1H), 6.93 (dd, J1=7.8, J2=4.8Hz, 1H), 5.31 (dd, J=8.8, 2.4Hz, 1H), 4.36 (dd, J=11.6, 2.4Hz, 1H), 3.98 (dd, J=11.6, 8.8Hz, 1H)
[0437] Step D (R)-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine 5-oxide
[0438] To a solution of (3R)-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine (150 mg, 605.63 μmol) in DCM (5 mL) was added 85% m-CPBA (620 mg, 727 μmol). The mixture was stirred at 25 °C for 1 h. The reaction mixture was diluted with saturated aqueous NaHCO3 (20 mL) and extracted with DCM (20 mL x 2). The combined organic layers were dried over Na2SO4, filtered and concentrated to give (3R)-3-(4-chlorophenyl)-5-oxido-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-5-ium (145 mg, 90.7% yield), which was used in the next step without purification. LC-MS: m / z 264.2 (M+H) + .
[0439] Step E (R)-8-chloro-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine
[0440] A mixture of (3R)-3-(4-chlorophenyl)-5-oxido-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-5-ium (145 mg, 550 μmol) in POCl3 (422 mg, 2.75 mmol) was stirred at 90 ° C for 1 h. The reaction mixture was concentrated. The residue was diluted with saturated aqueous NaHCO3 (20 mL) and extracted with EtOAc (20 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the crude product (3R)-8-chloro-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine (80 mg, 51.6% yield). LC-MS: m / z 282.0 (M+H) + .
[0441] Step F (R)-tert-Butyl 4-(3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl)-3,6-dihydropyridine-1(2H)-carboxylate
[0442] To (3R) -8- chloro- 3- (4- chlorophenyl) -2,3- dihydro - [1,4] dioxino [2,3-b] pyridine (230mg, 815μmol) and 4- (4,4,5,5- tetramethyl -1,3,2- dioxaborolane -2- bases) -3,6- dihydropyridine -1 (2H) - tert-butyl formate (252mg, 815μmol) in THF (5mL) and H o (3mL) solution, XPhos Pd G (69.0mg, 81.5μmol) and Cs cO (531mg, 1.63mmol) were added. The reaction mixture was stirred at 80 ° C for 16h. After cooling, the reaction mixture was diluted with brine and extracted with EtOAc (50mL x 2). The organic layer was dried over anhydrous Na sO , filtered and concentrated. The residue was purified by flash silica gel chromatography (silica gel flash column, eluting with a 10-20% EtOAc / PE gradient) to provide (R)-tert-butyl 4-(3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl)-3,6-dihydropyridine-1(2H)-carboxylate (200 mg, 57.2% yield). LC-MS: m / z 429.2 (M+H) + .
[0443] Step G (R)-tert-Butyl 4-(3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl)piperidine-1-carboxylate
[0444] To a solution of tert-butyl 4-[(3R)-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (200 mg, 466 μmol) in EtOAc (5 mL) was added PtO2 (318 mg, 1.40 mmol) under N2 atmosphere. The suspension was degassed and purged with H2 three times. The mixture was stirred at 25 ° C. under H2 (35 Psi) for 16 h. After filtration, the filtrate was concentrated to give tert-butyl (R)-4-(3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl)piperidine-1-carboxylate (200 mg, 99% yield). LC-MS: m / z 431.2 (M+H) + .
[0445] Step H (R)-3-(4-chlorophenyl)-8-(piperidin-4-yl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine TFA salt
[0446] To a solution of (R)-tert-butyl 4-(3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl)piperidine-1-carboxylate (200 mg, 464 μmol) in DCM (2 mL) was added TFA (2 mL). The mixture was stirred at 25° C. for 2 h. The solvent was removed to give (3R)-3-(4-chlorophenyl)-8-(4-piperidinyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine TFA salt (150 mg, crude). LC-MS: m / z 331.2 (M+H) + .
[0447] Step I 2-((4-((R)-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl)piperidin-1-yl)methyl)-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0448] 2-((4-((R)-3-(4-chlorophenyl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-8-yl)piperidin-1-yl)methyl)-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 130) was synthesized according to the procedure described for the preparation of Example A5 (steps A to B) by using (R)-3-(4-chlorophenyl)-8-(piperidin-4-yl)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine TFA salt and (S)-methyl 2-(chloromethyl)-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate in step A. LC-MS: m / z 575.3 (M+H)+. 1H NMR (400MHz, DMSO-d6) δ8.28 (s, 1H), 8.20 (s, 1H), 7.81 (d, J = 8.4Hz, 1H), 7.74 (d, J = 5.0Hz, 1H), 7.64 (d, J = 8.6Hz, 1H), 7. 52 (s, 3H), 6.94 (d, J = 5.2Hz, 1H), 5.46 (d, J = 7.8Hz, 1H), 5.10 (d, J = 6.8Hz, 1H), 4.80 (dd, J1 = 15.2Hz, J2 = 7.2Hz, 1H), 4.66 ( d, J=14.4Hz, 1H), 4.52 (d, J=9.4Hz, 2H), 4.42-4.36 (m, 1H), 4.09 (d, J=10.8Hz, 1H), 3.95 (d, J=13.4Hz, 2H), 3.80 (d, J=13. 6Hz, 1H), 3.03 (s, 1H), 2.89 (d, J=8.6Hz, 2H), 2.77-2.71 (m, 1H), 2.47-2.42 (m, 1H), 2.29-2.16 (m, 2H), 1.80-1.61 (m, 4H).
[0449] Example Compound 128 was synthesized using a procedure similar to that described above in Example A11 using appropriate starting materials. Example A12 2-[[4-[(2R)-2-(4-chlorophenyl)-6-fluoro-2,3-dihydro-1,4-benzodioxan-5-yl]-1-piperidinyl]methyl]-3-[[(2S)-azetidin-2-yl]methyl]benzimidazole-5-carboxylic acid (Compound 129)
[0450] Step A 2-Bromo-3-fluoro-6-iodophenol
[0451] To a solution of 2-bromo-3-fluoro-phenol (9.42 g, 50 mmol) in CHCl₃ (30 mL) was added NIS (10 g, 44.4 mmol) and DMSO (771 mg, 9.86 mmol). The resulting mixture was stirred at 25°C for 3 h. The mixture was diluted with brine and extracted with EtOAc (100 mL x 2). The combined organic layers were washed with saturated aqueous Na₂SO₃ (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified by flash silica gel chromatography (silica gel flash column, 10-30% EtOAc / PE gradient as eluent) to afford 2-bromo-3-fluoro-6-iodo-phenol (3.8 g, 24% yield).
[0452] Step B 2-(2-Bromo-3-fluoro-6-iodophenoxy)-1-(4-chlorophenyl)ethan-1-one
[0453] To a solution of 2-bromo-3-fluoro-6-iodo-phenol (3.8 g, 12 mmol) and 2-bromo-1-(4-chlorophenyl)ethanone (2.80 g, 12 mmol) in MeCN (20 mL) was added KCO (3.31 g, 24.0 mmol). The mixture was stirred at 25°C for 4 h. The reaction mixture was diluted with H0 (50 mL) and extracted with EtOAc (50 mL x 2). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated. The residue was purified by flash silica gel chromatography (silica gel flash column, 10-20% EtOAc / PE gradient as eluent) to give 2-(2-bromo-3-fluoro-6-iodo-phenoxy)-1-(4-chlorophenyl)ethanone (3 g, 53.3% yield).
[0454] Step C (S)-2-(2-bromo-3-fluoro-6-iodophenoxy)-1-(4-chlorophenyl)ethan-1-ol
[0455] To a solution of formic acid (15 mL) and TEA (75 mL) was added RuCl[(S,S)-Tsdpen](p-pinene) (407 mg, 639 μmol). The mixture was stirred at 25°C for 1 h, followed by the addition of 2-(2-bromo-3-fluoro-6-iodo-phenoxy)-1-(4-chlorophenyl)ethanone (6 g, 12.8 mmol). The resulting mixture was stirred at 25°C for 4 h. The reaction mixture was diluted with water and extracted with EtOAc (50 mL x 2). The combined organic layers were dried over NaSO, filtered, and concentrated. The residue was purified by flash silica gel chromatography (silica gel flash column, eluting with a 10-40% EtOAc / PE gradient) to afford (S)-2-(2-bromo-3-fluoro-6-iodophenoxy)-1-(4-chlorophenyl)ethan-1-ol (2.5 g, 5.30 mmol). 1 H NMR (400MHz, CDCl3) δ7.72 (dd, J1=8.8Hz, J2=6.0Hz, 1H), 7.40-7.47 (m, 2H), 7.38-7.33 (m, 2H), 6.77 (t, J=8.4Hz, 1H), 5.28 (d, J=8.8Hz, 1H), 4.21-4.12 (m, 1H), 4.12-4.02 (m, 1H), 3.14 (d, J=2.0Hz, 1H).
[0456] Step D (R)-5-Bromo-2-(4-chlorophenyl)-6-fluoro-2,3-dihydrobenzo[b][1,4]dioxine
[0457] To a solution of (1S)-2-(2-bromo-3-fluoro-6-iodo-phenoxy)-1-(4-chlorophenyl)ethanol (500 mg, 1.06 mmol) in toluene (5 mL) was added CuI (20.20 mg, 106.00 μmol), 1,10-phenanthroline (38.2 mg, 212 μmol) and CsCO (691 mg, 2.12 mmol). The reaction mixture was stirred at 120 ° C for 16 h. After cooling, the reaction mixture was diluted with water and extracted with EtOAc (50 mL x 2). The combined organic layers were dried over NaSO, filtered and concentrated. The residue was purified by flash silica gel chromatography (silica gel flash column, eluting with a 10-20% EtOAc / PE gradient) to give (2R)-5-bromo-2-(4-chlorophenyl)-6-fluoro-2,3-dihydro-1,4-benzodioxine (250 mg, 68.7% yield). LC-MS: m / z 343.2 (M+H) + . 1 H NMR (400MHz, CDCl3) δ7.45-7.39(m, 2H), 7.38-7.33(m, 2H), 6.94-6.87(m, 1H), 6.76-6.64(m, 1H ), 5.06 (d, J=8.8Hz, 1H), 4.49 (dd, J1=11.6Hz, J2=1.6Hz, 1H), 4.04 (dd, J1=11.2, J2=9.4Hz, 1H)
[0458] Step E (R)-tert-Butyl 4-(2-(4-chlorophenyl)-6-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate
[0459] To a solution of (2R)-5-bromo-2-(4-chlorophenyl)-6-fluoro-2,3-dihydro-1,4-benzodioxine (250 mg, 728 μmol) and tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (270 mg, 873 μmol) in dioxane (2 mL) and H O (0.2 mL) was added Pd(dppf)Cl (53.2 mg, 72.8 μmol) and K CO (201 mg, 1.46 mmol). The reaction mixture was stirred at 80 ° C for 16 h. After cooling, the reaction mixture was diluted with water and extracted with EtOAc (50 mL x 2). The combined organic layers were dried over Na SO , filtered and concentrated. The residue was purified by flash silica gel chromatography (silica gel flash column, elution with a 0-20% EtOAc / PE gradient) to give (R)-tert-butyl 4-(2-(4-chlorophenyl)-6-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate (200 mg, 61.7% yield).
[0460] 1 H NMR (400MHz, CDCl3) δ7.38-7.30 (m, 2H), 7.30-7.23 (m, 2H), 6.82 (dd, J1=9.0Hz, J2=5.3Hz, 1H), 6.62 (t, J =8.4Hz, 1H), 4.97 (d, J=8.8Hz, 1H), 4.40 (dd, J1=11.6Hz, J2=1.2Hz, 1H), 3.96 (dd, J1=11.0, J2=9.6Hz, 1H)
[0461] Step F (R)-tert-Butyl 4-(2-(4-chlorophenyl)-6-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine-1-carboxylate
[0462] To a solution of tert-butyl 4-[(2R)-2-(4-chlorophenyl)-6-fluoro-2,3-dihydro-1,4-benzodioxan-5-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (200 mg, 449 μmol) in EtOAc (3 mL) was added PtO2 (102 mg, 449 μmol) under N2 atmosphere. The suspension was degassed and purged with H2 three times. The mixture was stirred at 25 ° C. under H2 (35 Psi) for 16 h. After filtration, the filtrate was concentrated to give tert-butyl 4-[(2R)-2-(4-chlorophenyl)-6-fluoro-2,3-dihydro-1,4-benzodioxan-5-yl]piperidine-1-carboxylate (100 mg, 50% yield). LC-MS: m / z 348.1 (M+H-Boc) + .
[0463] Step G (R)-4-(2-(4-chlorophenyl)-6-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine TFA salt
[0464] To a solution of tert-butyl 4-[(2R)-2-(4-chlorophenyl)-6-fluoro-2,3-dihydro-1,4-benzodioxan-5-yl]piperidine-1-carboxylate (100 mg, 223 μmol) in DCM (2 mL) was added TFA (2 mL). The reaction mixture was stirred at 25 ° C. for 3 h. The mixture was concentrated to give 4-[(2R)-2-(4-chlorophenyl)-6-fluoro-2,3-dihydro-1,4-benzodioxan-5-yl]piperidine TFA salt (50 mg, crude), which was used in the next step without purification. LC-MS: m / z 348.1 (M+H) + .
[0465] Step H 2-((4-((R)-2-(4-chlorophenyl)-6-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidin-1-yl)methyl)-1-(((S)-azetidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid
[0466] 2-[[4-[(2R)-2-(4-chlorophenyl)-6-fluoro-2,3-dihydro-1,4-benzodioxol-5-yl]-1-piperidinyl]methyl]-3-[[(2S)-azetidin-2-yl]methyl]benzimidazole-5-carboxylic acid (Compound 129) was synthesized according to the procedure described for the preparation of Example A5 (Steps A to B) by using (R)-4-(2-(4-chlorophenyl)-6-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)piperidine TFA salt and (S)-methyl 2-(chloromethyl)-1-(azetidin-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate in Step A. LC-MS: m / z 592.2 (M+H). 1 H NMR (400MHz, DMSO-d6) δ8.27 (s, 1H), 7.80 (d, J=8.4Hz, 1H), 7.63 (d, J=8.4Hz, 1H), 7.51 (s, 4H), 6.91-6.80 (m, 1H), 6. 75-6.61 (m, 1H), 5.23 (d, J=8.4Hz, 1H), 5.12 (d, J=6.2Hz, 1H), 4.78 (dd, J1=14.8Hz, J2=7.2Hz, 1H), 4.68-4.62 (m, 1H), 4.55-4.48 (m, 2H), 4.40 (d, J=7.6Hz, 1H), 4.12-4.03 (m, 1H), 3.94 (d, J=12.8Hz, 1H), 3.76 (d, J=13.6Hz, 1H), 3.02 (d, J=10.3Hz, 2H), 2.85 (d, J=9.7Hz, 2H), 2.70 (d, J=9.4Hz, 2H), 2.26-2.17 (m, 1H), 2.12-2.05 (m, 2H), 1.65-1.53 (m, 2H). Example A13 2-({4-[(2R)-2-[1-(2,2-difluoroethyl)-1H-indazol-6-yl]-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazole-6-carboxylic acid (Compound 102)
[0467] Step A 6-Bromo-1-(2,2-difluoroethyl)-1H-indazole
[0468] To a solution of 6-bromo-1H-indazole (5.0 g, 25.38 mmol) in DMF (50 mL) was added 1,1-difluoro-2-iodoethane (4.9 g, 25.38 mmol) and Cs2CO3 (16.5 g, 50.75 mmol). The reaction was stirred at 25 ° C for 16 h. After the reaction was complete, the reaction was diluted with H2O (300 mL) and extracted with ethyl acetate (300 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by flash silica gel chromatography (silica gel flash column, eluent: 0-10% EtOAc / PE gradient) to give 6-bromo-1-(2,2-difluoroethyl)-1H-indazole (3. g, 57.6% yield). 1 H NMR (400MHz, DMSO-d6) δ8.20 (d, J=1.2Hz, 1H), 8.12 (s, 1H), 7.76 (d, J=8.4Hz, 1H), 7.33 (dd, J1=8.4Hz, J2=1.2Hz, 1H), 6.59-6.31 (m, 1H), 5.02-4.94 (m, 2H).
[0469] Step B 1-(1-(2,2-difluoroethyl)-1H-indazol-6-yl)ethan-1-one
[0470] To a solution of 6-bromo-1-(2,2-difluoroethyl)-1H-indazole (2.0 g, 7.66 mmol) in DMF / H2O (16 mL / 2 mL) was added 1-(vinyloxy)butane (2.3 g, 22.98 mmol), K2CO3 (4.2 g, 30.64 mmol), Pd(OAc)2 (172 mg, 0.77 mmol) and 1,3-bis(diphenylphosphino)propane (632 mg, 1.53 mmol). The reaction mixture was stirred at 80 ° C. under N2 in a sealed tube for 24 h. After the reaction was complete, the reaction was filtered and concentrated, and the residue was purified by flash silica gel chromatography (silica gel flash column, eluent: 0-15% EtOAc / PE gradient) to give 1-(1-(2,2-difluoroethyl)-1H-indazol-6-yl)ethan-1-one (660 mg, 38.4% yield). LC-MS: m / z 225.1 (M+H) + .
[0471] Step C 2-Bromo-1-(1-(2,2-difluoroethyl)-1H-indazol-6-yl)ethan-1-one
[0472] To a solution of 1-(1-(2,2-difluoroethyl)-1H-indazol-6-yl)ethan-1-one (660 mg, 2.94 mmol) in THF (8 mL) was added pyridinium tribromide (942 mg, 2.94 mmol). The reaction was stirred at 40 ° C for 2 h. After cooling, the reaction was quenched with H2O (100 mL) and extracted with ethyl acetate (100 mL). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by reverse phase ISCO (0-80% CH3CN in water (0.1% NH4HCO3)) to give 2-bromo-1-(1-(2,2-difluoroethyl)-1H-indazol-6-yl)ethan-1-one (470 mg, 52.7% yield). LC-MS: m / z 302.9 (M+H) + .
[0473] Step D 2-({4-[(2R)-2-[1-(2,2-difluoroethyl)-1H-indazol-6-yl]-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazol-6-carboxylic acid
[0474] 2-({4-[(2R)-2-[1-(2,2-difluoroethyl)-1H-indazol-6-yl]-2,3-dihydro-1,4-benzodioxol-5-yl]piperidin-1-yl}methyl)-1-{[(2S)-azetidin-2-yl]methyl}-1H-1,3-benzodiazol-6-carboxylic acid (Compound 102) was synthesized according to the procedure described for the preparation of Example A12 (Steps B to H) by using 2-bromo-1-(1-(2,2-difluoroethyl)-1H-indazol-6-yl)ethan-1-one and 2,6-dibromophenol in Step B. LC-MS: m / z 644.4 (M+H) + . 1H NMR (400MHz, DMSO-d6) δ8.27 (s, 1H), 8.19 (s, 1H), 7.88 (s, 1H), 7.85-7.78 (m, 2H), 7.64 (d, J=8.4Hz, 1H), 7.31 (d, J=8.0Hz, 1 H), 6.89-6.78 (m, 3H), 6.43 (m, 1H), 5.38 (dd, J1=8.4Hz, J2=2.0Hz, 1H), 5.17-5.06 (m, 1H), 4.97-4.89 (m, 2H), 4.83 (dd, J1=1 5.6Hz, J2=7.2Hz, 1H), 4.68(dd, J1=14.8Hz, J2=2.4Hz, 1H), 4.55-4.47(m, 2H), 4.43-4.34(m, 1H), 4.12(dd, J1=19.2Hz, J2=1 8.0Hz, 1H), 3.96 (d, J=2.4Hz, 1H), 3.82 (d, J=13.6Hz, 1H), 3.79 (d, J=13.2Hz, 1H), 3.06-2.97 (m, 1H), 2.94-2.81 (m, 2H), 2.75 -2.65(m, 1H), 2.47-2.40(m, 1H), 2.35-2.18(m, 2H), 1.85-1.55(m, 4H). 19 F NMR (377MHz, DMSO-d6) δ-121.77.
[0475] The following molecules were synthesized using similar procedures to those described in the above examples using appropriate starting materials. Biological Examples Biological Example 1: cAMP Assay
[0476] It is known that activation of the GLP-1 receptor will stimulate cyclic AMP (cAMP) production in cells, which indicates primary coupling primarily to the Gas subunit of the G protein heterotrimeric complex. Evidence suggests that signaling through Gas-induced cAMP stimulation leads to the desired pharmacological response regarding insulin release from pancreatic β cells.
[0477] To optimize functional activity against Gαs coupling, a HEK293 / CRE-Luc cell line generated from HDB stably expressing the GLP-1 receptor was used. Compound working solutions (Agilent Technologies Bravo) were prepared at 200× concentrations in 384-well Echo LDV plates (Labcyte, catalog number LP-0200) using 1 / 2 log serial dilutions. 50 nL / well of the 200× concentration compound working solutions were transferred to 384-well white low-volume plates (Greiner, catalog number 784075) using a Labcyte ECHO550. 1×10 5 A suspension of 10 cells / mL HEK293 / GLP1R / CRE-LUC (HD Biosciences) cells was prepared in assay buffer [DPBS containing 0.5 mM IBMX (Sigma, catalog number I5879) and 0.1% BSA (GENVIEW, catalog number FA016-100g)]. 10 μL of the cell suspension was added to each well of a previously generated assay plate (1000 cells / well) containing 50 nL of compound at a 200× concentration using a ThermoFisher Multidrop Combi. The plate was sealed and incubated at 37°C with 5% CO2 for 30 minutes.
[0478] After incubation, the cAMP assay signal was generated using the cAMP Dynamics 2 Kit (Cisbio). 5 μL of cAMP-d2 working solution was added to each well, followed by 5 μL of anti-cAMP antibody-cryptate working solution using a ThermoFisher Multidrop Combi. Incubate at room temperature for 1 hour in the dark. Fluorescence was read at 665 and 615 nm using a PerkinElmer EnVision Reader. % Activity = 100% x (Average RLU of test sample - Average RLU of vehicle control) / (Average RLU of MAX control - Average RLU of vehicle control)
[0479] Table 2 shows the bioactivity of the compounds in the GLP-1R agonist cAMP stimulation assay (EC 50 ). Table 2
Claims
1. Compound of formula I: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, wherein: Ring A is in Bond represents a single bond or a double bond; Wherein X is N or CH, and Y is O, CH2, CHR 3 , or C(R 3 )2; Z 1 Is N or CR 4 ; Z 2 Is N or CR 4 ; Ring B does not exist; or Ring B exists and together with the carbon atom of the benzene ring to which it is fused forms C 5-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein Ring B is independently optionally substituted with 1 to 5 R 1 ; p is 0, 1, 2, or 3; n is 0, 1, 2, or 3; m is 0, 1, 2, or 3; R 1 are independently halogen, cyano, nitro, oxo, -OR 10 , -SR 10 ,-N(R 10 )2,-C(O)R 10 ,-C(O)OR 10 ,-OC(O)R 10 ,-OC(O)OR 10 ,-C(O)N(R 10 )2,-NR 10 C(O)R 10 ,-OC(O)N(R 10 )2,-NR 10 C(O)OR 10 , -NR 10 C(O)N(R 10 )2,-S(O)R 10 , -S(O)2R 10 ,-S(O)N(R 10 )2,-S(O)2N(R 10 )2,-NR 10 S(O)R 10 , -NR 10 S(O)2R 10 , -NR 10 S(O)N(R 10 )2,-NR 10 S(O)2N(R 10 )2,C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Halogenated alkyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z; R 2 is hydrogen, heterocyclic, C 1-6 Alkyl, or C substituted with 1-6 Alkyl: C 1-6 Alkoxy, C 1-6 Thioalkoxy, C 1-6 Halogenated alkoxy, S(O)2(C 1-6 Alkyl), C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, phenyl, or 5-membered to 6-membered heteroaryl; wherein C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, phenyl, or 5-membered to 6-membered heteroaryl are each optionally substituted with 1 to 4 R 12 ; R 3 is cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 cycloalkyl; or Two R's 3 Together with the carbon atoms to which they are attached, they form C 3-10 Cycloalkyl or heterocyclic group; wherein C 3-10 Cycloalkyl or heterocyclyl are each independently optionally substituted with 1 to 2 halogens; R 4 are independently hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 5 is hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 6 is hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 7 is hydrogen, cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl; R 10 are each independently hydrogen, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(O)R 20 ,-C(O)OR 20 ,-C(O)N(R 20 )2,-S(O)R 20 , -S(O)2R 20 ,-S(O)N(R 20 )2, or -S(O)2N(R 20 )2; where C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z 1a ; R 12 Each independently selected from cyano, halogen, hydroxy, SH, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Halogenated alkyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 3-6 Cycloalkyl, amino, C 1-6 Alkylamino, and di-C 1-6 Alkylamino; Z is independently halogen, cyano, nitro, oxo, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, heteroaryl, -L 1 -C 1-9 Alkyl, -L 1 -C 2-9 Alkenyl, -L 1 -C 2-9 Alkynyl, -L 1 -C 3-10 Cycloalkyl, -L 1 -heterocyclyl, -L 1 -aryl, or -L 1 -heteroaryl; wherein C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z 1a ; L 1 Each independently represents -O-, -S-, -NR 20 -, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NR 20 -,-NR 20 C(O)-,-OC(O)NR 20 -,-NR 20 C(O)O-,-NR 20 C(O)NR 20 -, -S(O)-, -S(O)2-, -S(O)NR 20 -,-S(O)2NR 20 -,-NR 20 S(O)-,-NR 20 S(O)2-,-NR 20 S(O)NR 20 -, or -NR 20 S(O)2NR 20 -; R 20 are each independently hydrogen, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein R 20 C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-10 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 Z 1a ; Z 1a Each is independently halogen, hydroxy, cyano, nitro, oxo, -SH, -NH2, -NH-C 1-9 Alkyl, -N(C 1-9 Alkyl)2,-SC 1-9 Alkyl, C 1-9 Alkoxy, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-6 Cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein Z 1a -NH-C 1-9 Alkyl, -N(C 1-9 Alkyl)2, -SC 1-9 Alkyl, C 1-9 Alkoxy, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 3-6 Cycloalkyl, heterocyclyl, aryl, or heteroaryl are each independently optionally substituted with 1 to 5 groups selected from C 1-9 alkyl, oxo, halogen, hydroxy, and cyano substituents; The prerequisite is that any one or more of the following conditions occur: A) Ring A is B)R 5 and R 6 One is not hydrogen; C)R 2 is optionally substituted with 1 to 4 R 12 a heterocyclic group; or D) At least one R 12 Yes-C(O)-C 1-6 alkyl.
2. The compound according to claim 1, wherein Ring A is:
3. The compound according to claim 1, wherein the compound is represented by Formula IA: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.
4. The compound according to claim 1, wherein the compound is represented by Formula IB: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.
5. The compound according to claim 1, wherein the compound is represented by formula IC: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.
6. The compound according to claim 1, wherein the compound is represented by Formula ID: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.
7. The compound according to claim 1, wherein the compound is represented by Formula IE: or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof.
8. A compound according to any one of the preceding claims, wherein R 5 is cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl.
9. A compound according to any one of the preceding claims, wherein R 6 is cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl.
10. A compound according to any one of the preceding claims, wherein part yes 11. A compound according to any one of the preceding claims, wherein Ring B is present.
12. A compound according to any one of the preceding claims, wherein part yes 13. A compound according to any one of the preceding claims, wherein R 1 are each independently halogen, cyano, or C 1-9 Halogenated alkyl.
14. A compound according to any one of the preceding claims, wherein p is 1.
15. A compound according to any one of the preceding claims, wherein at least one R 4 Not hydrogen.
16. A compound according to any one of the preceding claims, wherein Z 2 It's CR 4 ; and Z 2 R 4 is cyano, halogen, hydroxyl, C 1-9 Alkyl, C 2-9 Alkenyl, C 2-9 Alkynyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-9 Alkoxy, C 1-9 Halogenated alkyl, C 1-9 Haloalkoxy, or C 3-10 Cycloalkyl.
17. A compound according to any one of the preceding claims, wherein R 2 is a heterocyclic group or substituted with C 3-6 C of a cycloalkyl group, a 3-membered to 6-membered heterocyclic group, or a 5-membered to 6-membered heteroaryl group 1-6 Alkyl; wherein heterocyclic, C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, or 5-membered to 6-membered heteroaryl are each optionally substituted with 1 to 4, or 1 to 3, or 1 to 2, or 1 R 12 .
18. A compound according to any one of the preceding claims, wherein R 2 is a heterocyclic group or substituted with C 3-6 C of a cycloalkyl group, a 3-membered to 6-membered heterocyclic group, or a 5-membered to 6-membered heteroaryl group 1-6 Alkyl; wherein heterocyclic, C 3-6 Cycloalkyl, 3-membered to 6-membered heterocyclyl, or 5-membered to 6-membered heteroaryl, each optionally substituted with 1 to 4, or 1 to 3, or 1 to 2, or 1 cyano, halogen, C 1-6 Alkyl, C 1-6 Cyanoalkyl, or -C(O)-C 1-6 alkyl.
19. A compound according to any one of the preceding claims, wherein R 2 is a heterocyclic group optionally substituted with 1 to 5 substituents independently selected from halogen, cyano, hydroxy, C 1-6 Alkyl, C 1-6 Halogenated alkyl, C 1-6 Cyanoalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, and C 3-6 Cycloalkyl.
20. A compound according to any one of the preceding claims, wherein R 2 Is replaced by C 1-6 3-6 membered heterocyclic group of alkoxy.
21. A compound according to any one of the preceding claims, wherein R 4 are each independently hydrogen or halogen.
22. A compound according to any one of the preceding claims, wherein R 5 is hydrogen or a halogen.
23. A compound according to any one of the preceding claims, wherein R 6 is hydrogen, halogen, or C 1-9 Alkoxy.
24. A compound according to any one of the preceding claims, wherein R 5 is hydrogen or halogen; and R 6 Is a halogen or C 1-9 Alkoxy.
25. A compound according to any one of claims 1 to 23, wherein R 5 is a halogen; and R 6 is hydrogen, halogen, or C 1-9 Alkoxy.
26. A compound according to any one of the preceding claims, wherein R 7 It's hydrogen.
27. A compound according to any one of the preceding claims, wherein Z 1 It's N.
28. A compound according to any one of claims 1-15 and 17-27, wherein Z 2 It's N.
29. A compound according to any one of the preceding claims, wherein part yes 30. A compound selected from Table 1, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof.
31. A pharmaceutical composition comprising a compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and a pharmaceutically acceptable excipient.
32. A method of treating a GLP-1 related disease, disorder or condition, comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, or a pharmaceutical composition according to claim 31.
33. The method of claim 32, wherein the disease, disorder or condition is selected from the group consisting of type 1 diabetes, type 2 diabetes, early-onset type 2 diabetes, idiopathic type 1 diabetes (type 1b), atypical diabetes of the young (YOAD), maturity-onset diabetes of the young (MODY), latent autoimmune diabetes of adults (LADA), obesity, weight gain from other medications, gout, excessive sugar cravings, hypertriglyceridemia, dyslipidemia, malnutrition-associated diabetes, gestational diabetes, kidney disease, disorders of adipocyte function, sleep apnea, visceral fat deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral arterial disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attack, atherosclerotic cardiovascular disease, traumatic brain injury, peripheral vascular disease, disorders of endothelial function, impaired vascular compliance, restenosis, thrombosis, hypertension, pulmonary arterial hypertension, restenosis after angioplasty, intermittent claudication, hyperglycemia, postprandial lipidosis, metabolic acidosis, ketosis, hyperinsulinemia, dysglucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorder, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, premenstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, macular degeneration, cataract, glomerulosclerosis, arthritis, osteoporosis, addiction treatment, cocaine dependence, bipolar disorder / major depressive disorder, skin and connective tissue disorders, foot ulcer, psoriasis, primary polydipsia, nonalcoholic steatosis hepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), ulcerative colitis, inflammatory bowel disease, colitis, irritable bowel syndrome, Crohn's disease, short bowel syndrome, Parkinson's disease, Alzheimer's disease, cognitive function disorders, schizophrenia, polycystic ovary syndrome (PCOS), or any combination thereof.
34. A method of treating type 2 diabetes in a patient in need thereof, comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1-30, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, or a pharmaceutical composition according to claim 31.
35. A method of regulating insulin levels in a patient in need thereof, the method comprising administering to the patient in need thereof an effective amount of a compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, or a pharmaceutical composition according to claim 31.
36. A method of regulating blood glucose levels in a patient in need thereof, the method comprising administering to the patient in need thereof an effective amount of a compound according to any one of claims 1 to 30, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, or a pharmaceutical composition according to claim 31.
37. The method of any one of claims 32-36, further comprising administering an additional therapy or therapeutic agent to the patient.
38. The method of claim 37, wherein the additional therapy or therapeutic agent is selected from an antidiabetic agent, an antiobesity agent, a GLP-1 receptor agonist, an antiemetic, an agent for treating nonalcoholic steatohepatitis (NASH), gastric electrical stimulation, dietary monitoring, physical activity, or a combination thereof.
39. A method for preparing a compound of Formula I according to claim 1, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, the method comprising contacting a compound of Formula I-1 with a compound of Formula I-2 under conditions sufficient to yield a compound of Formula I, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof: wherein LG is a leaving group; R is hydrogen or C optionally substituted with phenyl 1-6 alkyl.
40. The method of claim 39, wherein the method further comprises a hydrolysis or transesterification step before or after the contacting.
Citation Information
Patent Citations
Anti-nausea drug combinations
US10071088B2
Combinations of amisulpride and another anti-emetic for treating nausea and vomiting
US10322106B2
Use of amisulpride as an anti-emetic
US10525033B2
Compositions and methods for treating centrally mediated nausea and vomiting
US10828297B2
GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US20060275288A1
